(19) Europäisches Patentamt
European Patent Office
Office européen des brevets

(11) EP 2 502 491 B1

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention
of the grant of the patent:
10.05.2017 Bulletin 2017/19

(51) Int Cl.:
A01N 1/02 (2006.01)   *C12N 9/40* (2006.01)
C07K 14/78 (2006.01)

(21) Application number: **12165987.4**

(22) Date of filing: **31.10.2006**

(54) **Novel alpha-galactosidases**

Neue a-galactosidasen

Nouvelles a-galactosidases

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

(30) Priority: **31.10.2005 US 731845 P**
07.08.2006 US 836000 P

(43) Date of publication of application:
26.09.2012 Bulletin 2012/39

(62) Document number(s) of the earlier application(s) in accordance with Art. 76 EPC:
10165154.5 / 2 250 884
06827104.8 / 1 945 269

(73) Proprietor: **Velico Medical, Inc.**
Beverly, MA 01915-6122 (US)

(72) Inventors:
• **Liu, Qiyong Peter**
Newton, MA Massachusetts 02459 (US)
• **Clausen, Henrick**
2840 Holte (DK)

(74) Representative: **Cooley (UK) LLP**
Dashwood
69 Old Broad Street
London EC2M 1QS (GB)

(56) References cited:
US-A1- 2003 157 474

• **J. Xu ET AL: "Hypothetical protein.", , 1 June 2003 (2003-06-01), XP055033853, DOI: 10.1126/science.1080029 Retrieved from the Internet: URL:http://www.uniprot.org/jobs/201207252G 03TYD7ED.txt [retrieved on 2012-07-25]**
• **XU JIAN ET AL: "A genomic view of the human-Bacteroides thetaiotaomicron symbiosis", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, WASHINGTON, DC; US, vol. 299, no. 5615, 28 March 2003 (2003-03-28), pages 2074-2076, XP002330198, ISSN: 0036-8075, DOI: 10.1126/SCIENCE.1080029**
• **J. Xu ET AL: "A Genomic View of the Human-Bacteroides thetaiotaomicron Symbiosis, Supporting Online Material", Science, 28 March 2003 (2003-03-28), pages 2074-2076, XP055033880, Retrieved from the Internet: URL:http://www.sciencemag.org/content/supp l/2003/03/27/299.5615.2074.DC1/Xu.SOM.pdf [retrieved on 2012-07-25]**
• **OLSSON M L ET AL: "UNIVERSAL RED BLOOD CELLS-ENZYMATIC CONVERSION OF BLOOD GROUP A AND B ANTIGENS//GLOBULES ROUGES UNIVERSELS-CONVERSION ENZYMATIQUE DES ANTIGENS DE GROUPES SANGUINS A ET B", TRANSFUSION CLINIQUE ET BIOLOGIQUE, ARNETTE-BLACKWELL, PARIS, FR, vol. 11, no. 1, 1 February 2004 (2004-02-01), pages 33-39, XP001204350, ISSN: 1246-7820**

EP 2 502 491 B1

(Cont. next page)

- **GOLDSTEIN J ET AL: "GROUP B ERYTHROCYTES ENZYMATICALLY CONVERTED TO GROUP O SURVIVE NORMALLY IN A B AND O INDIVIDUALS", SCIENCE (WASHINGTON D C), vol. 215, no. 4529, 1982, pages 168-170, XP002559071, ISSN: 0036-8075**
- **KUWAHARA ET AL: "Conserved hypothetical protein [Bacteroides fragilis YCH46]", GENBANK,, 20 April 2004 (2004-04-20), XP002559070,**
- **LIU QIYONG P ET AL: "Identification of a GH110 subfamily of alpha 1,3-galactosidases - Novel enzymes for removal of the alpha 3Gal xenotransplantation antigen", March 2008 (2008-03), JOURNAL OF BIOLOGICAL CHEMISTRY, VOL. 283, NR. 13, PAGE(S) 8545-8554 ISSN: 0021-9258**

Remarks:

The file contains technical information submitted after the application was filed and not included in this specification

Description

FIELD OF THE INVENTION

[0001]   This invention relates to a novel family of polypeptides having α-galactosidase activities, demonstrating unique substrate specificities and superior kinetic properties, that are used for removal of the immunodominant monosaccharides on blood products and tissues. Specifically this invention provides a novel family of $\alpha 3$ glycosidases, used for the enzymatic removal of type B antigens from blood group B and AB reactive blood products, and the Galili antigen from non-human animal tissues, thereby converting these to non-immunogenic cells and tissues suitable for transplantation.

BACKGROUND OF THE INVENTION

[0002]   As used herein, the term "blood products" includes whole blood and cellular components derived from blood, including erythrocytes (red blood cells) and platelets.

[0003]   There are more than thirty blood group (or type) systems, one of the most important of which is the ABO system. This system is based on the presence or absence of antigens A and/or B. These antigens are found on the surface of erythrocytes and platelets as well as on the surface of endothelial and most epithelial cells. The major blood product used for transfusion is erythrocytes, which are red blood cells containing hemoglobin, the principal function of which is the transport of oxygen. Blood of group A contains antigen A on its erythrocytes. Similarly, blood of group B contains antigen B on its erythrocytes. Blood of group AB contains both antigens, and blood of group O contains neither antigen.

[0004]   The blood group structures are glycoproteins or glycolipids and considerable work has been done to identify the specific structures making up the A and B determinants or antigens. The ABH blood group specificity is determined by the nature and linkage of monosaccharides at the ends of the carbohydrate chains. The carbohydrate chains are attached to a peptide (glycoprotein) or lipid (glycosphingolipid) backbone, which are attached to the cell membrane of the cells. The immunodominant monosaccharide determining type A specificity is a terminal $\alpha 1$-3 linked *N*-acetylgalactosamine (GalNAc), while the corresponding monosaccharide of B type specificity is an $\alpha 1$-3 linked galactose (Gal). Type O cells lack either of these monosaccharides at the termini of oligosaccharide chains, which instead are terminated with $\alpha 1$-2 linked fucose (Fuc) residues.

[0005]   A great diversity of blood group ABH carbohydrate structures are found due to structural variations in the oligosaccharide chains that carry ABH immunodominant saccharides. Table 1 lists structures reported in man and those that have been found on human red cells or in blood extracts. For a review, see, Clausen & Hakomori, Vox Sang 56(1): 1-20, 1989). Red cells contain ABH antigens on N-linked glycoproteins and glycosphingolipids, while it is generally believed that O-linked glycans on erythrocytes glycoproteins, mainly glycophorins, are terminated by sialic acid and not with ABH antigens. Type 1 chain glycosphingolipids are not endogenous products of red cells, but rather adsorbed from plasma.

Table I:

Histo-Blood Group ABH Immunoreactive Determinants of Human Cells[1]				
Name	**Hapten Structure**	**Type of Glycoconjugate**	**Found on RBC**	**No**

A type 1, ALe[d]	GalNAcα1-3Galβ1-3GlcNAcβ1-R
	               2
	            Fucα1
		Glycolipid
		N-linked
		O-linked
			Glycolipid	1

A type 1, ALe[b]	GalNAcα1-3Galβ1-3GlcNAcβ1-R
	               2 4
	            Fucα1 Fucα1
		Glycolipid
		N-linked
		O-linked
			Glycolipid	2

A type 2, A	GalNAcα1-3Galβ1-4GlcNAcβ1-R
	               2
	            Fucα1
		Glycolipid
		N-linked
		O-linked
			Glycolipid
			N-linked
				3

A type 2, ALe[y]	GalNAcα1-3Galβ1-4GlcNAcβ1-R
	               2 3
	            Fucα1 Fucα1
		Glycolipid
		N-linked
		O-linked
			Glycolipid?	4

(continued)

Histo-Blood Group ABH Immunoreactive Determinants of Human Cells[1]				
Name	**Hapten Structure**	**Type of Glycoconjugate**	**Found on RBC**	**No**

A type 3, O-linked	GalNAcα1-3Galβ1-3GalNAcα1-O-Ser/Thr
	  ` 2
	    Fucα1
		O-linked		5

A type 3, Repetitive	GalNAcα1-3Galβ1-3GalNAcα1-3Galβ1-4GlcNAcβ1-R
	    2 2
	    Fucα1 Fucα1
		Glycolipid	Glycolipid	6

A type 4, Globo	GalNAcα1-3Galβ1-3GalNAcβ1-3Galα1-R
	    2
	    Fucα1
		Glycolipid	Glycolipid?	7

A type 4, Ganglio	GalNAcα1-3Galβ1-3GalNAcβ1-3Galβ1-R
	    2
	    Fucα1
		Glycolipid		8

B type 1, BLe^d	Galα1-3Galβ1-3GlcNAcβ1-R
	    2
	    Fucα1
		Glycolipid
		N-linked
		O-linked
			Glycolipid	9

B type 1, BLe^b	Galα1-3Galβ1-3GlcNAcβ1-R
	    2 4
	    Fucα1 Fucα1
		Glycolipid
		N-linked
		O-linked
			Glycolipid	10

B type 2, B	Galα1-3Galβ1-4GlcNAcβ1-R
	    2
	    Fucα1
		Glycolipid
		N-linked
		O-linked
			Glycolipid
			N-linked
				11

B type 2, BLe^y	Galα1-3Galβ1-4GlcNAcβ1-R
	    2 3
	    Fucα1 Fucα1
		Glycolipid
		N-linked
		O-finked
			Glycolipid?	12

B type 3, O-linked	Galα1-3Galβ1-3GalNAcα1-O-Ser/Thr
	    2
	    Fucα1
		O-linked		13

B type 4, Globo	Galα1-3Galβ1-3GalNAcβ1-3Galα1-R
	    2
	    Fucα1
		Glycolipid?	Glycolipid?	14

B type 4, Ganglio	Galα1-3Galβ1-3GalNAcβ1-3Galβ1-R
	    2
	    Fucα1
		Glycolipid?		15

H type 1, Le^d	Galβ1-3GlcNAcβ1-R
	    2
	  Fucα1
		Glycolipid
		N-linked
		O-linked
			Glycolipid	16

H type 1, Le^b	Galβ1-3GlcNAcβ1-R
	    2 4
	  Fucα1 Fucα1
		Glycolipid
		N-linked
		O-linked
			Glycolipid	17

H type 2, H	Galβ1-4GlcNAcβ1-R
	    2
	  Fucα1
		Glycolipid
		N-linked
		O-linked
			Glycolipid
			N-linked
				18

(continued)

Histo-Blood Group ABH Immunoreactive Determinants of Human Cells[1]				
Name	**Hapten Structure**	**Type of Glycoconjugate**	**Found on RBC**	**No**
H type 2, Le^y	Galβ1-4GlcNAcβ1-R 2 3 Fucα1 Fucα1	Glycolipid N-linked O-linked	Glycolipid?	19
H type 3, O-linked	Galβ1-3GalNAcα1-O-Ser/Thr 2 Fucα1	O-linked		20
H type 3, H-A	Galβ1-3GalNAcα1-3Galβ1-4GlcNAcβ1-R 2 2 Fucα1 Fucα1	Glycolipid	Glycolipid (A RBC)	21
H type 4, Globo	Galβ1-3GalNAcβ1-3Galα1-R 2 Fucα1	Glycolipid	Glycolipid	22
H type 4, Ganglio	Galβ1-3GalNAcβ1-3Galβ1-R 2 Fucα1	Glycolipid		23
Thomsen-Friedenrich Tf, T	Galβ1-3GalNAcα1-O-Ser/Thr	O-linked	O-linked (+SA)	24
Gal-A, T cross-react.	Galβ1-3GalNAcα1-3Galβ1-4GlcNAcβ1-R 2 Fucα1	Glycolipid	Glycolipid (A RBC)	25
Tn, A cross-react.	GalNAcα1-O-Ser/Thr	O-linked	O-linked (+SA)	26

[1]Adapted from Clausen and Hakomori, Vox Sang 56(1): 1-20, 1989. Designations: "?" indicates potential glycolipid structures which have not been reported to date.

[0006] Blood group A and B exist in several subtypes. Blood group A subtypes are the most frequent, and there are three recognized major sub-types of blood type A. These sub-types are known as A_1, A intermediate (A_{int}) and A_2. There are both quantitative and qualitative differences that distinguish these three sub-types. Quantitatively, A_1 erythrocytes have more antigenic A sites, *i.e.,* terminal *N*-acetylgalactosamine residues, than A_{int} erythrocytes which in turn have more antigenic A sites than A_2 erythrocytes. Qualitatively, A_1 erythrocytes have a dual repeated A structure on a subset of glycosphingolipids, while A_2 cells have an H structure on an internal A structure on a similar subset of glycolipids (Clausen et al., Proc. Natl. Acad. Sci. USA 82(4): 1199-203,1985, Clausen et al., J. Biol. Chem. 261(3): 1380-7, 1986). These differences between A_1 and weak A subtypes are thought to relate to differences in the kinetic properties of blood group A isoenzyme variants responsible for the formation of A antigens (Clausen et al., J. Biol. Chem. 261(3): 1388-92, 1986). The differences of group B subtypes are believed to be solely of quantitative nature.

[0007] Blood of group A contains antibodies to antigen B. Conversely, blood of group B contains antibodies to antigen A. Blood of group AB has neither antibody, and blood group O has both. Antibodies to these and other carbohydrate defined blood group antigens are believed to be elicited by continuous exposure to microbial organism carrying related carbohydrate structures. An individual whose blood contains either (or both) of the anti-A or anti-B antibodies cannot receive a transfusion of blood containing the corresponding incompatible antigen(s). If an individual receives a transfusion of blood of an incompatible group, the blood transfusion recipient's antibodies coat the red blood cells of the transfused incompatible group and cause the transfused red blood cells to agglutinate, or stick together. Transfusion reactions and/or hemolysis (the destruction of red blood cells) may result therefrom.

[0008] In order to avoid severe transfusion reactions due to the presence of antibodies to the A and B blood group

antigens the blood group of the donor and the recipient are matched before blood transfusions by typing methods. For example, a blood type A recipient can be safely transfused with type A blood, which contains compatible antigens, but not type B blood, which would trigger an adverse immune response in the recipient. Because type O blood contains no A or B antigens, it can be transfused into any recipient with any blood type, *i.e.,* recipients with blood types A, B, AB or O. Thus, type O blood is considered "universal", and may be used for all transfusions. Hence, it is desirable for blood banks to maintain large quantities of type O blood. However, there is a paucity of blood type O donors. Therefore, it is desirable and useful to remove the immunodominant A and B antigens on types A, B and AB blood in order to maintain large quantities of universal blood products.

[0009] In an attempt to increase the supply of type O blood, methods have been developed for converting type A, B and AB blood to type O blood. Although, enzymatic conversion of both group B and group A red cells have been achieved in the past, these older processes have several disadvantages, particularly that they require excessive quantities of enzyme, and the specificities of many glycan modifying enzymes are not restricted to cleavage of only the blood group A or B antigens.

[0010] As will be explained below, the present invention provides for a family of polypeptides having highly refined substrate specificities, and better kinetic properties, that can be used to generate tissues and blood products lacking immunodominant antigens, thereby providing an efficient and cost-effective commercial process to supply, e.g. universal (non-immunogenic) blood cells for transplant, and even animal tissues for xenotransplantation into humans.

CONVERSION OF BLOOD GROUP B CELLS:

[0011] Enzymatic conversion of type B blood using purified or recombinant Coffee bean (Coffea canephora) α-galactosidase has been achieved using 100-200 U/ml (U.S. Pat. No. 4,427,777; Zhu et al., Arch Biochem Biophys 1996; 327(2): 324-9; Kruskall et al., Transfusion 2000; 40(11): 1290-8). The specific activity of Coffee bean α-galactosidase was reported to be 32 U/mg using p-nitrophenyl α-D-Gal with one unit (U) defined as one μmole substrate hydrolyzed per minute (Zhu et al., Arch Biochem Biophys 1996; 327(2): 324-9). Enzymatic conversions were done at pH 5.5 with approximately 6 mg/ml enzyme at 80-90% hematocrit, and the resulting converted O cells functioned normally in transfusion experiments and no significant adverse clinical parameters were observed (Kruskall et al., Transfusion 2000; 40(11): 1290-8). This data along with earlier publications, clearly demonstrate that enzymatic conversion of red blood cells is feasible and that such enzyme group B converted O (B-ECO) cells can function as well as matched type untreated cells in transfusion medicine. Nevertheless, the quantities of enzymes required for seroconversion in these studies, even with recombinant production of the enzyme, renders this method for generating ECO cells impractical mainly for economical reasons.

[0012] Claims of protocols for improved conversion of B cells using recombinant Glycine max α-galactosidase with a specific activity of approximately 200 U/mg have been reported using 5-10 units of enzyme/ml blood (with 16% hematocrit) (see, U.S. Pat. Nos. 5,606,042; 5,633,130; 5,731,426; 6,184,017). The Glycine max α-galactosidase was thus used at 25-50 μg/ml, which represents a significant reduction in enzyme protein quantities required (50-200 fold) (Davis et al., Biochemistry and Molecular Biology International, 39(3): 471-485, 1996). This reduction is partly due to the higher specific activity of the Glycine max α-galactosidase (approximately 6 fold) as well as different methods used for conversion and evaluation. The 200 U/ml enzyme used in the study of Kruskall et al., (Transfusion, 40(11): 1290-8, 2000) was worked out for full unit (approximately 220 ml packed cells) conversions at 80-90% hematocrits and thoroughly analyzed by standard blood bank typing as well as by more sensitive cross-match analysis. Furthermore, the efficiency of conversion was evaluated by analysis of survival and induced immunity in patients receiving multiple transfusions of converted cells. The enzymatic conversions were done in test tubes in ml scale at 16% hematocrit, as described in U.S. Pat. No. 5,606,042 (and 5,633,130; 5,731,426; 6,184,017) with Glycine max α-galactosidase, and the conversion efficiency not evaluated by cross-match analysis. Conversion of cells at 16% hematocrit required 10 U/ml, while conversions at 8% required 5 U/ml, indicating that converting at increased hematocrit requires more enzyme although higher cell concentrations were not tested. Thus, part of the reduction in enzyme protein quantities required compared to protocols reported by Kruskall et al., (Transfusion 2000; 40(11): 1290-8), is related to the concentration (hematocrit) of cells used in conversion, and this may represent more than 5-10 fold, although direct comparison is not possible without further experimentation. The U.S. Pat. No. 5,606,042 (and 5,633,130; 5,731,426; 6,184,017) further provides improvements in the conversion buffer using Na citrate and glycine at less acidic pH (preferably pH 5.8) and including additional protein in the form of BSA (bovine serum albumin) for stabilization. Interestingly, the conversion buffer developed for the Glycine max α-galactosidase was found not to be applicable to Coffee bean α-galactosidase. Although, some improvement in the conversion of B cells may be provided by U.S. Pat. No. 5,606,042 (and 5,633,130; 5,731,426; 6,184,017), it is clear that at least more than 0.5 mg of enzyme is required per ml packed type B red cells using the disclosed protocol. It is likely that considerable more enzyme than this is required to obtain cells fully converted to O cells by the most sensitive typing procedures used in standard blood bank typing protocols. Furthermore, the protocol requires introduction of additional extraneous protein (BSA or human serum albumin) as well as exposing blood products to a significant acidic pH.

[0013] Bakunina *et al.* (Bakunina et al. Biochemistry (Moscow) 1998, p1420) has claimed the identification and isolation of a novel α-galactosidase from the marine bacterium *Pseudoalteromonas* spp. (KMM 701). The isolated enzyme preparation was purified to a specific activity of 9.8U/mg using the substrate pNP-Gal and had an apparent molecular weight by gel filtration of 195kD. The enzyme preparation efficiently cleaved the monosaccharide substrate pNP-Gal with an apparent Km for pNP-Gal of 0.29 mM as well as several unbranched disaccharides with terminal α-galactose including melibiose and Galα1-3Gal, and hence does not show high specificity for blood group B. This enzyme will therefore cleave unbranched oligosaccharides with terminal α-Gal such as the linear B structure as well as the P_1 antigen. The enzyme was reported to have a neutral pH optimum (*i.e.*, a pH optimum ranging from about 6.5 to about 7.7) and to convert blood group B cells with 24 h incubation reaction time to cells typing as group O cells. However, details of the conversion procedure and enzyme consumption were not described, and the efficiency of conversion evaluated by standard typing procedures with licensed typing reagents remains to be tested. Purification to homogeneity, cloning and recombinant expression of the enzyme will likely be required to provide the quantities and quality of enzyme protein required for enzymatic conversion of red cells.

[0014] We have disclosed (U.S.S.N. 10/251,271) the identification and partial characterization of a novel α-galactosidase activity with high specific activity and highly restricted substrate specificity for the blood group B antigen. The enzyme activity was identified by screening more than 2,400 bacterial and fungal isolates and found in only a few bacteria. The enzyme was partly purified from cell lysates of *Streptomyces griseoplanus* strain #2357 (ATCC deposit No. PTA-4077) and partial amino acid sequence information was obtained.

[0015] It is evident from the above that further improvements in conversion of B cells is required in order to make this a practical and commercially applicable technology. Necessary improvements include obtaining more efficient and specific α-galactosidase enzymes, which allow conversion to take place preferable at neutral pH and without extraneous protein added.

ASSAYS TO DETERMINE αGAL CLEAVING GLYCOSIDASE ACTIVITIES:

[0016] Past methods for searching, identification and characterization of exo-glycosidases have generally relied on the use of simple monosaccharide derivatives as substrates to identify saccharide and potential linkage specificity. Derivatized monosaccharide, or rarely oligosaccharide, substrates include without limitation p-nitrophenyl (pNP), benzyl (Bz), 4-methyl-umbrelliferyl (Umb), and 7-amino-4-methyl-coumarin (AMC). The use of such substrates provides easy, fast, and inexpensive tools to identify glycosidase activities, and makes large scale screening of diverse sources of enzymes practically applicable. However, the kinetic properties and fine substrate specificities of glycosidase enzymes may not necessarily be reflected in assays with such simple structures. It is also possible that novel enzymes with high degree of specificity and/or selective efficiency for complex oligosaccharide and unique glycoconjugate structures exists, but that these may have been overlooked and remain unrecognized due to methods of analysis. Thus, in order to identify and select the optimal exo-glycosidase for a particular complex oligosaccharide or glycoconjugate structure it is preferable to use such complex structures in assays used for screening sources of enzymes. Furthermore, preferred assays used for screening include selection for preferable kinetic properties such as pH requirement and performance on substrates, e.g., attached to the membrane of cells.

[0017] In prior studies, all α-galactosidases (EC 3.2.1.22) and α-*N*-acetylgalactosaminidases (EC 3.2.1.49) used for removing the B and A antigens of blood cells had been identified and characterized using primarily p-nitrophenyl monosaccharide derivatives. Interestingly, most of these α-galactosidase and α-*N*-acetylgalactosaminidase enzymes used in past studies are evolutionary homologs as evidenced by significant DNA and amino acid sequence similarities. Thus, the human α-galactosidase and α-*N*-acetylgalactosaminidase are close homologs (Wang et al., J Biol Chem, 265: 21859-66, 1990), and other enzymes previously used in blood cell conversion including the chicken liver α-*N*-acetylgalactosaminidase, fungal acremonium α-*N*-acetylgalactosaminidase, and bacterial α-galactosidases all exhibit significant sequence similarities. Sequence analysis of all known O-glycoside hydrolases have been grouped in 85 distinct families based on sequence analysis, and the above mentioned α-galactosidases and α-*N*-acetylgalactosaminidases are grouped in family 27 (http://afmb.cnrs-mrs.fr/~pedro/CAZY/ghf_32.html). These enzymes are characterized by having a retaining mechanism of catalysis and use aspartic acid as the catalytic nucleophile (Henrissat, Biochem Soc Trans, 26(2): 153-6, 1998 ; Rye & Withers, Curr Opin Chem Biol, 4(5): 573-80, 2000). The primary structure of a bacterial α-*N*-acetylgalactosaminidase from Clostridium perfringens was reported to be dissimilar and non-homologous to eukaryote α-*N*-acetylgalactosaminidases (Calcutt et al. FEMS Micro Lett 214:77-80, 2002), and is grouped in a distantly related glycosidase family 36, which also contains α-galactosidases and α-*N*-acetylgalactosaminidases (http://afmb.cnrs-mrs.fr/~pedro/CAZY/ghf_32.html). The catalytic mechanism of this group of enzymes is predicted to be similar to that of enzymes from family 27 because some sequence similarity exists between enzymes of the two families.

SUMMARY OF THE INVENTION

[0018]   The present invention provides compositions and methods for the specific enzymatic removal of the immuno-dominant monosaccharides specifying the blood group B antigens, namely α1,3-D-galactose, according to the claims.

[0019]   This disclosure provides a novel family of homologous polypeptides, which have 20% or more overall amino acid sequence identity with SEQ NO. 2). These polypeptides exhibit α-galactosidase activity across a neutral pH optimum, and demonstrate high substrate specificity for blood group B or Galilli antigen structures. and no or insignificant activity with αGal or αGalNAc-pNP monosaccharide substrates. Certain members of this family show no or insignificant activity with linear α1-3 linked Gal. Other polypeptides in this family will cleave linear structures, but show no or insignificant activity with P antigens and Galα1-4 linkages. The novel polypeptides and gene family disclosed by the present invention has applications for use in the removal of immunodominant monosaccharides, αGal and Galilli, from complex oligosaccharide targets such as those close to the true A and B carbohydrate antigens of the surface of cells in blood products, and the Galilli antigen from animal tissues.

[0020]   In another aspect, this disclosure provides methods for the sero-conversion of all blood group AB and B red cells, resulting in the removal of immunodominant B antigens from type B and AB cells. The removal of B antigens can be determined, for example by standard blood bank serological typing. According to the methods of this invention, the B antigens are removed using the polypeptides described, that (i) have highly restricted specificity for blood group B antigens, (ii) have optimal performance at neutral pH with blood group oligosaccharides; and (iii) are active in red blood cell conversion at a slightly acidic to slightly basic, and preferably a neutral pH (pH from about 6 to about 8). These methods comprise the steps of: (a) contacting a blood product with one or more of these polypeptides, under approximately neutral pH conditions, for a period of time sufficient to remove the immunodominant B antigens, and (b) removing the polypeptide and digested antigen fragments from the seroconverted blood product.

[0021]   In another disclosure methods for the removal of all detectable B antigens from group B or AB red cells, using α-galactosidases that (i) have highly restricted specificity for blood group B antigens; and (ii) are active in red blood cell conversion with blood group oligosaccharides, over an approximately neutral pH range (pH about 6 to about 8), are provided.

[0022]   In another aspect, there are disclosed sero-converted erythrocytes. The sero-converted erythrocytes are characterized as: (i) having been converted from a type B or type AB erythrocyte to a non-B erythrocyte (having no detectable B antigens, as determined by standard blood bank serological typing) seroconverted using a polypeptide of the family described herein.

[0023]   In yet another aspect, the disclosure includes a modified red blood cell comprising: a group B erythrocyte or a group AB erythrocyte that lacks immunodominant B epitopes but displays α1-4Gal epitopes, including the P1 and P[k] blood group antigens. In one aspect, the blood
cell substantially lacks immunodominant B epitopes as determined by serological typing or hemagglutination assays, and also lacks linear α1-3 linked Gal structures. In another disclosure, the blood cell substantially lacks immunodominant B epitopes as determined by serological typing or hemagglutination assays, but retains linear α1-3 linked Gal structures.

[0024]   In yet another aspect, the disclosure includes a modified red blood cell prepared by the method comprising: obtaining a group B erythrocyte or a group AB erythrocyte, suspending the erythrocyte in a buffer solution having an approximately neutral pH (about pH 6 to about pH 8), and contacting the erythrocyte with an alpha galactosidase polypeptide thereby substantially cleaving from the erythrocyte the immunodominant B epitopes. In various embodiment, the enzyme used to process the erythrocyte includes at least 10 contiguous amino acids of the polypeptide (or the nucleotide sequence encoding same) as specified by: SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, or SEQ ID NO: 8. In certain embodiments, the enzymatic processing of the erythrocyte is performed at from about pH 6.0 to about pH 8.0, preferably about pH 6.5 to about pH 7.5, or more preferably about pH 7.0 to about pH 7.5. In currently preferred embodiments, enzymatic processing of the erythrocyte is performed using 0.01-1000 μg of enzyme per ml blood cells, preferably 0.1-500 μg of enzyme per ml blood cells, more preferably 1-100 μg of enzyme per ml blood cells. Most preferably enzymatic processing of antigens from the erythrocyte preparation is accomplished using 1-10 μg enzyme/ml blood cells.

[0025]   In one aspect, the invention includes a method of preparing a modified red blood cell, comprising: obtaining group B or group AB erythrocytes, suspending them in a buffer solution having an approximately neutral pH, and contacting it with an enzyme of the polypeptide sequence specified as SEQ ID NO: 8, thereby cleaving the immunodominant B epitopes on the group B or group AB erythrocyte as determined by serological typing or hemagglutination assays. The blood cell substantially lacks immunodominant B epitopes as determined by serological typing or hemagglutination assays, and also lacks linear α1-3 linked Gal structures, or the blood cell substantially lacks immunodominant B epitopes as determined by serological typing or hemagglutination assays, but retains linear α1-3 linked Gal structures.

[0026]   In yet another aspect, the disclosure includes a method of treating a subject, comprising: identifying a subject in need of type A, O or AB blood, the subject being seropositive for anti-B antibodies; obtaining a modified blood cell preparation of seroconverted B cells, or obtaining the same by the methods described herein, and; transfusing the

modified blood cell preparation into the subject, wherein the subject does not immunologically reject the transfused blood cells.

[0027] In another aspect, the invention includes use of a purified polypeptide, the polypeptide having the sequence:

SEQ ID NO: 8, wherein the enzyme displays α3 galactosidase activity. In certain disclosures, the purified enzyme, comprises: a polypeptide having at least 10 amino acids of the following sequence numbered accordingly when aligned with SEQ ID. NO:2: M at residue 10; G at residue 47; G at residue 84; Y at residue 86; Y at residue 99; N at residue 102; K at residue 114; T at residue 127; G at residue 130; G at residue 132; G at residue 139; N at residue 156; D at residue 160; P at residue 164; G at residue 205; R at residue 277; R at residue 281; F at residue 287; G at residue 308; Q at residue 312; I at residue 317; R at residue 333; D at residue 340; G at residue 346; G at residue 349; G at residue 360; D at residue 363; D at residue 364; N at residue 367; H at residue 369; G at residue 370; T at residue 371; G at residue 396; E at residue 462; N at residue 463; T at residue 465; T at residue 467; P at residue 468; R at residue 483; G at residue 484; L at residue 486; T at residue 489; N at residue 498; I at residue 508; D at residue 513; W at residue 517; E at residue 519; G at residue 521; D at residue 525; I at residue 528; N at residue 531; F at residue 533; I at residue 549; P at residue 553; I at residue 573; A at residue 590; G at residue 595; N at residue 601; and, I at residue 629; where the polypeptide has at least 20% identity with SEQ ID NO: 2, and where the polypeptide also has α3 galactosidase activity. In one disclosure, the polypeptide demonstrates specificity for branched alpha galactose structures but not linear alpha galactose structures. In another disclosure, the polypeptide demonstrates specificity for linear alpha galactose structures but not α1-4 gal structures. In one disclosure, the purified enzyme comprises a polypeptide including nine contiguous amino acids having the sequence DD(P/A)(V/I)N(V/I)HGT (SEQ ID NO: 10). In another disclosure, the purified enzyme comprises a polypeptide including twenty-one contiguous amino acids having the sequence:

DXXXW(Y/F)E(S/T)GXXXD(L/V)(L/T)I(K/R)XNXF, (SEQ ID NO: 11) where X can be any amino acid. In one disclosure, the purified enzyme includes functional equivalents thereof having α3 galactosidase activity. In certain disclosures, the polypeptide includes a truncated variant lacking a signal sequence.

[0028] In another aspect, the invention includes a method of producing an α-galatosidase comprising the sequence of SEQ ID NO:8, comprising: obtaining a nucleic acid encoding: or SEQ ID NO: 8; expressing the nucleic acid in a cell transfected therewith; to obtain an expressed enzyme and purifying the expressed enzyme from the cell. In various disclosures, the invention includes a non-naturally occurring prokaryotic cell, comprising: an expression vector not found in a wild-type prokaryotic cell, the expression vector having a nucleic acid sequence encoding a polypeptide having the sequence specified by: SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, or SEQ ID NO: 8. It will be appreciated that due to the degeneracy of the genetic code, the recombinant enzyme can be optimized for expression in the particular host organism, as is generally known to those skilled in the art.

[0029] The invention relates to a family of α-galactosidases, and more particularly to the use of these to catalyze the removal of substantially all of the immunodominant B antigens on B and AB erythrocytes. The most preferred α-galactosidases are those that are active at a neutral pH, and catalyze removal of the immunodominant B antigens on B and AB erythrocytes and not other lipid-linked straight-chain carbohydrate αGal epitopes such as, P1 antigen (Gal α1,4 Gal β1,4 GlcNAc β1,3 Gal β1,4 Glc β1 ceramide) and Pk antigen (Gal α1,4 Gal β1,4 Glc β1 ceramide, also known as globotriosylceramide (Gb3Cer)/CD77). Particular α-galactosidases from this family are described below as, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, the fragment SEQ ID NO: 1 and the consensus sequence of SEQ ID NO: 9.

[0030] In yet another aspect, this disclosure provides methods for the screening and selection of enzymes with the above described preferred unique characteristics and methods of purification and amino acid sequencing useful for cloning and expression of the genes encoding these enzymes. These methods provide for bacterial isolates producing such preferred enzymes. Such other applications and features of the invention will be apparent from the detailed description that follows.

[0031] In yet another aspect, this invention provides compositions and methods for the enzymatic removal of the immunodominant monosaccharides on tissues, such as a tissue for xenotransplantation. Specifically the present invention provides a novel family of α3-glycosidases (as described above), used for the enzymatic removal of the Galili antigen from non-human animal tissues, thereby converting these to non-immunogenic tissues suitable for transplantation. Examples of an α3-galactosidase include, but are not limited to, of any of SEQ ID NO: 2-9.

[0032] The method of preparing a tissue for xenotransplantation comprises incubating tissue to be obtained from a non-human animal source with a polypeptide having the sequence specified by SEQ ID NO:8 thereby removing immunodominant α1-3 linked terminal galactose residues from the tissue, and isolating the tissue from the polypeptide and the enzymatically removed galactose, thereby rendering the tissue suitable for xenotransplantation into humans. In one embodiment, the tissue from a non-human animal source is porcine connective tissue. In another embodiment, the

porcine connective tissue is a ligament.

[0033]   In another embodiment, the tissue from a non-human animal source is an organ including liver, kidney, or heart. In yet another embodiment, the tissue from a non-human animal source is non-immunogenic injectable collagen; bone xenografts; soft tissue and proteoglycan-reduced soft tissue xenografts; xenograft heart valves; meniscal xenografts; and tissue matrices, wherein the tissues are α1,3-galactose-deficient tissues that have been modified using an the polypeptide of any of SEQ ID NO: 8.

BRIEF DESCRIPTION OF THE **DRAWINGS**

[0034]

FIG. 1 illustrates HPTLC analysis of α-galactosidase activity in the culture supernatant of *Streptomyces griseoplanus* grown in rich media (See Table II for formulations) with the AMC labeled blood group B tetrasaccharide substrate. The fermentation was carried out in for 1 day in YM and 3 days in BP media, at 30 °C, 220 rpm. Assays were performed by mixing equal volumes of the culture supernatant and 0.1 mM B-tetra in 100 mM NaPO4 (pH 6.8), and incubated at room temperature for 1 hr. One μL was sampled from each reaction and quickly applied onto HPTLC. Designations: NE, no enzyme control; Ctrl, positive control reaction by using Coffee bean α-galactosidase; CS, culture supernatant of *S. griseoplanus;* S, substrate, *i.e.,* B tetrasaccharide; B-tetra, B tetrasaccharide; H-tri, H trisaccharide; Origin: the position in HPTLC where samples were applied. The TLC plate was developed in chloroform-methanol-water (vol/vol/vol: 60/35/8). The plate was scanned and photographed by a Bio-Rad Fluor-S MultiImager with Quantity One - 4.1.1 software.

FIG. 2 illustrates a HPTLC analysis of enzyme assays of *Streptomyces griseoplanus* culture supernatants, recovered from cultures grown in minimal media with 18 different carbon sources, with the AMC labeled blood group B tetras-accharide substrate. Assays were performed by mixing equal volumes of each culture supernatant and 0.025 mM B-tetra in 100 mM NaPO4 (pH 6.8), and incubated at room temperature. One μL was sampled from each reaction at 1 hr and spotted onto TLC plate. The carbon sources, indicated by number 1-18 at the top of the panel, are 18 different sugars used in the fermentation as shown in Table III. Designations: B-tetra: B tetrasaccharide, the substrate; H-tri: H trisaccharide, the product of the B-tetra substrate by α-galactosidase cleavage (The fast moving products above H-tri indicate the presence of fucosidase and β-galactosidase in the culture supernatants that cause further degradation of H trisaccharide into di- and monosaccharrides). Fermentations: Cryostocks of *Streptomyces grise-oplanus* were thawed and inoculated into YM (~1:5-10, v/v) and incubated at 30°C, 220 rpm, for 24 hrs. The culture was passed onto BP media (~1:20, v/v) and fermentation was continued for 72 hrs. The mycelia, harvested from 100 mL of BP culture by centrifugation, were washed 3 times using basal minimal media (the minimal media lack of carbon source and trace metal/vitamin additives) to eliminate the rich media as much as possible. The pellet was then re-suspended in 100 mL of 2X basal minimal media with additives. The mycelia suspension was then aliquoted into 50 mL conical tubes at 2.5 mL/tube. Different carbon sources and water were then added to a final concentration of 0.5% and a final volume of 5.5 mL. Each carbon source was tested in duplicate. The 36 cultures of 5.5 mL of each, with 18 different carbon sources were incubated at 30 °C, 220 rpm. Aliquot of 0.16 mL of culture was sampled from each tube at 43 and 71 hours.

FIG. 3 illustrates an HPTLC analysis of enzyme assays of culture supernatant of *Streptomyces griseoplanus* grown in minimal media with either galactose or lactose as the sole carbon source with the AMC labeled blood group B tetrasaccharide substrate. Assays were performed by mixing equal volumes of each culture supernatant and 0.1 mM B-tetra in 100 mM NaPO4 (pH 6.8), and incubated at room temperature. One μL was sampled from each reaction at 20 min and applied onto a HPTLC plate for analysis. Designations: B-tetra: B tetrasaccharide, the substrate; H-tri: H trisaccharide, the product of the B-tetra substrate by α-galactosidase cleavage (The fast moving products above H-Tri indicate the presence of fucosidase and β-galactosidase in the culture supernatants that cause further degradation of H-Trisaccharide into di- and monosaccharrides); Carbon source: #4, galactose; #7, lactose; NE, no enzyme control; Ctrl, positive control reaction by using Coffee bean α-galactosidase.

FIG. 4 illustrates an HPTLC analysis of the enzyme assay of α-galacotosidase activity in the protein solution after passing CEX or DEAE column with B-tetra substrate. About 450 ml of *Streptomyces griseoplanus* supernatant, harvested from 800 mL of culture in an 1 liter fermenter fermentation grown in minimal media with galactose, stored frozen at -80°C, was thawed at for 24 hrs at 4°C and centrifuged for 30 min at 4°C, 20,000 rpm. The recovered supernatant was passed through a 15 mL cation exchange chromatography column (CEX) (Macro-Prep High S Support, BioRad, Cat. #156-0031), pre-equilibrated with 40 mM NaPO4, 10 mM NaCl (pH 6.8). The flowthrough containing the enzyme activity was collected. The column was washed sequentially with 40 ml of equilibration buffer,

40 mL of the same buffer with a slightly increased pH (7.3). The flowthrough and washes were pooled and loaded directly onto a 2.5 mL DEAE column (DEAE Sepharose, Sigma, Cat. # DEF100) pre-equilibrated with CEX equilibration buffer and the flowthrough was collected. The column was washed with 50 ml of CEX equilibration buffer to remove the residual enzyme from the column. The pooled protein solution of DEAE flowthrough and wash (-600 mL) was concentrated using Centricon Plus 80 Centrifugal filter devices (Millipore Cat.#UFC5LGC02) and buffer-exchanged into 10 mM NaPO4 (pH 7.0) in the same device to a final volume of 23 mL.

FIG. 5 illustrates HPTLC analysis of α-galacotosidase activity in various fractions from Hydroxyapatite step with B-tetra substrate. The protein sample in 10 mM NaPO4, pH 7.0, was loaded onto a 2.5 mL Hydroxyapatite column (Bio-Gel HT Hydroxyapatite, Bio-Rad Cat. # 130-0150), pre-equilibrated with 10 mM NaPO4 (pH 7.0). The column was washed with equilibration buffer and washed/eluted stepwisely with increasing amount of NaPO4 (10 to 100 mM). No activity can be detected in the flowthrough, indicating the effective binding of the enzyme to the column in the presence of 10 mM NaPO4 (pH 7.0). The appearance of enzyme activity in 30 mM NaPO4 wash and nearly complete lack of activity in 100 mM NaPO4 wash indicate simple elution of the enzyme from the Hydroxyapatite column just by using 30-50 mM NaPO4 (pH 7.0). Designations: Pre, protein solution before being loaded onto the column; FT, flowthrough.

FIG. 6 illustrates HPTLC analysis result of α-galacotosidase activity in fractions from Cibacron Blue 3GA step with B-tetra substrate. The pooled activity fractions from Hydroxyapatite step was diluted 1:1 with H2O and applied onto a 2.5 mL of Cibacron Blue column (Cibacron Blue 3GA, Sigma, Cat. # C-1285), equilibrated with 10 mM Tris (pH 7.5). The column was washed with the equilibration buffer and further washed/eluted with equilibration buffer with increased amount of salt as indicated at the bottom of the panel. The enzyme activity was distributed between 100 and 400 mM NaCl washes. Designations: Pre, protein solution before being loaded onto the column; FT, flowthrough.

FIG. 7 illustrates HPTLC analysis of α-galacotosidase activity in various fractions from AEX step with B-tetra substrate. The pool of enzyme activity fractions from Cibacron Blue was concentrated and buffer-exchanged into 40 mM Tris, 10 mM NaCl (pH 8.5), to a final volume of 3.7 mL. The protein solution was loaded onto an 1 mL of AEX column (Macro-Prep High Q Support, Bio-Rad Cat. # 156-0051), pre-equilibrated with 40 mM Tris, 10 mM NaCl, pH 8.5. The column was first washed with equilibration buffer and then washed/eluted with the same buffer containing increasing amount of salt as indicated at the bottom of the panel. Designations: Pre, protein solution before being loaded onto the column; FT, flowthrough; Washes/Elutes, column wash and/or elution samples; [NaCl] (mM), the salt concentration in the wash/elution buffer; Fraction #, fractions collected in each wash/elution step; B-tetra, B tetrasaccharide, the substrate; H-tri, H trisaccharide, the product (the faster moving product above H-tri indicates the presence of contaminating fucosidase activity in the protein sample that cause further degradation of H trisaccharide into disaccharride).

FIG. 8 illustrates a SDS-NuPAGE (Novex 4-12% Bis-Tris Gel with MOPS buffer, stained with SilverQuest Silver Staining kit, Mark12 Unstained Standard, all Invitrogen products) analysis of *Streptomyces griseoplanus* α-galactosidase activity purified by AEX. The HPTLC analysis of enzyme assays of fraction #3 of the wash/elution sample at each salt concentration in the AEX step as shown in FIG. 7, was placed at the top of the gel for easy comparison of the enzyme activity and protein band (s) on the gel. A single protein band, ∼ 70 kDa, indicated by an arrow at right side of the panel labeled with putative α-galactosidase, is shown in the peak α-galactosidase activity. Designations: B-tetra, B tetrasaccharide, the substrate; H-tetra, H trisaccharide, the product.

FIG. 9 illustrates comparative analyses of S12 chromatography fractions of partially purified *Streptomyces griseoplanus* α-galactosidase by SDS-NuPAGE and enzyme activity assay using B tetrasaccharide, analyzed by HPTLC. The putative 70 kD α-galactosidase band is indicated by an arrow at right side of the panel using Rainbow Molecular Weight Marker (Amersham, Cat. # RPN800). Designations: Ctrl, NEB A-zyme of known concentration; B-tetra, B tetrasaccharide, the substrate; H-tri, H trisaccharide, the product.

FIG. 10 illustrates the alignment of the peptide obtained by Edman sequencing of HPLC fractionated trypsin digest of a novel *Streptomyces griseoplanus* α-galactosidase (SEQ ID NO: 1), with a hypothetical protein from *Streptomyces avermitilis* (GenBank access # BAC74979.1, GI:29610934, SEQ ID NO: 2). The amino acids in SEQ ID NO: 2 that correspond to those of SEQ ID NO: 1 are underlined. The alignment was obtained by blast analysis of the peptide using "search for short, nearly exact matches" against NCBI nr database [(Score = 51.5 bits (114), Expect = 3e-06; Identities = 18/29 (62%), Positives = 24/29 (82%), Gaps = 0/29 (0%)]. The amino acid sequence is shown in a single-letter code. The identical residues are indicated by bold capital letters, similar residues by plain bold letters, and different residues by small letters.

FIG. 11 illustrates an HPTLC analysis of enzyme assays of culture supernatant and pellet lysate of *Streptomyces avermitilis* grown in YM media (See Table II for formulations) with the AMC labeled blood group B tetrasaccharide and 4-methylumbelliferyl α-D-galactopyranoside (α-Gal pNP) substrates. The fermentation was carried out in for 3 days at 30°C, 220 rpm. Assays were performed by mixing equal volumes of the culture supernatant and 0.1 mM B-tetra or 0.5 mM of α-Gal pNP in 100 mM NaPO4 (pH 6.8) and incubated at room temperature overnight. One μL was sampled from each reaction and quickly applied onto HPTLC. Designations: NE, no enzyme control; Ctrl, positive control reaction by using Coffee bean α-galactosidase; CS, culture supernatant of S. *avermitilis;* PT, pellet lysate; B-tetra, B tetrasaccharide; H-tri, H trisaccharide; MU, 4-methylumbelliferone, the cleavage product of α-Gal pNP; Origin: the position in HPTLC where samples were applied. The TLC plate was developed in chloroform-methanol-water (vol/vol/vol: 60/35/8). The plate was scanned and photographed by a Bio-Rad Fluor-S MultiImager with Quantity One -4.1.1 software.

FIG. 12 illustrates protein sequence alignment of the putative novel α-galactosidase from *Streptomyces avermitilis* (SEQ ID NO: 2) with a number of the first protein hits of unknown functions by blasting SEQ ID NO: 2 against NCBI nr databases. The alignment was performed using CLUSTALW multiple alignment (NPS@: Network Protein Sequence Analysis, TIBS 2000: 25;147-150, Combet C., Blanchet C., Geourjon C. and Deléage G.). Alignment data: Alignment length : 665; Identity (*) : 59 is 8.87 %; Strongly similar (:) : 86 is 12.93 %; Weakly similar (.) : 42 is 6.32 %; Different: 478 is 71.88 %. The sequences are as follows: SA (625 residues SEQ ID NO: 2); BTα (568 residues SEQ ID NO: 3); BFα1 (605 residues SEQ ID NO: 4); BFα2 (605 residues SEQ ID NO: 5); BFβ1 (595 residues SEQ ID NO: 6); BFβ2 (595 residues SEQ ID NO: 7); BTβ (615 residues SEQ ID NO: 8). SEQ ID NO: 9 is a consensus sequence of the sequences SEQ ID NOs: 2-8. Designations: SA, BT and BF, the putative α-galactosidases from *Streptomyces avermitilis* MA-4680, Bacteroides thetaotaomicron VPI-5482 and Bacteroides fragilis, respectively; α and β: 2 different copies of α-galactosidases from B. thetaotaomicron VPI-5482; α1 and β1: 2 different copies of α-galactosidases from B. fragilis YCH46; α2 and /β2: two different copies of α-galactosidases from *B. fragilis* NCTC 9343.

FIG. 13 illustrates an HPTLC analysis of the enzyme activities, of whole cell lysates of the cell pellet from IPTG induced cultures of *E, coli* clones (containing plasmids expressing the recombinant α-galactosidase gene from *Streptomyces avermitilis)*, with the AMC labeled blood group B tetrasaccharide substrate. One mL of TB medium with antibiotics (48.2 g of EZmix Terrific Broth, Sigma T-91790, 8 mL of glycerol, 34 mg of Chloamphenicol, and 30 mg of Kanamycin per liter medium) was added to each 1.5 mL microtube containing the agar plug carrying a single colony. The cap was closed and incubation was performed overnight at 37°C, 250 rpm. One half mL of an overnight culture was inoculated into 10 mL of medium in a 50 mL conical tube and the incubation was carried under the same conditions. The cell density reached 0.3-0.6 OD600nm in about 2 hrs at 220 rpm. The culture was removed from the shaker and kept at room temperature for -20 min. Meanwhile, the temperature of the incubator was lowered to ~26°C. IPTG was then added to each culture at a concentration of 0.1 mM and all cultures were re-placed in the shaker and agitated at 220 rpm, to start protein induction. A 0.5 mL aliquot was removed aseptically from each tube in 1 hr and the cells pelleted with a bench top centrifuge at the highest setting for 5 min. Twenty μL of lysis buffer (0.9 mL of 40 mM NaPO4, 10 mM NaCl, pH 6.8, 0.1 mL of BugBuster 10X, Novagen 70921-4, 1 mg lysozyme/mL, and 5 μL of benzonase, Novagen 70664-3, per milliliter lysis buffer) was added to each tube to suspend the pellet and lyse the cells, which was assisted by pipetting the suspension up and down a few times. The lysis was completed in 5-10 min. An aliquot (2.2 μL) of the crude whole lysate was analyzed subsequently by mixing with equal volume of a substrate solution containing 0.1 mM of B-tetra in 100 mM NaPO4 (pH 6.8) and incubated at room temperature. One μL of the digestion was removed in 10 min and spotted onto a HPTLC plate. Designations: Ctrl, positive control reaction by using Coffee bean α-galactosidase; 1 and 2: whole lysates from two individual colonies of the same construct expressing the full length novel galactosidase from *Streptomyces avermitilis;* B-tetra, B tetrasaccharide; H-tri, H trisaccharide; Origin: the position in HPTLC where samples were applied. The TLC plate was developed in chloroform-methanol-water (vol/vol/vol: 60/35/8). The plate was scanned and photographed by a Bio-Rad Fluor-S MultiImager with Quantity One -4.1.1 software. FIG. 14 confirmed that the novel B-zyme can be efficiently expressed in *E, coli,* but as inclusion bodies. Therefore, expression needs to be optimized or an efficient refolding method needs to be developed for the application of this novel B-zyme.

FIG. 14 illustrates a SDS-NuPAGE analysis of α-galactosidase (SEQ ID NO: 2) expressed in *E. coli* (Novex 4-12% Bis-Tris Gel with MOPS buffer, stained with Colloidal Blue Staining kit, Mark12 Unstained Standard, all Invitrogen products). The lystate from each culture was prepared similarly as described in FIG. 13 legend with an increased scale. An aliquot of the each whole lysate was centrifuged at 14,000 g for 5 min. at RT. The supernatant was removed. Twelve μL of whole lysate or supernatant was mixed with 4 μL of 4X LDS buffer, supplemented 10% (v/v) β-mecaptoethanol. The pellet was suspended in 1 X LDS sample buffer, supplemented with 2.5% (v/v) β-mecap-

toethanol, at a ratio of 16 μL sample buffer / 12 μL of whole lysate. All samples were heated at 70°C for 10 min for SDS-NuPAGE analysis. Designations: WL, whole lysate; Sup, supernatant; PT, pellet; U, sample prepared from un-induced culture; I, sample prepared from induced culture.

FIG. 15 illustrates Multiple ClustalW (BoxShade 3.21) protein sequence alignment of the putative novel α-galactosidase family to identify conserved regions for the design of degenerate primers. Identical residues and conserved substitutions are highlighted in black and dark gray. The aligned sequences are from *S. avermitilis* MA-4680, B. thetaiotaomicron VPI-5482 and *B. fragilis* NCTC 9343. The two sequences from B. fragilis YCH624, nearly identical to those from *B. fragilis* NCTC 9343, are not included. The conserved regions used to design a pair of degenerate primers to clone the partial α-galactosidase gene from *S. griseoplanus* 2357 are indicated with a forward arrow for forward primer and backward arrow for reverse primer.

FIG. 16 illustrates protein sequence of a S. *griseoplanus* α-galactosidase highlighting the regions corresponding to the primers used for cloning. The forward and reverse primers are colored dark and light gray respectively. Degenerate primers are underlined.

FIG. 17 illustrates a HPTLC analysis of enzyme assays of purified recombinant FragB α-galactosidase with a panel of oligosaccharides of diverse structures. Reactions were performed at room temperature with 10 nmole of substrate and 21 ng of enzyme in 10 μL of 10 mM NaPO4, pH 6.8/2.5 mM NaCl, supplemented with 0.25 mg/mL of BSA. One μL of enzyme assays was removed at desired time points and spotted onto a silica gel-coated TLC plate (EMD Chemicals, NJ), which was developed in chloroform-methanol-water (vol/vol/vol: 30/60/10) for 15 min and product developments were detected by Orcinol/H_2SO_4 staining. Designations: Reaction time for each substrate from left to right: 0 (sampled from control reaction containing no enzyme), 5, 10, 20, 40 and 80 min. Detailed structures of the substrates are described in Table V. The cleavage of the substrate resulted increased migration as observed for B-tri, B-di and linear B, but not for P_1, P^k and A-tri, indicating the lack of cleavages.

FIG. 18 illustrates a HPTLC analysis of enzyme assays of purified recombinant FragB B-zyme with AMC-B-tetra under different pH. Reactions were performed at room temperature with 1 nmole of substrate and ~8 ng of enzyme in 10 μL of buffer at pH 2.0 to 9.0, supplemented with 0.25 mg/mL of BSA. One μL of enzyme assays was removed at desired time points and spotted onto a HPTLC plate, which was developed in chloroform-methanol-water (vol/vol/vol: 60/35/8). The plate was scanned and photographed by a Bio-Rad Fluor-S Multilmager with Quantity One - 4.1.1 software. The 1 X buffers used in the reactions were derived from 2 X buffers described as follows: pH 2.0, 0.1 M citric acid; pH 2.5 - 5.5, 0.1 M citric acid/0.2 M Na2HPO4; pH 6.0-7.5, 0.2 M NaH2PO4/0.2 M Na2HPO4; pH 8.0-9.0, 0.2 M Tris/HCl. Assay mixtures were sampled at 5 (top panel) and 10 min (bottom panel). Designations: B-tetra, B tetrasaccharide; H-tri, H trisaccharide; Origin: the position in HPTLC where samples were applied.

FIG.19. illustrates the analysis of the enzyme activity under different pH using chromogenic para-nitrophenyl derivative, Galα-pNP. Assays were carried out by using 2.5 mM substrate, 8.5 μg enzyme in 400 μl of buffers between pH 2.0 - 9.0 as described in the legend of FIG.17, at 26°C for 5 min, terminated with 600 μL of 1.0 M Na_2CO_3 and, read at 405 nm. A molar extinction coefficient of 18,300 was used to calculate the amount of released nitrophenol. One unit was defined as the amount of enzyme required to cleave 1 μmole of substrate per minute under the experimental condition. The specific activity at each pH was then calculated and plotted versus pH.

FIG. 20 illustrates the substrate specificity of Bacteroides fragilis α-galactosidases. Enzyme assays were carried out without enzyme (-) and with ~30 ng enzyme (+), -1.0 mM substrate in 10 μL of 10 mM NaPO$_4$, pH 6.8, 2.5 mM NaCl, supplemented with 0.25 mg/mL BSA. Reactions were monitored by TLC during incubation at 26°C and the 2 hr time point is shown. Cleavages of the branched blood group B trisaccharide (B-tri) to the H disaccharide (H-di) by BFα2 (FragA) α-galactosidase, and all B structures by BFβ1 (FragB) α-galactosidase, were complete within 5-20 min (not shown), whereas no cleavage of other oligosaccharide substrates were detected after 2 hr incubation. The TLC plates were developed in chloroform/methanol/water (30/60/10, v/v/v) for 15 min and stained by heating with 0.05% Orcinol in 0.5M H_2SO_4.

DETAILED DESCRIPTION OF THE INVENTION

[0035]   This invention is directed to the development and application of a screening and selection strategy for novel α-galactosidases with preferred specificities for the blood group B structures, and with preferred performance in the enzymatic conversion of blood products and animal tissues, over an approximately neutral pH range. Table 1 lists the complex structures of antigens found on blood cells.

[0036] For the purpose of this invention, blood group B active oligosaccharide derivatives were synthesized or produced by enzymatic removal of αGal from various substrates. Furthermore, glycosphingolipids with structures 3, 6, 21, and 25 were purified from human erythrocytes or produced therefrom by glycosidase treatments as previously described (Clausen et al., Proc. Natl. Acad. Sci. USA 82(4): 1199-203, 1985, Clausen et al., J Biol Chem. 261(3): 1380-7, 1986, Clausen et al., Biochemistry 25(22): 7075-85, 1986, Clausen et al., J Biol Chem. 262(29): 14228-34, 1987). Thin-layer chromatography assays to quantitatively determine removal of αGal or αGalNAc from the AMC derivatives or glycosphingolipids were developed.

[0037] Preferred α-galactosidases have high substrate specificity for blood group B branched saccharide structures, a generally neutral pH optima and can be produced cost-effectively as recombinant proteins in unicellular organisms such as bacteria and yeast. Our prior patent application (U.S.S.N. 10/251,271 developed a screening assay for the preferred enzyme activities using B tetrasaccharide AMC derivative substrates, and measured enzyme activities at neutral pH. Further, activities were compared to activities using p-nitrophenyl monosaccharide derivatives in order to identify activities with preference or exclusivity for the complex substrates. In that application, we disclose the use of this screening assay on a large panel of bacterial and fungal isolates (3100), and therein we identified several bacterial isolates expressing α-N-acetylgalactosaminidase or α-galactosidase activities measured with A or B tetrasaccharide AMC substrates, but no or insignificant levels of activity with the corresponding p-nitrophenyl monosaccharide substrates. One of each of these activities was further analyzed after sero- and genotyping these as Streptomyces strains. Analysis of strain #8 was determined to have α-N acetylgalactosaminidase activity revealed that the activity was insoluble and was associated with the cell mass. Strain #8 was deposited on February 14, 2002 with the American Type Culture Collection (ATCC) and has been assigned ATCC Deposit No. PTA-4076. In contrast, strain #2357 was determined to have α-galactosidase activity, and the activity was determined to be soluble, found in the supernatant of transformed cells lysed by French press. Strain #2357 was deposited on February 14, 2002 with the American Type Culture Collection and was assigned ATCC Deposit No. PTA-4077. Because it is considerable simpler to purify a soluble protein, we chose to initially purify and sequence the protein from strain #2357.

[0038] The enzyme that we found in the soluble fraction of strain #2357 was partially purified. Detailed analysis of the substrate specificity of the partially purified α-galactosidase demonstrated an unprecedented fine specificity for the branched B blood group structures, but no linear structures capped by α1-3 or α1-4 galactose residues were cleaved by this enzyme. Analysis of its pH optimum showed the preferred conditions to be pH 5.5 to 7.0. The identified α-galactosidase activity is therefore highly preferred over enzymes known in the prior art due to its restricted substrate specificity, high specific activity for group B structures, and pH optimum. SDS-PAGE analysis of the resulting partially purified crude extract revealed 3-4 protein bands in the 40-80 kDa region having the α-galactosidase activity. Gel filtration analysis of the preparation showed the activity migrated comparable to BSA, indicating a globular protein having a molecular weight of about 40-80 kDa. A single short sequence was obtained:

Phe-Ala-Asn-Gly-Leu-Leu-Leu-Thr(SEQ ID NO: 1).

[0039] Subsequent to these studies, and as disclosed in the present invention, we have discovered a new family of polypeptides, having α-galactosidase activities, and have developed methods for their induction, purification, sequencing and cloning. As discussed below, the polypeptide family is distinct from the previously partially purified protein from strain #2357, and notably these family members do not contain the sequence shown as SEQ ID NO: 1. The new induction strategy involves growth of the appropriate bacterium on defined carbon sources and minimal medium, which results in a significant increase in production of the α-galactosidase polypeptides. Known α-galactosides (generally having an acidic pH optimum and substrate specificity for Galα-pNP or other simple monosaccharides) are not secreted in griseoplanus and related Streptomyces strains under the same growth conditions that produces these novel polypeptides.

[0040] The present invention therefore provides a novel method for the recombinant expression and purification of certain α-galactoside polypeptides. This purification strategy applied in combination with the novel growth and induction methods resulted in successful purification to apparent homogeneity of the α-galactosidase polypeptides in sufficient quantities for amino acid sequencing, and blood product and tissue conversions.

[0041] The following successive steps were used to achieve purification to apparent homogeneity: cell broth supernatant derived from cultures of S. *griseoplanus* #2357 was first passed unbound successively though CEX and DEAE columns (FIG. 4). Subsequently the activity was bound and eluted successively on a Hydroxyapatite column (FIG. 5), a Cibacron Blue column (FIG. 6), and finally an AEX column (FIGs. 7 and 8). Throughout the purification scheme the protein was followed by an analysis of its enzymatic activity in various fractions; the final protein product was also analyzed by SDS-NuPAGE. Identification of the α-galactosidase protein was obtained by comparison of protein banding pattern by SDS-NuPAGE silver staining and AEX and S12 gel filtration chromatographies (FIGs. 8-9). Only one band migrating as 70 kD by SDS-NuPAGE and S12 gel filtration, corresponded with the observed α-galactosidase activity. The protein identified as described, was finally separated by NuPAGE gel electrophoresis and the Coomassie stained 70 kD band was cut out of the gel and submitted for amino acid sequence analysis. Internal amino acid sequence

information was obtained by mass spectrometric analysis (MALDI-TOF) and Edman degradation after trypsin digestion. None of the short sequences obtained showed high degree of identity with known sequences in public databases (GenBank). A Blast database search of a 30 amino acid peptide (the longest peptide sequence obtained by internal sequencing and confirmed by MS/MS, using "Search for short, nearly exact matches") identified a putative open reading frame predicted to encode a protein (SEQ ID NO: 2) from the genome sequence of *Streptomyces avermitilis* (GenBank access # BAC74979.1, GI:29610934). The complete genome of *Streptomyces griseoplanus* is not available and no related sequences derived from this genus were identified in database searches. *Streptomyces avermitilis* and *Streptomyces griseoplanus* are closely related. We therefore tested if *Streptomyces avermitilis* also contained the identified α-galactosidase activity, which was previously demonstrated to be very rare among bacterial isolates including many *Streptomyces* isolates.

[0042]   *Streptomyces avermitilis* (ATCC 31267) culture supernatant was assayed for secreted α-galactosidase and as shown in FIG. 11, clear evidence of the presence of α-galactosidase activities in both culture supernatant and pellet lysate was observed, as determined by digestion of B-tetra oligosaccharide substrates. However, the cleavage of a simple substrate (α-Gal pNP) by the secreted *Streptomyces avermitilis* α-galactosidase was negligible. In contrast, complete cleavage of α-Gal pNP was observed for the *Streptomyces avermitilis* α-galactosidase obtained from the cellular fraction. Therefore, the secreted and cellular α-galactosidases are probably not of the same identities. Part of the secreted galactosidase is likely to be the novel α-galactosidase that prefers branched substrate to simple (linear) substrates, while most of the cellular α-galactosidase activities if not all are observed to have conventional glycosidase activities. The similarities of the polypeptide from S. *avermitilis* (SEQ ID NO: 2) to the α-galactosidase from S. *griseoplanus* with respect to secretion into culture broth, predicted molecular weight, and the sequence similarities with S. *griseoplanus,* indicates that the S. *avermitilis* protein represents a homologue of the originally identified S. *griseoplanus* derived α-galactosidase.

[0043]   The identified from S. *avermitilis* polypeptide (SEQ ID NO: 2) consists of 625 amino acids and showed no significant similarity to any other known proteins. Back searches with SEQ ID NO: 2 identified several novel protein sequences (SEQ ID NO: 3-8) from exclusively prokaryotic genomes, with sequence similarities shown as follows in Table 1A:

Table 1A

Identity (overall %) of *Bacteroides* α-Galactosidases to the *S. avermitilis* Enzyme.				
SEQ ID NO.	GI NO.	Abbr.	Amino Acids	Identity to SA (%)
2	gi|29833810|ref|NP-828444.1| S. *avermitilis*	SA	625	100
3	gi|29340474|gb|AAO78266.1| Bacteroides thetalotaomicron VPI-5482	BTα	568	30.35
4	gi|53715733|ref|YP_101725.1| Bacteroides fragilis YCH46	BFα1	605	30.23
5	gi|60495103|emb|CAH09922.1| Bacteroides fragilis NCTC 9343	BFα2	605	29.30
6	gi|60491830|emb|CAH06588.1| Bacteroides fragilis NCTC 9343	BFß1	595	24.30
7	gi|53712216|ref|YP_098208.1| Bacteroides fragilis YCH46	BFß2	595	24.30
8	gi|29341569|gb|AAO79356.1| Bacteroides thetaiotaomicron VPI-5482	BTß	615	22.82

[0044]   All polypeptides identified were analyzed by multiple sequence alignments as shown in FIG. 12; a consensus sequence is provided as SEQ ID NO: 9. These polypeptides represent a new family of novel α-galactosidases, that have unique substrate specificity described in more detail below, and having the common feature of an approximately neutral pH optima.

[0045]   The gene sequences for these members of this α-galactosidase family have allowed development of recombinant expression systems for these polypeptides, using a variety of prokaryotic or eukaryotic cells and expression systems, and permit purification of recombinant forms of these enzymes using established protein purification procedures (for example HIS tag expression and purification systems).

EXAMPLES

Enzyme assays:

[0046]   Substrates consisting of a series of complex blood group ABH oligosaccharide structures, such as 7-amino-4-methyl-coumarin derivatives were custom synthesized by Alberta Chemical Research Council (see, U.S.S.N. 10/251,271). Other substrates were available from different suppliers (Sigma-Aldrich). All reagents used were of analytical grade or higher. Standard enzyme assays were performed as follows with the different substrates.

[0047]   Typical assays were performed by the following procedure: Protein samples were incubated with AMC labeled oligosaccharide at 0.05 mM concentration, with MU-labeled monosaccharide at 0.25 mM concentration, in 2.2-10 μL reaction in 50 mM NaPO4 (pH 6.8) for the desired time at 26°C or room temperature. One μL aliquot was taken at various time points and spotted onto HPTLC to follow product development. The TLC plate was developed in chloroform-methanol-water (vol/vol/vol: 60/35/8). The plate was scanned and photographed by a Bio-Rad Fluor-S Multilmager with Quantity One -4.1.1 software. One unit of enzyme activity is defined as the amount of enzyme required to cleave 1 μmole of substrate per minute under the experimental conditions.

Fermentations:

[0048]   The formulations of various media were listed in Table II. Fermentations in flask and 50 mL conical tubes were performed under standard conditions: 30°C, 220 rpm for the desired length of time. The fermentation was performed at pH 6.8, 30°C, 300-600 rpm, DO = 50%.

Table II.

Medial[1] formulations for growing *Streptomyces griseoplanus* for the production of α-galactosidase polypeptides

YM Medium	
Components	g/L
Yeast extract	3
Malt extract	3
Bacto Soytone	5
Glucose	10

BP Medium	
Components	g/L
Bacto Soytone	15
Malt extract	5
Yeast extract	5
Pharmamedia	5
KH2PO4	1
MgSO4-7H2O	1
CaCO3	2.5
Glucose	25
N-Acetylglucosamine[2]	0.1

Minimal Medium	
Components	g/L
(NH4)2SO4	2
MgSO4·7H2O	0.6
0.2M NaH2PO4 / K2HPO4 pH 6.8	7.5 mL
CaCl2	0.1
ZnSO4·7H2O	0.1
FeSO4·7H2O	0.1
MnCl2·4H2O	0.1

(continued)

Minimal Medium	
Carbon source[2]	5
Trace mineral supplement (ATCC Cat. # MD-TMS)[2]	10 mL
Vitamins supplment (ATCC Cat. # MD-TMS)[2]	10 mL

1. All media without the indicated components were sterilized at 121 °C for 25 min.
2. Components were sterilized by 0.22 μm filtration and added to the desired recipe after sterilization.

EXAMPLE 1: INDUCTION OF α-GALACTOSIDASE EXPRESSION IN *STREPTOMYCES GRISEOPLANUS*

[0049]   *S. griseoplanus* was shown in the past to be capable of producing a secreted novel α-galactosidase when grown in proper media, although this enzyme was never purified to homogeneity. A cryostock of this microorganism was inoculated into 5 to 10 volumes of YM media and grown for 24 hrs at 30°C, 220 rpm, in shaking flasks or 50 mL conical tubes depending on the scale of the culture. The YM culture was then inoculated into about 20 volumes of BP media for continuing incubation under the same conditions, to induce production of the galactosidase. The enzyme activity associated with the culture usually peaks in 3 days. The culture supernatant containing the enzyme activity was harvested by centrifugation. FIG. 1 shows a HPTLC analysis of the enzyme assay of a typical spent culture media supernatant with the substrate B-tetra. The identified α-galactosidase was expressed in a very low volumetric yield both in total lysates of cells as well secreted into the medium (approximately -0.1 U/L culture as analyzed by the B-tetra AMC enzyme assay described under general methods). Therefore, it was largely impossible to isolate sufficient amount of pure protein for sequencing (see, U.S.S.N. 10/251,271). The low expression level of the desired protein, the heterogeneity and protein richness of the rich media, were considered to represent the main factors for the difficulty to purify enough activity for protein identification.

[0050]   It was considered necessary in the present study, to develop a strategy to induce expression and secretion of the enzyme to achieve a higher starting specific activity. One approach was to use an alternative carbon source instead of glucose. Another approach was to reduce the complexity of the media by using homogeneous media with little organic materials in particular the protein content, *i.e.,* the minimal media. The isolation of the enzyme activity from such media was expected to be easier and yields of enzyme at each step were expected to be increased.

[0051]   Considering that the growth of the microorganism in minimal media is very slow and the sensitivity of α-galac-tosidase production to the growth media composition, *S. griseoplanus* was first grown in rich media following the standard protocol, *i.e.*, 24 hrs in YM, 72 hrs in BP. The mycelia were then harvested from the culture by centrifugation. The pelleted mycelia were washed thoroughly with basal minimal media (minimal media lack of carbon source and additives) to eliminate the residual rich media as much as possible. The mycelia pellet was then re-suspended in minimal media lacking a carbon source, which can be easily distributed for carbon source screening as detailed in FIG. 2. The small scale tube cultures were performed under standard fermentation condition. Small aliquots were sampled at different time points and supernatants were recovered for α-galactosidase analysis. A total of 18 carbon sources were studied as shown in Table III. The HPTLC analysis of enzyme assays of culture supernatants with B-tetra are shown in FIG. 2. The complete disappearance of the substrates using 70 hrs fermentation supernatants in lane 4 and 7 clearly distinguish galactose and lactose from other carbon sources in their ability to produce the α-galactosidase. Under current assay condition, 25 pmol of substrate/μL of protein sample, 50 mM NaPO4 (pH 6.8), 1 hr at room temperature, the volumetric yield of the α-galactosidase activity can be calculated as follows:

$$25 \text{ pmol}/(1 \text{ μL} * 60 \text{ min}) \approx 0.4 \text{ mU/mL or } 0.4 \text{ U/L.}$$

[0052]   The yield is much higher than a typical yield obtained from rich media culture (~0.1 U/L). Furthermore, the yield is probably underestimated since lack of time point before 1 hr may have missed the end point of the reactions. The preliminary result shows great potential of using minimal media to facilitate α-galactosidase production and purification.

[0053]   To confirm the remarkable observation using minimal media, we re-evaluated the leading carbon source ga-lactose and lactose for the novel α-galactosidase induction. FIG. 3 shows the HPTLC analysis of reaction assays of fermentation samples taken at different time points grown in minimal media with galactose and lactose as carbon sources. About 90% of the substrate was cleaved by 3 day culture samples in 20 min, which translated to about 4 U/L of culture supernatant. Therefore, as shown in FIG. 3, galactose (lane #4) and surprisingly lactose (lane #7) induced significant α-galactosidase activity. Then conditions for growth and induction using galactose identified above were used without further optimization to develop large-scale fermentations of the Streptomyces strain #2357 for isolation of the enzyme. As will be evident from the following examples these conditions were essential for the successful isolation and identification

of the resultant α-galactosidase protein, which was different from the enzyme originally disclosed by U.S.S.N. 10/251,271.

Table III. Carbon sources used for screening novel α-galactosidase induction from *Streptomyces griseoplanus* using minimal media.

Carbon Source #	Carbon Source
1	Carob tree crenel flour
2	Dextrin from potato starch
3	D(-) Fructose
4	D(+) Galactose
5	D(+) Glucosamine
6	Glycerol
7	D(+) Lactose monohydrate
8	Malt extract
9	D(+) Maltose monohydrate
10	D-Mannitol
11	D(+) Mannose
12	D(+) Raffinose
13	L(-) Sorbose
14	Starch
15	Sucrose
16	Xylitol
17	D(+) Xylose
18	D(+) Glucose

EXAMPLE 2: PURIFICATION OF A α-GALACTOSIDASE EXPRESSED IN *STREPTOMYCES GRISEOPLANUS* STRAIN #2357

[0054]   A new purification strategy was developed for the novel enzyme since the starting material was substantially different than that used for the partial purification described previously (see, U.S.S.N. 10/251,271). The following steps were used to achieve purification to apparent homogeneity: cell broth supernatant (450 ml), derived from 800 mL of culture carried out in an 1 L fermenter as described in Example 1, was subjected to 30 min's high speed centrifugation at 20,000 rpm, 4°C. The supernatant was applied to a 15 ml CEX column (Macro-Prep High S support, BioRad, Cat. #156-0031), pre-equilibrated with 40 mM NaPO4, 10 mM NaCl (pH 6.8), and washed with 40 ml of the equilibration buffer and 40 mM PO4, 10 mM NaCl (pH 7.3), respectively. The flowthrough and the two washes containing the α-galactosidase activity were pooled (FIG. 4, panel A), and applied onto a second column of 2.5 mL DEAE (DEAE Sepharose, Sigma, Cat. # DEF100) pre-equilibrated with 40 mM NaPO4, 10 mM NaCl (pH 6.8). The column was then washed with 50 ml of the equilibration buffer. A total of 600 ml containing the α-galactosidase activity was collected from the flowthrough and the wash (FIG. 4, panel B). They were pooled, concentrated with a Centricon Plus 80 Centrifugal filter devices (Millipore Cat. # UFC5LGC02), and buffer-exchanged to 10 mM NaPO4 (pH 7.0) in the same device to a final volume of 23 mL.

[0055]   The 23 ml buffer-exchanged sample was applied to a 2.5 ml Hydroxyapatite column (BioRad, Cat. #103-0150) pre-equilibrated with 10 mM NaPO4 (pH 7.0). The column was washed with 5 ml of the equilibration buffer, and the α-galactosidase activity was eluted stepwise with a NaPO4 gradient buffer (10 mM/step) from 20 to 100 mM (pH 7.0). The α-galactosidase activity eluted in fractions with 30-50 mM NaPO4 (FIG. 5). The active fractions were pooled and diluted 1:1 with H2O and applied to a 2.5 ml Cibacron Blue column (Sigma, Cat. # C-1285) pre-equilibrated with 10 mM Tris (pH 7.5). The column was washed with 10 ml of 10 mM Tris (pH 7.5) and 5 ml of 10 mM Tris, 80 mM NaCl (pH 7,5). The α-galactosidase activity was eluted with 25 ml of elution buffer containing 10 mM Tris (pH 7.5) with increased amount of salt (FIG. 6). The enzyme eluate was concentrated and buffer-exchanged into 40 mM Tris, 10 mM NaCl (pH 8.5) with Centricon YM10 centrifugal filter devices (Millipore Cat. #4205) to a final volume of 3.7 mL. Finally, the buffer-exchanged eluate was applied to a 1 ml AEX column (BioRad, Cat. #156-0031), pre-equilibrated with 40 mM Tris, 10 mM NaCl (pH 8.5). The column was washed with 5 ml equilibration buffer and the α-galactosidase activity was eluted with a NaCl gradient in 40 mM Tris (FIG. 7).

[0056]   Analyses of the eluate fractions of the AEX column were performed by SDS-NuPAGE and a single band with apparent molecular weight of 70 kD was observed after silver staining (SilverQuest, Invitrogen, Cat. #LC6070) (FIG. 8).

Further verification of the identity of the isolated α-galactosidase was provided by gel filtration chromatography. A S12 column (Superose 12™, Amersham, Cat.#17-5173-01) was equilibrated and run with 150 mM ammonium acetate. Partially purified α-galactosidase as described above was applied (250 μl volume) and 45 fractions (0.5 ml/fraction at 1 ml/min flow rate) were collected (FIG. 9). Fractions #19-21 contained the major protein peak (uv 280 nm). Fractions 19-22 were analysed for α-galactosidase with B-tetra AMC and 10 μl of each was analyzed by a 4-12% gradient SDS-NuPAGE using 10 and 20 ng of NEB A-zyme as controls (lane 2 & 3). As shown in FIG. 9 the peak α-galactosidase activity correlates fully with the 70 kD band by SDS-PAGE.

EXAMPLE 3: AMINO ACID SEQUENCING OF PURIFIED α-GALACTOSIDASE FROM *STREPTOMYCES GRISEO-PLANUS* STRAIN #2357

[0057] Approximately 1 μg α-galactosidase protein as estimated by NuPAGE was prepared as described in Example 2. The protein was separated by 4-12% NuPAGE and stained with Colloidal Blue Staining Kit (Invitrogen, Cat.# LC6025). After destaining of the gel with H2O, the stained 70 KD bands were excised and washed with HPLC grade H_2O and 50% acetonitrile in H_2O. The sliced gel was subjected to direct sequence analysis at the Harvard Microchemistry Facility, Harvard University. Briefly, gel slices were reduced with DTT and alkylated with iodoacetamide, and then digested with trypsin in 25 mM ammonium bicarbonate buffer. The trypsin digest was analyzed by microcapillary reverse-phase HPLC nano-electrospray tandem mass spectrometry (μLC/MS/MS) on a Finnigan LCQ DECA XP Plus quadrupole ion trap mass spectrometer. Preliminary sequencing of peptides was facilitated by database correlation with the algorithm SE-QUEST. MS/MS peptide sequences were then reviewed for consensus with known proteins and the results manually confirmed for fidelity. No sequences from the NCBI nr or est databases correlated with this data.

[0058] Several attempts to obtain the N-terminal sequence of the undigested protein had failed to generate any sequencing information, suggesting that the N-terminus was blocked. In order to obtain internal sequence information peptides from the trypsin digest of the NuPAGE gel slices containing ~5 μg of the desired protein was fractionated by HPLC on a 0.3x150mm C18 column. Three wavelengths were monitored; 205nm (for amide bonds), 277nm and 292nm (for aromatic amino acids Trp and Tyr) via a diode array detector. A few of the best peaks/fractions were screened by MALDI to select peaks for Edman sequencing. Blast database searches using "search for short, nearly exact matches" against the NCBI nr database did not identify any identical sequences with any of the obtained peptide sequences. However, search using a 30 amino acid peptide sequence shown as SEQ ID NO: 12, the longest obtained peptide sequence and confirmed by MS/MS, did identify a candidate putative protein (SEQ ID NO: 2) predicted from the genome sequence of *Streptomyces avermitilis* (GenBank access # BAC74979.1, GI:29610934) that showed weak sequence similarity to SEQ ID NO: 12, the obtained griseoplanus peptide sequence (illustrated in FIG. 10).

SEQ ID NO: 12: TVIDVTDFGADPSGKADSAAAVSAAMAHAK

[0059] The genome of *Streptomyces griseoplanus* is not available and no related sequences were identified in database searches. Notably, this sequence is not shared by the α-galactosidase described in our prior disclosure (and herein as SEQ ID NO: 1). *Streptomyces avermitilis* and *Streptomyces griseoplanus* are closely related. We therefore tested if *Streptomyces avermitilis* also contained the novel α-galactosidase, since the previous α-galactosidase was demonstrated to be very rare among many of the Streptomyces isolates tested (see, U.S.S.N. 10/251,271).

[0060] *Streptomyces avermitilis* (ATCC 31267) was cultured in YM media and the culture supernatant was assayed for secreted α-galactosidase using the AMC labeled B tetrasaccharide and a monosaccharide α-Gal pNP as substrates. As shown in FIG. 11, clear evidence of the presence of α-galactosidase activities in both culture supernatant and pellet lysate as analyzed by B-tetra oligosaccharide. However, the cleavage of a simple substrate α-Gal pNP is negligible by the secreted α-galactosidase activities. In contrast, complete cleavage of α-Gal pNP was observed for the cellular α-galactosidase(s).

[0061] The identified putative protein consisted of 625 amino acids (SEQ ID NO: 2) and showed no significant identity to any other known proteins. Back searches with the identified protein sequence identified very few protein sequences with low sequence similarities exclusively from prokaryotic genomes. All sequences identified were analyzed by multiple sequence analysis as shown in FIG. 12.

EXAMPLE 4: RECOMBINANT EXPRESSION AND CHARACTERIZATION OF IDENTIFIED α-GALACTOSIDASE GENE FROM *STREPTOMYCES AVERMITILIS*

[0062] The predicted full coding sequence of the identified *Streptomyces avermitilis* gene, 1878 base pairs in length, encoding the putative protein (SEQ ID NO: 2) of 625 amino acids (full length) was amplified by PCR (polymerase chain reaction) using the primer pair AVER1 (5'-GCGAATTCCCATGGCTCACGGATGCTCCGGAGGG-3' SEQ ID NO: 13)/ AVER3 (5'-GCCTCGAGAAGCTTCTAGTCCGTGACCACGGAGGTGTTC-3' SEQ ID NO: 14), digested with Ncol/HindlII

restriction enzyme (restriction sites in primers underlined), and cloned into the Ncol/Hindlll site of the bacterial expression vector pPET28 (Novagen, Cat. No. 70777-3) forming the pZQ-B002a construct. Given the fact that the gene possesses an internal Ncol site at position 1490, insertion of the full-length gene construct was performed using a two-step cloning procedure. The expression construct was sequenced in full for confirmation. The generated full length expression construct pZQ-B002a was used to transform the *E. coli* strain Rosetta (BL21-DE3)pLysS (Novagen Cat. No. 70956-3), and plated out on LB-agar plates in the presence of Chloramphenicol (34μg/ml) and Kanamycin (50μg/ml).

[0063] For initial analysis of the protein expression, induction was performed at 26°C instead of the more common 37°C with a low concentration of inducer (0.1 mM IPTG), a condition favoring the formation of soluble proteins. The induced cell pellet was lysed by a detergent based chemical method and whole lysate was assayed directly under standard condition for the novel B-zyme activity without being clarified. As shown in FIG. 13, the cleavage of the AMC labeled blood group B tetrasaccharide substrate was readily detectable as indicated by the formation of H trisaccharide using crude lysate generated from cultures induced only for 1 hr. This result unambiguously demonstrates the protein from *Streptomyces avermitilis* (SEQ ID NO: 2) is indeed a novel galactosidase, a characteristic activity shared by other members of this family of proteins. FIG. 14 confirms that SEQ ID NO: 2 can be efficiently expressed in *E. coli,* but is recovered in inclusion bodies. Therefore, denaturation, extraction of the enzyme from inclusion bodies, and refolding are first necessary, for producing this polypeptide in *E. coli.*

EXAMPLE 5: ENZYMATIC CONVERSION OF B RED BLOOD CELLS TO O PHENOTYPE CELLS USING EX-PRESSED α-GALATOSIDASE AS EVALUATED BY ROUTINE TYPING PROTOCOLS

[0064] Conversion Protocol One - Enzymatic conversion reactions were performed in 1 ml reaction mixtures containing 200 mM glycine, pH 6.8, and 3 mM NaCl with 30 % packed red blood cells (pRBCs) and enzyme as indicated. Fresh whole blood was obtained from Oklahoma Blood Institute (Oklahoma City, OK) and buffy coat removed. RBCs were prewashed 1:1 and 1:4 vol/vol in conversion buffer before addition of enzyme, and reactions incubated for 60 min with gentle mixing at 26°C, followed by four repeat washing cycles with 1:4 vol/vol of saline by centrifugation at 1,000 rpm. The washed enzyme-treated B-ECO RBCs were ABO typed according to standard blood banking techniques using various commercially available monoclonal antibody reagents ((Immucor Gamma Anti-B (Gamma Biologicals/Immucor, Norcross, Ga.); Ortho Anti-B (Ortho Clinical Diagnostics, Raritan, N.J.); and Diagast Anti-B (Diagast Laboratories, France)).

[0065] Conversion Protocol Two - B red cells (Beth Israel Deaconess Medical Center, Boston, MA) are drawn into EDTA tubes and stored at 4°C for up to seven days, and are washed three times in PBS (Phosphate Buffered Saline, pH 7.4), and resuspended to 10% in a solution of PBS and 7.5% PEG (pH 7.4). Cells are treated with recombinant α-galactosidase (10-500 U/ml) at 30°C for 180 min while shaking. Cells are washed three times in 0.9% saline and resuspended to 3-5% in saline for typing.

[0066] Conversion Protocol Three - B red cells (Beth Israel Deaconess Medical Center, Boston, MA) are drawn into EDTA tubes and leukoreduced B red cells (American Red Cross, New England Region, Dedham, MA) are frozen in Glycerolyte 57, (Baxter Healthcare Corporation, Fenwal Division: Deerfield, IL) according to the AABB Technical Manual, 13th edition, Method 6.6 and stored at -70°C. Prior to enzyme treatment cells are deglycerolized using 9.0% saline, 2.5% saline, and 0.9% saline (see, Method 125 of Immunohematology Methods by the American Red Cross), then resuspended to a hematocrit of 50% in a solution of PBS and 7.5% PEG (pH 7.4) and recombinant α-galactosidase (200 U/ml) is added. Reactions are incubated at 37°C with shaking for 4 hours, followed by three washes in 0.9% saline, and final suspension to 3-5% in saline for typing.

[0067] Conversion Protocol Four - Origin and storage of cells is the same as described under protocol B. Deglycerolized red cells are washed twice in PCI (pH 7.4) with 150 mM NaCl and resuspended to a hematocrit of 50% in PCI (pH 7.4) with 150 mM NaCl. Cells are treated with recombinant α-galactosidase (200 U/ml) at 37°C with shaking for 4 hours, followed by three washes in 0.9% saline, and final suspension to 3-5% in saline for typing.

[0068] Approved typing reagents used in hemagglutination assays are murine monoclonal antibodies and plant lectins obtained from Ortho Clinical Diagnostics, Raritan, N.J.; Gamma Biologicals/Immucor, Norcross, Ga. Non-FDA approved reagents included murine monoclonal anti-B antibodies to blood group B variants produced by H. Clausen (Clausen et al., Proc. Natl. Acad. Sci. USA 82(4): 1199-203, 1985, Clausen et al., J Biol Chem. 261(3): 1380-7, 1986, Clausen et al., Biochemistry 25(22): 7075-85, 1986, Clausen et al., J Biol Chem. 262(29): 14228-34, 1987). Typing reagents are used according to the manufacturers recommendations and other monoclonal antibodies as determined by titrations.

[0069] Hemagglutination Assay (room temperature).

[0070] A 3-5% suspension of washed red cells in isotonic blood bank saline is prepared. One drop (approx 50 microliters) of anti-B antibody reagent is added. One drop (approx 50 microliters) of the red cell suspension is added. Tubes are mixed and centrifuged for 15 seconds at 3500 rpm. Cells are resuspended by gentle agitation and examined macroscopically for agglutination. The agglutination is graded according to Method 1.8 in the AABB Technical Manual, 13th edition.

[0071]   As described in the previous examples, preferred enzymes for use in removing blood group B epitopes from red cells are likely to have particularly good kinetic properties with oligosaccharide substrates resembling the blood group B antigens. Such preferred kinetic properties could be represented by preferred or exclusive substrate specificities for the blood group B oligosaccharides, and low or no activity with simple monosaccharide derivatives such as mon-osaccharide-pNP substrates. Preferred kinetic properties could also be represented by a particularly low Km for relevant substrates. Further preferred kinetic properties consist of neutral pH optimum of reactions with relevant blood group active substrates, and other reaction conditions that are compatible with the integrity and functions of red cells. Other preferred properties of the enzyme such as size, charge, solubility, and other physico-chemical properties may also relate to performance in enzymatic conversion of red cells. The novel α-galactosidase with improved kinetic properties was identified from various bacterial strains as described and provides an enzyme with the above mentioned preferred characteristics, that exhibits superior performance in red cell conversions.

Table 3A: Agglutination Results of human red cells converted with FragA or FragB recombinant αgalactosidases.

Routine Conversion Protocol (200 Glycine, pH 6.8, 3 mM NaCl)		Immucor Anti-B		Diagast Anti-B	
Frag B enzyme	Dose µg/ml	IS	4°C	IS	4°C
Human B Cells	10	0	0	0	0
	5	0	0	0	0
	2.5	0	0	0	0
	1.25	0	0	0	0
	0.625	0	W+	W+	1+
	0.3125	0	1+	1+	1+
Frag A enzyme					
Human B Cells	10	0	0	0	0
	5	0	0	0	0
	2.5	0	0	0	0
	1.25	0	0	0	0
	0.625	0	W+	W+	1+
	0.3125	1+	1+	1+	2+

EXAMPLE 6: CLONING AND DNA SEQUENCING OF α-GALACTOSIDASE FROM *STREPTOMYCES GRISEOPLA-NUS* STRAIN #2357 AND DEDUCTION OF ITS AMINO ACID SEQUENCE

[0072]   The isolation and purification of the endogenous α-galactosidase from *S. griseoplanus* 2357 was described in Example 2. The partial amino acid sequencing of purified α-galactosidase that generated a 30 amino acid peptide was described in Example 3. Blast search using this peptide against 'nr' database (GenBank) identified a family of putative α-galactosidases. The sequences for the 5 α-galactosidases were submitted to the EMBL/GenBank/DDBJ databases and assigned the following accession numbers: AM109953 (*Streptomyces avermitilis*), AM109954 and AM109955 (Bacteroides fragilis), AM109956 and AM109957 (Bacteriodes thetaiotaomicron). Multiple sequence alignment of puta-tive α-galactosidases identified a few conserved regions (FIG. 15). The open reading frame encoding a putative α-ga-lactosidase from *Streptomyces griseoplanus* was cloned based on 5' and 3' rapid amplification of genomic ends (RAGE). Initial degenerate primers were based on the conserved regions determined from multiple sequence alignment of putative α-galactosidase sequences. Degenerate sense and anti-sense primers dAVER7 (5'-TTCGGXGTXGTXKGKCAGT-WCAGXGAGAA-3' SEQ ID NO: 15)/dAVER9 (5'-GTXCCXTGXATXTTXATXGGXTCXTCGTG-3' SEQ ID NO: 16), where X= inosine and K= G or T, were used to PCR amplify a single 185bp BZyme specific DNA fragment from *Streptomyces griseoplanus* genomic DNA. PCR product was cloned into pCR4 vector (Invitrogen) and sequenced generating pCR4-dAVER7/9. *Streptomyces griseoplanus* α-galactosidase specific primers GRIS10 (5'-ATCGACTCGGTCACCTTCAAG-

GCCGAC-3 SEQ ID NO: 17) and GRIS11 (5'-AAGACGCTGTTGGTGATGCGTACGGTGC-3' SEQ ID NO: 18) were derived from pCR4-dAVER7/9. *Streptomyces griseoplanus* genomic DNA was endonuclease treated to completion with restriction endonuclease HaeII, size fractionated by 0.8% agarose gel electrophoresis and 2-3kbp fractionated DNA was purified by Qiagel purification (Qiagen). Purified DNA was ligated to a double stranded HaeII adapter EBRETTE3 (5'-GCG*CTCGAAATTAACCCTCACTAAAGGGG*AATTCGGTACCCTCGAGGCGC-3' SEQ ID NO: 19)/EBRETTE4 (5'-CTCGAGGGTACCGAATTCCGGAA-3' SEQ ID NO: 20) encoding a T7 binding site (underlined) and HaeII restriction overhang (shown in italics). Adapter ligated DNA was used in 5' RAGE using 10ng adapter ligated DNA, T7/GRIS11 or 3'RAGE using 10ng T7/GRIS10. Generated 5' and 3' RAGE products were cloned into pCR4 generating 5'-T7/GRIS11-pCR4 and 3'-T7/GRIS10-pCR4 and fully sequenced. The overlapping 5'-T7/GRIS11-pCR4 and 3'-T7/GRIST10-pCR4 sequences represent 1593bp of the full coding BZyme gene sequence. Remaining 5'and 3' sequence was obtained by repeated RAGE on fractionated BamHI digested *Streptomyces griseoplanus* genomic DNA, BamHI adapter EBRETTE3/6 (5'-*GATC*GCGCCTCGAGGGTACCGAATTCCGGAA-3' SEQ ID NO: 21) ligated (BamHI overhang shown in italics). Complete 5' sequence was obtained using 10ng adapter ligated DNA and T7/GRIS22 (5'-CGCTTCGGCGTCCGTTCG-GGCCAG-3' SEQ ID NO: 22) and 3' sequence using T7/GRIS24 (5'-CCGGTGCACCGCAACGTCCTCATC-3' SEQ ID NO: 23). Generated 5' and 3' RAGE products were cloned into pCR4 generating 5'-T7/GRIS22-pCR4 and 3'-T7/GRIS24-pCR4 and fully sequenced. 5'-T7/GRIS22-pCR4 contained a predicted initiating start methionine and 3'-T7/GRIS24-pCR4 contained an in frame stop codon, completing the full 2184 bp coding sequence of *Streptomyces griseoplanus* α-galactosidase gene (SEQ ID NO: 24) encoding a 727 amino acid α-galactosidase (SEQ ID NO: 25). The sequence was submitted to GenBank (accession number AM259273). The regions in protein sequence of the α-galactosidase from which the primers were derived are described in FIG. 16.

EXAMPLE 7: RECOMBINANT EXPRESSION AND CHARACTERIZATION OF IDENTIFIED α-GALACTOSIDASE GENE FROM BACTEROIDES FRAGILIS

[0073] FragB α-galactosidase (SEQ ID NO: 6) expression construct was cloned from genomic bacterial DNA by PCR. The FragB α-galactosidase gene, lacking the coding region for the putative amino terminal signal peptide 1-24, was lifted from Bacteroides fragilis genomic DNA (ATCC 25285D) by PCR using primers BFRAGB2 (5'-GCG<u>GGATCC</u>CGGGATGGGACGTGTTTATGACATTTCCCAGTTTGGC-3' SEQ ID NO: 24)/BFRAGB3 (5'-GCCTCGAG<u>AAGCTT</u>TCACTCTGAAATCTTCACGTTTGTCACTCG-3' SEQ ID NO: 25) and amplified using Pfu Ultra polymerase (Stratagene). Restriction enzyme overhangs for BamH I and Hind III in the above primers are underlined. After digestion with BamH I and Hind III, the amplified polynucleotide products were inserted into the bacterial expression vector pET28 (Novagen) in frame and downstream of the plasmid encoded 6xHis tag to generate plasmid pZQ-B006a. For the construction of a non tagged expression vector, the 6xHis tag in pET28 vector was removed by NcoI/BamHI digestion followed by insertion of a double stranded oligo PETNCBAF (5'-CATGGATCCCAGGCCTCCGGATG-3' SEQ ID NO: 26)/(GATCCATCCGGAGGCCTGGGATC-3' SEQ ID NO: 27) creating plasmid pET28-δHis. The FragB construct described above encoding the His-tagged protein was sub-cloned into the pET28-δHis BamHI/HindIII site to create plasmid pZQ-B006c for the expression of the untagged FragB α-galactosidase. All constructs were fully sequenced on a 377 ABI Prism instrument (Applied Biosystems). For protein expression, pZQ-B006c was transformed into *E. coli,* Rosetta2 (DE3) (Invitrogen). The *E. coli* clone was grown in 1X Terrific Broth (Sigma), supplemented with 34 μglmL of Chloramphenicol and 50 μg/mL of Kanamycin at 37 °C, 220 rpm to ~0.6 OD at 600 nm and IPTG was added to 0.5 mM to induce the target protein expression. The culture was harvested after 3 hrs, by centrifugation at 3000 xg for 30 min. The cell pellet was stored at -20°C. The cell pellet harvested from 350ml culture was lysed using 1X BugBuster (Invitrogen) in 25 mM NaOAc, pH 5.5/10 mM NaCl, supplemented with 5 μL of Benzonase (Invitrogen), and stirred for 1 hr at room temperature. The whole lysate was clarified by centrifugation at 40,000 x g, 5°C, for 30 min. The cell debris, containing over 90% enzyme activity, was re-suspended in 10 mM NaPO4, pH 6.8/400 mM NaCl and stirred at room temperature for 30 min. High speed centrifugation was repeated to recover the supernatant containing the enzyme activity. The resulting supernatant was loaded onto a 5-ml Hydroxyapatite column, pre-equilibrated with 10 mM NaPO4, pH 7.0. The column was washed with 20 mL of equilibration buffer, followed by elution using a NaPO4 gradient, pH 7.0, from 10 to 400 mM. The enzyme activities, eluted between 200-400 mM NaPO4, pH 7.0, were pooled, concentrated and buffer exchanged with an Amicon (Grace) centrifugal device Plus 70, into 10 ml of 40 mM Tris, 400 mM NaCl/pH 7.5. The protein solution was allowed to pass through a 5-ml Phenyl Sepharose High Performance column (Amersham), pre-equilibrated with the dialysis buffer, and the column was washed with 10 mL of dialysis buffer after loading. The flow through and wash were pooled, adjusted to pH 8.5 with 1 M Tris, diluted with equal volume of H$_2$O. The resulting protein solution was subjected to another passage column step, 2.3 mL of Macro-Prep High Q, pre-equilibrated with 40 mM Tris, pH 8.5/10 mM NaCl, and the column was washed with 10 mL of equilibration buffer. The flow through and wash were pooled and buffer exchanged into 7 ml of 10 mM NaPO4, pH 6.8/50 mM NaCl. The protein concentration was determined by Pierce's BCA Protein Assay Kit.

[0074] The purified FragB α-galactosidase was evaluated for its ability to cleave the branched carbohydrate chain

substrate B-tetra under standard conditions (1 nmole of substrate in 10 μL of 100 mM NaPO$_4$, pH 6.8/50 mM NaCl), and the purified enzyme demonstrated extremely high specific activity toward the B-tetra substrate: ~5-10 U/mg. The pH optimum of the purified FragB α-galactosidase was evaluated with the B-tetra-AMC substrate across a pH range of 2.0 to 9.0 and the results are shown in FIG. 17. The FragB enzyme has a broad optimal pH range between 4.5 and 7.5. Analysis with the more sensitive/quantitative colorimetric assay gives the similar conclusion as shown in FIG. 18, although the enzyme's activity was seen at the low end of the pH range tested, *i.e.*, activity was observed down to ~pH 4.2, a subtle difference in activity which is not detectable by using the TLC based AMC-B-tetra assay. Therefore, the novel enzyme can be used successfully under acidic conditions to neutral condition and even slightly basic conditions, *i.e.*, about pH 4 to about pH 7.4 or greater. In currently preferred embodiments, the enzyme is used within a pH range of about 6.0 to about 7.5, and more preferably about pH 6.5 to about pH 7.5. The currently most preferred pH range for the novel enzyme are those conditions mimicking the physiological pH of circulating arterial or venous blood, in order to minimize pH effects on the blood cells themselves and not because of pH limitations on enzyme activity and performance.

[0075]   The FragA α-galactosidase (SEQ ID NO: 5) was cloned similarly by PCR from the same genomic DNA as for FragB α-galactosidase, and expressed similarly as His$_6$ tag protein at the N-terminus in Rosetta (DE3) pLysS (Novagen). Expressed soluble protein was purified to homogeneity by successive immobilized metal affinity chromatography (IMAC), cation and anion exchange chromatography. The purified protein was shown to be similar to the endogenous S. *griseoplanus* α-galactosidase (strain 2357) in terms of specific activity for branched substrate, substrate specificity and pH optima. Analysis of activity with.a blood group B tetrasaccharide-AMC substrate in the pH range of 2-9 showed that the enzyme has a broad optimum between 5 and 7.5. The substrate specificity of the FragA α-galactosidase was determined with a diverse panel of oligosaccharide structures and a remarkably stringent specificity for α1-3 linked galactose in the branched blood group B structure was found (FIG. 20). The enzyme cleaved neither α4Gal linkages found in P1 and P^k blood group antigens nor the α3Gal linkage in linear B structure without fucose.

EXAMPLE 8: BACTEROIDES FRAGILIS α-GALACTOSIDASE EFFICIENTLY CLEAVES LINEAR B OLIGOSAC-CHARIDES AT A NEUTRAL PH

[0076]   Further analysis of the substrate specificity of recombinant purified FragB α-galactosidase surprisingly revealed that this enzyme (in contrast to the earlier purified α-galactosidase from S. *griseoplanus*) exhibited low activity with the Galα-pNP substrate (~1.6 U/ml using the buffer system 100 mM NaPO$_4$, pH 6.8/50 mM NaCl) (Table IV).

Table IV. Comparison of the specific activities (U/mg) of FragB α-Galactosidase and Coffee Bean α-Galactosidase.

Substrate	Coffee Bean	*B. fragilis* (FragB)[1]
Galα-pNP	32 (pH 6.5)[2]	1.6 (pH 6.8)
Galα1-3(Fucα1-2)Galβ1-4Glc-AMC	0.017 (pH 5.5)[4]	9.4 (pH 6.8)

[1]This work.
[2]Derived from Zhu, A., Monahan, C., Zhang, Z., Hurst, R., Leng, L. & Goldstein, J. (1995) Arch Biochem Biophys 324, 65-70.
[3]not determined.
[4]Derived from US patent application, publication number 20050208655.

[0077]   This prompted us to test the substrate specificity with substrates having different α1-3Gal and α1-4Gal linkages. As shown in FIG. 19, FragB showed high activity with linear α1-3Gal linkages (B-di and Linear B) in addition to the blood group B oligosaccharide structures. Interestingly, the activity of FragB with the Galα1-3Gal disaccharide was very high (~12 U/mg at pH 6.8) suggesting that this enzyme is suitable for efficient cleavage of the linear B antigen (Galα1-3Galβ1-4GlcNAcβ1-R, where R is any oligosaccharide structure) also known as the Galili antigen (Galili U (2005) Immunol Cell Biol 83:674-86). The Galili antigen is a major xenotransplantation barrier antigen found on most animal tissues except old world monkeys and man (Galili U (2005) Immunol Cell Biol 83:674-86). Xenotransplantation of e.g. pig tissues and cells into man results in hyperacute rejection mainly due to presence of high titers in man of IgG antibodies to the Galili antigen. To date only broadly reactive α-galactosidases such as Coffee bean derived enzymes with acidic pH optimums have been used for cleavage of the Galili antigen from cells and tissues. This may constitute a significant problem since all animal cells express large quantities of e.g. the globoseries P^k glycolipid structure (Galα1-4Galpβ1-4Glcβ1-Ceramide). It is more desirable to use α-galactosidase enzymes with higher efficiency, specificity and neutral pH optimum, such as those disclosed herein.

[0078]   The FragB α-galactosidase was specific for α1-3Gal linkages, and no significant cleavage of several α1-4Gal linkages (P$_1$ and P^k) was observed. This is similar to the α-galactosidase obtained from S. *griseoplanus,* but represents a property that is different from any other known α-galactosidase including the enzyme derived from Coffee bean. The results are summarized in Table V.

Table V. Substrate specificity of the α-galactosidases.

Substrates	Blood Group Specificity	Coffee Bean[1]	*S. griseoplanus*[1]	*B. fragilis*[2] (FragB)
Galα-pNP	NA[3]	+[4]	-[5]	+
Galα1-3Gal	B (B-di)	+	-	+
Galα1-3Galβ1-4GlcNAc	Linear B	+	-	+
Galα1-3(Fucα1-2)Gal	B-tri	+	+	+
Galα1-4Gal	P$_1$	+	-	-
Galα1-4Galβ1-4Glc	P^K	+	-	-
GalNAcα1-3(Fucα1-2)Gal	A-tri	-	-	-
Galα1-3(Fucα-2)Galβ1-4Glc-AMC	B-tetra	+	+	+
GalNAcα1-3(Fucα1-2)Galβ1-4Glc-AMC	A-tetra	-	-	-

[1]Derived from US patent 20050208655 (Ref.) and Zhu, A., Monahan, C., Zhang, Z., Hurst, R., Leng, L. & Goldstein, J. (1995) Arch Biochem Biophys 324, 65-70**.**
[2]This work.
[3]Not applicable.
[4]Activity readily detectable under assay conditions.
[5]Activity not readily detectable under assay conditions.

[0079]   The surprising finding that the FragB α-galactosidase may represent a novel highly efficient enzyme for cleavage of linear B (Galili epitopes) prompted us to test the suitability and efficiency of this enzyme in removing such epitopes from cell surfaces. Rabbit red blood cells contain glycolipids and glycoproteins oligosaccharide chains similar to human red cells, but while oligosaccharide chains in human red cells terminate in ABH structures depending on blood group status, oligosaccharides of rabbit red cells terminate with linear B (Galili epitopes) structures (Galβ1-3Galβ1-4GlcNAc). The lectin Bandeeira (Griffonia) simplicifolia IB4 is generally used to detect linear B (Galili epitopes) structures (Galili U (2005) Immunol Cell Biol 83:674-86), and as shown in Table VI this lectin strongly agglutinates rabbit (but not human) red cells.

Table VI: Agglutination of human and rabbit red cells with IB4 lectin and Routine Monoclonal Anti-B Typing Reagents.

RBC Type	Immucor/Gamma Anti-B		Diagast Anti-B		B4 Lectin
	IS	4°C	IS	4°C	10ug/ml
Native Rabbit Cells	2+	4+	4+	4+	4+
Native Human B Cells	4+	4+	4+	4+	1+
Native Human A Cells	0	0	0	0	0
Native Human O Cells	0	0	0	0	0

[0080]   Rabbit red cells therefore serve as an excellent model for analysis of the efficiency of α-galactosidases in the removal of the immunodominant α1-3Gal residue from linear B (Galili epitopes) structures from cell surfaces. Since we have previously developed an efficient conversion process for removal of immunodominant A-type antigens from blood cells using a purified *C. meningosepticum* α-N-acetylgalactosaminidase enzyme, operative using a Glycine pH 6.8 buffer system, we tested the same conditions for FragB cleavage of rabbit red cells in comparison with human blood group B red cells. As shown in Table VII, FragB efficiently removed IB4 lectin agglutination of rabbit red cells at very low doses,

almost comparable to what was required for FragB cleavage of blood group B from human red cells. The agglutination of rabbit red cells by the IB4 lectin was almost completely abolished by the enzyme treatment with 10g/ml enzyme dose giving only a microscopic reading (M+). Higher concentrations of enzyme or longer incubation complete abolish reactivity. The homologous gene FragA, however, only cleaved blood group B from human red cells.

Table VII: Agglutination Results of human and rabbit red cells digested with FragA or FragB glycan modifying enzymes.

Routine Conversion		Immucor Anti-B		Diagast Anti-B		B4 Lectin
Frag B enzyme	Dose ug/ml	IS	4°C	IS	4°C	10ug/ml
Human B Cells	10	0	0	0	0	0
	5	0	0	0	0	0
	2.5	0	0	0	0	0
	1.25	0	0	0	0	0
	0.625	0	W+	W+	1+	0
	0.3125	0	1+	1+	1+	0
Rabbit Cells	10	0	0	0	W+	M+
	5	0	0	0	W+	Vw+
	2.5	0	0	0	W+	W+
	1.25	0	0	0	1+	1+
	0.625	0	W+	W+	3+	1+
	0.3125	0	2+	4+	4+	2+
Frag A enzyme						
Human B Cells	10	0	0	0	0	0
	5	0	0	0	0	0
	2.5	0	0	0	0	0
	1.25	0	0	0	0	0
	0.625	0	W+	W+	1+	0
	0.3125	1+	1+	1+	2+	0
Rabbit Cells	10	4+	4+	4+	4+	3+
	5	4+	4+	4+	4+	3+
	2.5	4+	4+	4+	4+	3+
	1.25	4+	4+	4+	4+	3+
	0.625	4+	4+	4+	4+	3+
	0.3125	4+	4+	4+	4+	3+

[0081] This demonstrates that the purified FragB polypeptide isoform described as part of the novel α-galactosidase gene family reported herein, has unique substrate specificities that are different from several other members within this family, including the related genes observed in Streptomyces. Furthermore, that the FragB polypeptide described is suitable for enzymatic removal of immunodominant blood group B antigens from red cells, as well as for removal of the xenotransplantation Galili antigen from blood cells. The purified FragB polypeptide is thus superior to other currently known enzymes, with respect to its pH optimum (most preferably pH 6.5 to pH 7.5), its restricted substrate specificity to Galα1-3 linkages and its observed high specific activity.

[0082] Enzymatic removal of the immunodominant α1-3 linked terminal Galactose of the Galili antigens has important applications in the xenotransplantation field. The Galili antigen constitutes the most important barrier for xenotransplantation of organs, tissues, tendons, ligaments and cells from animals to man, and is the primary cause of the hyper-acute rejection phenomenon (Galili U (2005) Immunol Cell Biol 83:674-86). Approximately 10 % of normal healthy individuals serum IgG is directed to the Galili antigen. Enzymatic removal of the terminal galactose residue will expose common structures found in man, which may abrogate hyperacute rejection (Galili U (2005) Immunol Cell Biol 83:674-86).

[0083] The process described for enzymatic removal of the Galili antigen on rabbit cells in which cells are washed and incubated with the FragB α-galactosidase in a suitable buffer at neutral pH for a period of time results in efficient removal of the Galili epitope (Table VII). A similar process applied to animal organs, tissue, tendons, ligaments and cells, results in efficient removal of exposed Galili antigens.

[0084] The preferred process involves contacting the animal tissues or cells with the FragB α-galactosidase (or homologous members of the gene family with similar enzymatic activities) in a suitable buffer such as physiological saline, Glycine or other similar buffer systems described herein, at neutral pH of 5.5 to 8.0 and more preferably 6.5 to 7.5. The enzyme dose and time required for enzymatic removal of the immunodominant α1-3 linked terminal Galactose generally follows the digestion parameters described above for blood cells, but is evaluated empirically, as is determined by lectin and antibody based immunoassays such as immunocytology, immunohistology and ELISA using such suitable lectins such as the IB4 lectin or suitable monoclonal antibodies reactive with the Galili epitope (Galili U (2005) Immunol Cell Biol 83:674-86). When the reaction is complete, the enzyme modified animal organ, tissue, tendon, ligament or cells are washed with an appropriate buffer solution (such as physiological saline) to remove the enzyme solution. The animal tissues or cells lack immunodominant Galili antigens, and can now be used as an appropriate xenotransplant into a human subject in need of such a transplant. An example of this is an antigenically modified porcine ligament, which is used for the reconstruction of ruptured anterior cruciate ligament in a human patient. See for example, United States Patent 6,402,783.

[0085] Prior to treatment, the outer surface of the xenograft may optionally be pierced to increase permeability to agents used to render the xenograft substantially non-immunogenic. A sterile surgical needle such as an 18 gauge needle may be used to perform this piercing step, or, alternatively a comb-like apparatus containing a plurality of needles may be used. The piercing may be performed with various patterns, and with various pierce-to-pierce spacings, in order to establish a desired access to the interior of the xenograft. Piercing may also be performed with a laser. In one embodiment of the invention, one or more straight lines of punctures about three millimeters apart are established circumferentially in the outer surface of the xenograft.

[0086] Prior to implantation, the ligament xenograft of the invention may be treated with limited digestion by proteolytic enzymes such as ficin or trypsin to increase tissue flexibility or coated with anticalcification agents, antithrombotic coatings, antibiotics, growth factors, or other drugs which may enhance the incorporation of the xenograft into the recipient knee joint. The ligament xenograft of the invention may be further sterilized using known methods, for example, with additional glutaraldehyde or formaldehyde treatment, ethylene oxide sterilization, propylene oxide sterilization, or the like. The xenograft may be stored frozen until required for use.

[0087] The ligament xenograft of the invention, or a segment thereof, may be implanted into a damaged human knee joint by those of skill in the art using known arthroscopic surgical techniques. Specific instruments for performing arthroscopic techniques are known to those of skill in the art, which ensure accurate and reproducible placement of ligament implants. Initially, complete diagnostic arthroscopy of the knee joint is accomplished using known methods. The irreparably damaged ligament is removed with a surgical shaver. The anatomic insertion sites for the ligament are identified and drilled to accommodate a bone plug. The size of the bone plug can be about 9-10 mm in width by about 9-10 mm in depth by about 20-40 mm in length. The xenogeneic ligament is brought through the drill holes and affixed with interference screws. Routine closure is performed.

[0088] Using the polypeptides of the present invention thus permits removal of the Galili antigen from many different tissues types, using the modification procedures described herein and as may be further adapted to the particular tissues in view of the teachings provided, by a skilled artisan. These modified tissues are used for a variety of transplant procedures where non-immunogenic xenotransplants are required, as is described in the following: to create e.g. substantially non-immunogenic injectable collagen (see, U.S. Patent 7,064,187); for bone xenografts (see, U.S. Patent 6,972,041); for soft tissue and proteoglycan-reduced soft tissue xenografts (see, U.S. Patent 6,758,865 and 6,455,309); xenograft heart valves (see, U.S. Patent 6,383,732); and meniscal xenografts (see, U.S. Patent 6,093,204 and 5,984,858).

[0089] In another particularly preferred embodiment, the invention provides for tissue matrices preferably those made from α1,3-galactose-deficient tissues (see, U.S. Patent 6,933,326 and U.S. Patent Application 20050159822 and 20050028228). Methods of making and using these tissue matricies are described in the above patent and applications, and the de-galacosylation of the tissues is accomplished using the novel α3 galatosidases as described herein (SEQ ID NO: 2-9, or active fragments or functional equivalents thereof).

SEQUENCE LISTING

[0090]

5

<110> VELICO MEDICAL, INC.

<120> NOVEL ALPHA-GALACTOSIDASES

<130> 1395-0014

10

<140> EP
<141> 2006-10-31

<150> US 60/836,000
15 <151> 2006-08-07

<150> US 60/731,845
<151> 2005-10-31

20 <160> 29

<170> PatentIn version 3.5

<210> 1
25 <211> 8
<212> PRT
<213> Streptomyces griseoplanus

<400> 1
30

```
                    Phe Ala Asn Gly Leu Leu Leu Thr
                    1                   5
```

<210> 2
35 <211> 625
<212> PRT
<213> Streptomyces avermitilis

<400> 2
40

45

50

55

```
Met Ala His Gly Cys Ser Gly Gly Ala Met Ser Arg Phe Val Phe Leu
1               5               10              15

Gly Val Ala Leu Ala Leu Leu Gly Gly Ala Thr Ser Pro Ala Ala Ala
            20              25              30

Ala Pro Arg Val Thr Pro Val Val Asp Val Asp Asp Tyr Gly Ala
        35              40              45

Asp Pro Thr Gly Arg Thr Asp Ser Thr Pro Ala Val Ala Ala Ala Leu
    50              55              60

Arg His Ala Lys Ser Val Asp Arg Pro Val Arg Ile Val Phe Ser Lys
65              70              75              80

Gly Thr Tyr Gln Leu Tyr Pro Glu Arg Ala Glu Thr Arg Glu Leu Tyr
            85              90              95

Met Ser Asn Thr Val Gly Ala Asp Gln Arg Tyr Arg Asp Lys Lys Ile
            100             105             110
```

```
Gly Leu Leu Val Glu Asp Met His Asp Val Thr Val Asp Gly Gly Gly
        115             120             125

Ala Lys Leu Val His His Gly Leu Gln Thr Ala Phe Ala Ser Ile Arg
        130             135             140

Ser Thr Asp Val Thr Phe Gln Asn Phe Ser Phe Asp Tyr Ala Ala Pro
145             150             155             160

Glu Val Ile Asp Ala Thr Val Ala Thr Thr Gly Val Thr Asp Gly His
                165             170             175

Ala Tyr Arg Val Leu Lys Ile Pro Ala Gly Ser Pro Tyr Arg Val Asn
        180             185             190

Gly Thr His Ile Thr Trp Leu Gly Glu Thr Ser Pro Ala Thr Gly Gln
        195             200             205

Pro Tyr Trp Ser Gly Val Asp Gly Leu Gln Tyr Thr Gln Ile His Asp
        210             215             220

Pro Glu Ala Gln Arg Thr Trp Arg Gly Asp Asn Pro Leu Phe Asn Asp
225             230             235             240

Val Ala Ala Val Thr Asp Leu Gly Gly Arg Arg Ile Arg Ile Asp Tyr
                245             250             255

Thr Thr Ala Ala Arg Pro Ala Asp Ala Gly Leu Val Tyr Gln Met Arg
        260             265             270

Leu Ile Glu Arg Thr Glu Pro Gly Ala Phe Ile Trp Glu Ser Lys Asn
        275             280             285

Val Thr Met Arg Ser Met Asn Ala Tyr Tyr Leu Gln Ser Phe Gly Val
        290             295             300

Val Gly Gln Phe Ser Glu Asn Ile Ser Ile Asp Lys Val Asn Phe Ala
305             310             315             320

Pro Asp Pro Arg Ser Gly Arg Ser Thr Ala Ser Phe Ala Asp Phe Val
            325             330             335

Gln Met Ser Gly Val Lys Gly Lys Val Ser Ile Thr Arg Ser Leu Phe
        340             345             350

Asp Gly Pro His Asp Asp Pro Ile Asn Ile His Gly Thr Tyr Leu Glu
        355             360             365

Val Val Gly Lys Pro Gly Pro Ser Thr Leu Thr Leu Ala Tyr Lys His
```

```
                370                     375                         380


        Pro Gln Thr Ala Gly Phe Pro Gln Phe Ala Pro Gly Asp Glu Val Glu
        385             390             395             400

        Phe Ala Thr Lys Arg Thr Met Thr Pro Leu Ala Asp Ala His Ala Gln
                    405             410             415

        Val Thr Ala Val Asp Gly Pro Ser Gly Met Asp His Thr Lys Pro Leu
                420             425             430

        Thr Thr Met Thr Val Thr Phe Asp Arg Pro Val Pro Ala Gly Val Glu
                435             440             445

        Thr Gly Gly Thr Val Val Glu Asn Ile Thr Ala Thr Pro Ser Val Val
            450             455             460

        Ile Ser Gly Asn Val Phe Arg Asn Val Pro Thr Arg Gly Ile Leu Val
        465             470             475             480

        Thr Thr Arg Lys Pro Val Leu Ile Thr Gly Asn Arg Phe Asp Gly Met
                    485             490             495

        Ser Met Ala Ser Ile Tyr Val Ser Ala Asp Ala Tyr Gln Trp Tyr Glu
                    500             505             510

        Ser Gly Pro Val Ala Asp Leu Thr Ile Arg Gly Asn Ser Phe Thr Arg
                515             520             525

        Pro Ser Gly Pro Val Ile Phe Val Glu Pro Thr Asn Gln Val Ile Asp
            530             535             540

        Pro Ala Thr Pro Val His His Asn Ile Ser Val Glu His Asn Ser Phe
        545             550             555             560

        Asp Ile Gly Asp Val Thr Val Val Asn Ala Lys Ser Val Gly Gly Phe
                    565             570             575

        Ala Phe Thr Gly Asn Thr Val Arg Arg Leu Asp Gly Ala Asp His Pro
                580             585             590

        Pro Tyr Thr Ser Pro Leu Phe Val Phe His Gly Ser Ser Gly Ile Arg
                595             600             605

        Ile Ala Arg Asn His Tyr Asp Lys Gly Leu Asn Thr Ser Val Val Thr
            610             615             620


        Asp
        625
```

<210> 3
<211> 568
<212> PRT
<213> Bacteroides thetaiotaomicron

<400> 3

Met Met Ser Val Trp Phe Ile Gln Leu Ala Ile Phe Ala Gln Ser Arg
1   5   10   15

Ile Ile Glu Val Phe Pro Glu Gln Gly Lys Asp Ile Glu Asn Ile Ala
        20   25   30

Leu Ala Leu Lys Lys Ala Ala Asp Cys Lys Gly Arg Pro Val Thr Val
        35   40   45

Lys Phe Ser Pro Gly Ile Tyr Gln Leu Asp Arg Ala Lys Ser Ser Gln
    50   55   60

Val Leu Tyr Tyr Ile Ser Asn Thr Thr Ser Glu Leu Asp Asp Pro Asp
65   70   75   80

Pro Thr Lys His Ile Gly Leu Tyr Leu Asn Thr Leu Lys Asn Ile Thr
            85   90   95

Ile Asp Gly Cys Gly Ser Thr Leu Leu Met Asn Gly Glu Met Thr Ser
            100   105   110

Phe Val Leu Asp Lys Cys Glu Gly Ile Val Leu Lys Asn Phe Asn Ile
        115   120   125

Asp Tyr Lys His Pro Thr Gln Thr Glu Val Glu Val Leu Glu Glu Gly
    130   135   140

Asn Asp Tyr Leu Ile Val Gln Val His Pro Thr Ser Gln Tyr Arg Ile
145   150   155   160

Val Asp Ala Gln Leu Glu Trp Tyr Gly Asp Gly Trp Ser Phe Lys Asn
            165   170   175

Gly Ile Ala Gln Ser Tyr Asp Arg Ile Ser Glu Met Thr Trp Arg Ser
        180   185   190

Trp Ser Pro Met Glu Asn Leu Leu Arg Thr Val Glu Leu Arg Pro Asn
        195   200   205

Val Leu Tyr Leu Gln Tyr Lys Glu Lys Pro Gln Val Gly Leu His Thr
    210   215   220

Ile Phe Gln Met Arg Asp Ser Phe Arg Asp Glu Val Ser Gly Phe Val

32

Asn Arg Ser Lys Gly Ile Leu Leu Glu Asn Ile Asn Phe Tyr Tyr Leu
            245   250   255

Gly Asn Phe Gly Val Val Cys Gln Tyr Ser Glu Asn Ile Thr Val Asp
            260   265   270

Arg Cys Asn Phe Ala Pro Arg Pro Gly Ser Gly Arg Thr Asn Ala Gly
            275   280   285

Phe Ala Asp Phe Ile Gln Val Ser Gly Cys Arg Gly Met Ile Asp Ile
    290   295   300

Lys Asn Ser Arg Phe Ile Gly Ala His Asp Asp Pro Ile Asn Ile His
305   310   315   320

Gly Thr His Leu Arg Val Ile Glu Phe Leu Ser Asp Asn Arg Leu Lys
            325   330   335

Leu Arg Phe Met His Asp Gln Thr Phe Gly Phe Glu Ala Phe Phe Lys
            340   345   350

Gly Asp Asp Ile Glu Leu Val Asp Ser Arg Ser Leu Leu Val Val Gly
            355   360   365

Lys Cys Lys Val Lys Glu Ala Lys Leu Val Thr Pro Arg Glu Met Glu
    370   375   380

Leu Thr Leu Ser Ser Pro Leu Ser Ser Glu Val Met Gln Gln Lys Asp
385   390   395   400

Leu Val Ile Glu Asn Val Thr Trp Thr Pro Glu Val Arg Ile Thr Asn
            405   410   415

Asn Tyr Phe Ala Arg Val Pro Thr Arg Gly Ile Leu Ile Thr Thr Arg
            420   425   430

Arg Lys Ser Leu Ile Glu Gly Asn Thr Phe Tyr Gly Met Gln Met Ser
            435   440   445

Gly Ile Phe Val Ala Asp Asp Gly Leu Ser Trp Tyr Glu Ser Gly Pro
    450   455   460

Val His Asp Leu Thr Ile Arg Gln Asn Thr Phe Leu Asn Cys Gly Glu
465   470   475   480

Pro Ile Ile Ser Ile Asp Pro Glu Asn Arg Glu Tyr Lys Gly Ala Val
            485   490   495

```
His Lys Asn Ile Thr Ile Glu Glu Asn Tyr Phe Tyr Met Arg Lys Asn
        500                 505                 510

Ser Ser Cys Ala Ile Arg Ala Lys Ala Val Asp Gly Leu Met Ile Arg
        515                 520                 525

His Asn Leu Ile Tyr Ser Leu Asp Thr Glu Lys Asn Lys Glu Ser Asp
        530                 535                 540

Phe Ile Gln Met Tyr Asn Cys Asn Glu Val Thr Ile Lys Glu Asn Arg
545                 550                 555                 560

Val Gln Leu His His Leu Phe Lys
                565
```

<210> 4
<211> 605
<212> PRT
<213> Bacteroides fragilis

<400> 4

```
Met Lys Lys Tyr Leu His Ile Leu Pro Ala Cys Phe Leu Phe Tyr Ala
1               5                   10                  15

Ala Ala His Ala Gln Gln Lys Asp Thr Val Tyr Val Thr Asp Phe Gly
            20                  25                  30

Ala Val Pro Tyr Ser Tyr Glu Asn Cys Val Thr Gln Ile Gln Ala Ala
            35                  40                  45

Ile Asp Glu Cys Lys Arg Thr Gly Ala Lys Val Leu Ser Leu Pro Glu
        50                  55                  60

Gly Arg Tyr Asp Ile Trp Pro Glu Gly Ala Thr Arg Lys Glu Tyr Tyr
65                  70                  75                  80

Ile Ser Asn Thr Ser Thr Glu Gln Glu Cys Pro Ser Lys Val Lys Thr
                85                  90                  95

Val Gly Leu Met Leu His Glu Ile Asp Asp Leu Thr Ile Glu Gly Asn
            100                 105                 110

Gly Ala Thr Leu Met Tyr His Gly Lys Met Thr Thr Ile Ala Leu Glu
            115                 120                 125

His Cys Asn Gly Val Arg Ile Asn Asn Leu His Ile Asp Phe Glu Arg
            130                 135                 140

Pro Ala Gly Ser Glu Ile Gln Tyr Arg Lys Val Thr Gly Gly Glu Thr
```

```
            145                    150                    155                    160


        Glu Val Thr Leu His Arg Asp Thr Arg Tyr Glu Ile Val Asn Gly Lys
                    165                    170                    175


        Ile Arg Leu Tyr Gly Glu Gly Trp Arg Ser Asn Lys Asn His Cys Ile
                    180                    185                    190


        Glu Tyr Asp Pro Asp Thr Glu Ser Phe Thr Tyr Ser Gln Gly Trp Asn
                    195                    200                    205


        Thr Leu Ser Ala Ser Asp Ala Arg Glu Ile Ala Pro Gly Ile Val Arg
                    210                    215                    220


        Phe Asn Thr Pro Ala Glu Phe Met Pro Lys Ala Gly Asn Thr Leu Thr
        225                    230                    235                    240


        Val Arg Asp Ile Ile Arg Asp Gln Val Gly Phe Phe Ile Leu Glu Ser
                    245                    250                    255


        Lys Asn Ile Thr Leu Ser Arg Leu Gln Met His Tyr Met His Gly Leu
                    260                    265                    270


        Gly Ile Val Ser Gln Tyr Thr Glu Asn Ile Thr Met Asp Arg Val Lys
                    275                    280                    285


        Cys Ala Pro Arg Pro Asp Ser Gly Arg Leu Leu Ala Ala Ser Ala Asp
                    290                    295                    300


        Met Met His Phe Ser Gly Cys Lys Gly Lys Val Ile Ile Asp Ser Cys
        305                    310                    315                    320


        Tyr Phe Ala Gly Ala Gln Asp Asp Pro Val Asn Val His Gly Thr Asn
                    325                    330                    335


        Leu Arg Ala Leu Glu Lys Ile Asp Ala Gln Thr Leu Lys Leu Arg Phe
                    340                    345                    350


        Met His Gly Gln Ser Tyr Gly Phe Asn Ala Tyr Phe Lys Gly Asp Thr
                    355                    360                    365


        Val Ala Phe Ile Arg Ala Ala Thr Met Glu Arg Phe Ala Ser Ala Thr
                    370                    375                    380


        Val Arg Asp Val Arg Arg Ile Ser Asp Arg Ile Val Glu Val Arg Phe
        385                    390                    395                    400


        Asp Arg Asp Ile Pro Thr Ser Leu Glu Leu Asn His Asp Cys Val Glu
                    405                    410                    415
```

```
Asn Met Thr Cys Thr Pro Glu Val Glu Ile Arg Asn Ser Tyr Phe Thr
            420             425             430


Arg Thr Ser Thr Arg Gly Thr Leu Val Thr Thr Pro Arg Lys Val Val
            435             440             445


Ile Glu Asn Asn Thr Tyr Tyr Lys Thr Gly Met Ser Ala Ile Leu Ile
    450             455             460


Glu Ala Asp Ala Glu Gly Trp Tyr Glu Ser Gly Pro Val Lys Asp Val
465             470             475             480


Leu Ile Lys Gly Asn Thr Phe Ile Asp Cys Ala Tyr Asn Gly Gly Pro
            485             490             495


Gly His Ala Val Ile Ala Ile His Pro Ser Asn Lys Ile Ile Asp Ala
            500             505             510


Glu Arg Pro Val His Gln Asn Ile Arg Ile Glu Asp Asn Thr Phe Arg
            515             520             525


Thr Phe Asp Tyr Pro Val Leu Tyr Ala Lys Ser Thr Ala Gly Leu Leu
            530             535             540


Phe Arg Asn Asn Thr Ile Val Arg Thr Glu Thr Phe Pro Ala Ala Ser
545             550             555             560


Gly Asn Pro Tyr Val Phe Tyr Leu Asn Gly Cys Lys Lys Ala Val Ile
            565             570             575


Glu Gly Thr Val Phe Lys Gly Glu Thr Pro Arg Gln Ser Ile Lys Thr
            580             585             590


Glu Asn Met Lys Arg Lys Asp Leu Lys Thr Thr Ile Lys
            595             600             605
```

<210> 5
<211> 605
<212> PRT
<213> Bacteroides fragilis

<400> 5

```
Met Lys Lys Tyr Leu His Ile Leu Pro Ala Cys Phe Leu Phe Tyr Ala
1                 5                 10                15
```

```
Ala Ala His Ala Gln Gln Lys Asp Thr Val Tyr Val Thr Asp Phe Gly
            20                25                30
```

```
Ala Val Pro Tyr Ser Tyr Glu Asn Cys Val Thr Gln Ile Gln Ala Ala
```

```
                    35                     40                        45


        Ile Asp Glu Cys Lys Arg Thr Gly Ala Lys Val Leu Ser Leu Pro Glu
            50                  55                  60


        Gly Arg Tyr Asp Ile Trp Pro Glu Gly Ala Ile Arg Lys Glu Tyr Tyr
        65                  70                  75                  80


        Ile Ser Asn Thr Ser Thr Glu Gln Glu Cys Pro Ser Lys Val Lys Thr
                        85                  90                  95


        Val Gly Leu Met Leu His Glu Ile Asp Asp Leu Thr Ile Glu Gly Asn
                    100                 105                 110


        Gly Ala Thr Leu Met Tyr His Gly Lys Met Thr Thr Ile Ala Leu Glu
                    115                 120                 125


        His Cys Asn Gly Val Arg Ile Asn Asn Leu His Ile Asp Phe Glu Arg
            130                 135                 140


        Pro Ala Gly Ser Glu Ile Gln Tyr Arg Lys Val Thr Gly Gly Glu Thr
        145                 150                 155                 160


        Glu Val Thr Leu His Arg Asp Thr Arg Tyr Glu Ile Val Asn Gly Lys
                        165                 170                 175


        Ile Arg Leu Tyr Gly Glu Gly Trp Arg Ser Asn Arg Asn His Cys Ile
                    180                 185                 190


        Glu Tyr Asp Pro Asp Thr Glu Ser Phe Thr Tyr Ser Gln Gly Trp Asn
                    195                 200                 205


        Thr Leu Ser Ala Ser Asp Ala Arg Glu Ile Ala Pro Gly Ile Val Arg
            210                 215                 220


        Phe Asn Thr Pro Ala Glu Phe Met Pro Lys Ala Gly Asn Thr Leu Thr
        225                 230                 235                 240


        Val Arg Asp Ile Ile Arg Asp Gln Val Gly Leu Phe Ile Leu Glu Ser
                        245                 250                 255


        Lys Asn Ile Thr Leu Ser Arg Leu Gln Met His Tyr Met His Gly Leu
                    260                 265                 270


        Gly Ile Val Ser Gln Tyr Thr Glu Asn Ile Thr Met Asp Arg Val Lys
                    275                 280                 285


        Cys Ala Pro Arg Pro Asp Ser Gly Arg Leu Leu Ala Ala Ser Ala Asp
            290                 295                 300
```

```
Met Met His Phe Ser Gly Cys Lys Gly Lys Val Ile Ile Asp Ser Cys
305                 310             315                 320


Tyr Phe Ala Gly Ala Gln Asp Asp Pro Val Asn Val His Gly Thr Asn
                325             330                 335


Leu Arg Ala Leu Glu Lys Ile Asp Ala Gln Thr Leu Lys Leu Arg Phe
                340             345                 350


Met His Gly Gln Ser Tyr Gly Phe Asn Ala Tyr Phe Lys Gly Asp Thr
                355             360                 365


Val Ala Phe Val Arg Ala Ala Thr Met Glu Arg Phe Ala Ser Ala Thr
370                 375             380


Val Arg Asp Val Arg Arg Ile Ser Asp Arg Ile Val Glu Val Arg Phe
385                 390             395                 400


Asp Arg Asp Ile Pro Thr Ser Leu Glu Leu Asn His Asp Cys Val Glu
                405             410                 415


Asn Met Thr Cys Thr Pro Glu Val Glu Ile Arg Asn Cys Tyr Phe Thr
                420             425                 430


Arg Thr Ser Thr Arg Gly Thr Leu Val Thr Thr Pro Arg Lys Val Val
                435             440                 445


Ile Glu Asn Asn Thr Tyr Tyr Lys Thr Gly Met Ser Ala Ile Leu Ile
    450             455             460


Glu Ala Asp Ala Glu Gly Trp Tyr Glu Ser Gly Pro Val Lys Asp Val
465             470             475             480


Leu Ile Lys Gly Asn Thr Phe Ile Asp Cys Ala Tyr Asn Gly Gly Pro
                485             490             495


Gly His Ala Val Ile Ala Ile His Pro Ser Asn Lys Ile Ile Asp Ala
            500             505             510


Glu Arg Pro Val His Gln Asn Ile Arg Ile Glu Asp Asn Thr Phe Arg
                515             520             525


Thr Phe Asp Tyr Pro Val Leu Tyr Ala Lys Ser Thr Ala Gly Leu Leu
            530             535             540


Phe Arg Asn Asn Thr Ile Val Arg Thr Glu Thr Phe Pro Ala Val Ser
545                 550             555                 560
```

```
        Gly Asn Pro Tyr Val Phe Tyr Leu Asn Gly Cys Lys Lys Ala Val Ile
                        565             570                 575


        Glu Gly Thr Val Phe Glu Gly Glu Thr Pro Arg Gln Ser Ile Lys Thr
                        580             585                 590


        Glu Asn Met Lys Arg Lys Asp Leu Lys Thr Thr Ile Lys
                        595             600                 605
```

<210> 6
<211> 595
<212> PRT
<213> Bacteroides fragilis

<400> 6

```
Met Lys Thr Ile Leu Leu Phe Ala Leu Ser Leu Leu Leu Ser Leu Ser
1               5                   10                  15

Val Ser Asp Val Cys Ala Gln Glu Arg Val Tyr Asp Ile Ser Gln Phe
            20                  25                  30

Gly Leu Lys Ala Asn Ser Lys Lys Asn Ala Ser Pro Val Val Arg Lys
            35                  40                  45

Ala Ile Ala Lys Ile Lys Ala Glu Cys Arg Asp Gly Glu Lys Val Ile
        50                  55                  60

Leu Arg Phe Pro Ala Gly Arg Tyr Asn Phe His Glu Ala Gly Ser Thr
65                  70                  75                  80

Val Arg Glu Tyr Tyr Ile Ser Asn His Asp Gln Asp Asn Pro Lys Lys
                85                  90                  95

Val Gly Ile Ala Leu Glu Asp Met Lys Asn Leu Thr Ile Asp Gly Gln
            100                 105                 110

Gly Ser Glu Phe Val Phe Tyr Gly Arg Met Ile Pro Val Ser Leu Leu
            115                 120                 125

Arg Ser Glu Asn Cys Val Leu Lys Asn Phe Ser Ile Asp Phe Glu Gln
        130                 135                 140

Pro His Ile Ala Gln Val Gln Val Val Glu Asn Asp Pro Glu Lys Gly
145                 150                 155                 160

Ile Thr Phe Glu Pro Ala Pro Trp Val Asp Tyr Arg Ile Ser Lys Asp
                165                 170                 175

Ser Val Phe Glu Gly Leu Gly Glu Gly Trp Val Met Arg Tyr Ser Trp
            180                 185                 190
```

42

Gly Ile Ala Phe Asp Gly Lys Thr Lys His Val Val Tyr Asn Thr Ser
195 200 205

Asp Ile Gly Cys Pro Thr Lys Gly Ala Phe Glu Val Ala Pro Arg Arg
210 215 220

Ile Cys Ser Pro Lys Trp Lys Asp Ala Arg Leu Val Pro Gly Thr Val
225 230 235 240

Val Ala Met Arg Gly Trp Gly Arg Pro Thr Pro Gly Ile Phe Met Ser
245 250 255

His Asp Val Asn Thr Ser Leu Leu Asp Val Lys Val His Tyr Ala Glu
260 265 270

Gly Met Gly Leu Leu Ala Gln Leu Cys Glu Asp Ile Thr Leu Asp Gly
275 280 285

Phe Gly Val Cys Leu Lys Gly Asn Asn Asp Pro Arg Tyr Phe Thr Thr
290 295 300

Gln Ala Asp Ala Thr His Phe Ser Gly Cys Lys Gly Lys Ile Val Ser
305 310 315 320

Lys Asn Gly Leu Tyr Glu Gly Met Met Asp Asp Ala Ile Asn Val His
325 330 335

Gly Thr Tyr Leu Lys Val Ile Lys Arg Val Asp Asp His Thr Leu Ile
340 345 350

Gly Arg Tyr Met His Asp Gln Ser Trp Gly Phe Glu Trp Gly Arg Pro
355 360 365

Gly Asp Asp Val Gln Phe Val Arg Ser Glu Thr Met Glu Leu Ile Gly
370 375 380

Lys Gln Asn Gln Ile Thr Ala Ile Arg Pro Tyr Asp Lys Gly Glu Ile
385 390 395 400

Gln Gly Ala Arg Glu Phe Ser Ile Thr Phe Lys Glu Ala Ile Asp Pro
405 410 415

Ala Ile Asn Glu Lys Ser Gly Phe Gly Ile Glu Asn Leu Thr Trp Thr
420 425 430

Pro Glu Val Leu Phe Ala Gly Asn Thr Ile Arg Asn Asn Arg Ala Arg
435 440 445

```
Gly Thr Leu Phe Ser Thr Pro Lys Lys Thr Val Val Glu Asp Asn Leu
    450                 455                 460

Phe Asp His Thr Ser Gly Thr Ala Ile Leu Leu Cys Gly Asp Cys Asn
465                 470                 475                 480

Gly Trp Phe Glu Thr Gly Ala Cys Arg Asp Val Thr Ile Arg Arg Asn
                485                 490                 495

Arg Phe Ile Asn Ala Leu Thr Asn Met Phe Gln Phe Thr Asn Ala Val
            500                 505                 510

Ile Ser Ile Tyr Pro Glu Ile Pro Asn Leu Lys Asp Gln Gln Lys Tyr
        515                 520                 525

Phe His Gly Gly Lys Asp Gly Gly Ile Val Ile Glu Asp Asn Glu Phe
    530                 535                 540

Asp Thr Phe Asp Ala Pro Ile Leu Tyr Ala Lys Ser Val Asp Gly Leu
545                 550                 555                 560

Ile Phe Arg Asn Asn Val Ile Lys Thr Asn Thr Glu Phe Lys Pro Phe
                565                 570                 575

His Trp Asn Lys Asp Arg Phe Leu Leu Glu Arg Val Thr Asn Val Lys
            580                 585                 590

Ile Ser Glu
        595
```

<210> 7
<211> 595
<212> PRT
<213> Bacteroides fragilis

<400> 7

```
Met Lys Thr Ile Leu Leu Phe Ala Leu Ser Leu Leu Leu Ser Leu Ser
1               5               10              15

Val Ser Asp Val Cys Ala Gln Glu Arg Val Tyr Asp Ile Ser Gln Phe
            20              25              30

Gly Leu Lys Ala Asn Ser Lys Lys Asn Ala Ser Pro Val Val Arg Lys
        35              40              45

Ala Ile Ala Lys Ile Lys Ala Glu Cys Arg Asp Gly Glu Lys Val Ile
        50              55              60

Leu Arg Phe Pro Ala Gly Arg Tyr Asn Phe His Glu Ala Gly Ser Thr
65              70              75              80
```

```
    Val Arg Glu Tyr Tyr Ile Ser Asn His Asp Gln Asp Asn Pro Lys Lys
                    85              90                  95

    Val Gly Ile Ala Leu Glu Asp Met Lys Asn Leu Thr Ile Asp Gly Gln
                    100             105                 110

    Gly Ser Glu Phe Val Phe Tyr Gly Arg Met Ile Pro Val Ser Leu Leu
                    115             120                 125

    Arg Ser Glu Asn Cys Val Leu Lys Asn Phe Ser Ile Asp Phe Glu Gln
        130             135             140

    Pro His Ile Ala Gln Val Gln Val Val Glu Asn Asp Pro Glu Lys Gly
    145             150             155                 160

    Ile Thr Phe Glu Pro Ala Pro Trp Val Asp Tyr Arg Ile Ser Lys Asp
                    165             170                 175

    Ser Val Phe Glu Gly Leu Gly Glu Gly Trp Val Met Arg Tyr Ser Trp
                    180             185                 190

    Gly Ile Ala Phe Asp Gly Lys Thr Lys His Val Val Tyr Asn Thr Ser
                    195             200                 205

    Asp Ile Gly Cys Pro Thr Lys Gly Ala Phe Glu Val Ala Pro Arg Arg
                    210             215                 220

    Ile Cys Ser Pro Lys Trp Lys Asp Ala Arg Leu Val Pro Gly Thr Val
    225             230             235                 240

    Val Ala Met Arg Gly Trp Gly Arg Pro Thr Pro Gly Ile Phe Met Ser
                    245             250                 255

    His Asp Val Asn Thr Ser Leu Leu Asp Val Lys Val His Tyr Ala Glu
                    260             265                 270

    Gly Met Gly Leu Leu Ala Gln Leu Cys Glu Asp Ile Thr Leu Asp Gly
                    275             280                 285

    Phe Gly Val Cys Leu Lys Gly Asp Asn Asp Pro Arg Tyr Phe Thr Thr
        290             295             300

    Gln Ala Asp Ala Thr His Phe Ser Gly Cys Lys Gly Lys Ile Val Ser
    305             310             315                 320

    Lys Asn Gly Leu Tyr Glu Gly Met Met Asp Asp Ala Ile Asn Val His
                    325             330                 335
```

Gly Thr Tyr Leu Lys Val Ile Lys Arg Val Asp Asp His Thr Leu Ile
        340   345   350

Gly Arg Tyr Met His Asp Gln Ser Trp Gly Phe Glu Trp Gly Arg Pro
        355   360   365

Gly Asp Asp Val Gln Phe Val Arg Ser Glu Thr Met Glu Leu Ile Gly
        370   375   380

Lys Gln Asn Gln Ile Thr Ala Ile Arg Pro Tyr Asp Lys Gly Glu Ile
385   390   395   400

Arg Gly Ala Arg Glu Phe Ser Ile Thr Phe Lys Glu Ala Ile Asp Pro
                405   410   415

Ala Ile Asn Glu Lys Ser Gly Phe Gly Ile Glu Asn Leu Thr Trp Thr
        420   425   430

Pro Glu Val Leu Phe Ala Gly Asn Thr Ile Arg Asn Asn Arg Ala Arg
        435   440   445

Gly Thr Leu Phe Ser Thr Pro Lys Lys Thr Val Val Glu Asp Asn Leu
        450   455   460

Phe Asp His Thr Ser Gly Thr Ala Ile Leu Leu Cys Gly Asp Cys Asn
465   470   475   480

Gly Trp Phe Glu Thr Gly Ala Cys Arg Asp Val Thr Ile Arg Arg Asn
                485   490   495

Arg Phe Ile Asn Ala Leu Thr Asn Met Phe Gln Phe Thr Asn Ala Val
        500   505   510

Ile Ser Ile Tyr Pro Glu Ile Pro Asn Leu Lys Asp Gln Gln Lys Tyr
        515   520   525

Phe His Gly Gly Lys Asp Gly Gly Ile Val Ile Glu Asp Asn Glu Phe
        530   535   540

Asp Thr Phe Asp Ala Pro Ile Leu Tyr Ala Lys Ser Val Asp Gly Leu
545   550   555   560

Ile Phe Arg Asn Asn Val Ile Lys Thr Asn Thr Glu Phe Lys Pro Phe
                565   570   575

His Trp Asn Lys Asp Arg Phe Leu Leu Glu Arg Val Thr Asn Val Lys
        580   585   590

```
Ile Ser Glu
        595
```

<210> 8
<211> 615
<212> PRT
<213> Bacteroides thetaiotaomicron

<400> 8

```
Met Arg Thr Phe Leu Ser Leu Lys Thr Cys Leu Leu Ser Ala Leu Leu
1               5               10              15

Leu Cys Val Asn Ser Ile Ala Ala Ser Lys Ile Ile Ser Val Ser Asp
            20              25              30

Phe Gly Leu Lys Pro Asp Ser Arg Ile Asn Ala Val Pro Phe Ile Gln
        35              40              45

Lys Ala Ile Asp Ala Cys Lys Gln His Pro Gly Ser Thr Leu Val Phe
        50              55              60

Pro Lys Gly Arg Tyr Asp Phe Trp Ala Gln His Ala Ile Glu Lys Asp
65              70              75              80

Tyr Tyr Glu Thr Asn Thr Tyr Asp Val Asn Pro Lys Ile Leu Ala Val
            85              90              95

Leu Leu Glu Gln Ile Asn Asp Leu Thr Ile Asp Gly Asn Gly Ser Glu
            100             105             110

Phe Ile Met His Gly Arg Met Gln Pro Phe Thr Leu Asp His Cys Arg
            115             120             125

Asn Ile Thr Leu Lys Asn Phe Ser Val Asp Trp Glu Ile Pro Leu Thr
            130             135             140

Ala Gln Gly Ile Val Thr Gln Ser Thr Ser Glu Tyr Leu Glu Ile Glu
145             150             155             160

Ile Asp Ser His Gln Tyr Pro Tyr Ile Ile Glu Asn Lys Arg Leu Thr
            165             170             175

Phe Val Gly Glu Gly Trp Lys Ser Ser Leu Trp Ala Ile Met Gln Phe
            180             185             190

Asp Pro Asp Thr His Leu Val Leu Pro Asn Thr Gly Asp Asn Leu Gly
            195             200             205

Trp Arg Ser Tyr Asp Ala Thr Glu Ile Asn Pro Gly Leu Ile Arg Leu
210             215             220
```

49

```
Ser Asp Pro Lys Lys Glu Ala Asp Lys Phe Phe Pro Ala Pro Gly Thr
225             230             235             240

Val Leu Val Leu Arg His Ser Thr Arg Asp His Ala Gly Ile Phe Ile
            245             250             255

Tyr His Ser Met Asp Thr Lys Leu Glu Asn Val Lys Leu Phe His Thr
        260             265             270

Cys Gly Leu Gly Ile Leu Ser Gln Tyr Ser Lys Asn Ile Ser Phe Asn
        275             280             285

Asp Val His Ile Ile Pro Asn Thr Ser Lys Lys Arg Val Leu Ser Gly
    290             295             300

His Asp Asp Gly Phe His Phe Met Gly Cys Ser Gly Leu Leu Lys Ile
305             310             315             320

Glu Asn Cys Ser Trp Ala Gly Leu Met Asp Asp Pro Ile Asn Ile His
            325             330             335

Gly Thr Cys Ser Arg Ile Met Glu Val Leu Ser Pro Thr Arg Ile Lys
        340             345             350

Cys Lys Phe Met Gln Asp Met Ser Glu Gly Met Glu Trp Gly Arg Pro
        355             360             365

Asp Glu Thr Ile Gly Phe Ile Glu His Lys Thr Met Arg Thr Val Ala
    370             375             380

Thr Gly Lys Met Asn Lys Phe Glu Ala Leu Asn Lys Ala Glu Phe Ile
385             390             395             400

Ile Glu Leu Ser Val Pro Leu Pro Ala Gly Val Glu Ala Gly Tyr Val
            405             410             415

Ile Glu Asn Leu Thr Cys Thr Pro Asp Ala Glu Ile Arg Asn Cys His
            420             425             430

Phe Gly Ser Cys Arg Ala Arg Gly Leu Leu Val Ser Thr Pro Gly Lys
        435             440             445

Val Ile Ile Glu Asn Asn Val Phe Glu Ser Ser Gly Ser Ala Ile Leu
    450             455             460

Ile Ala Gly Asp Ala Asn Ala Trp Tyr Glu Ser Gly Ala Val Lys Asp
465             470             475             480
```

```
        Val Leu Ile Arg Asn Asn Asp Phe Arg Tyr Pro Cys Asn Ser Ser Ile
                    485                 490                 495


        Tyr Gln Phe Cys Glu Ala Val Ile Ser Ile Asp Pro Glu Ile Pro Thr
                    500                 505                 510


        Pro Glu Gln Lys Tyr Pro Tyr His Arg Asn Ile Arg Ile Met Asp Asn
                    515                 520                 525


        Thr Phe His Leu Phe Asp Tyr Pro Ile Leu Phe Ala Arg Ser Val Asn
                    530                 535                 540


        Gly Leu Thr Phe Ser Ser Asn Thr Leu Ile Arg Asp Thr Thr Tyr Gln
        545                 550                 555                 560


        Pro Tyr His Tyr Arg Lys Glu Gly Ile Thr Leu Glu Ala Cys Lys Ser
                    565                 570                 575


        Val Val Ile Ser Asn Asn Lys Ile Glu Gly Asp Val Leu Gly Arg Ile
                    580                 585                 590


        Val Thr Ile Glu Lys Met Lys Pro Ser Asp Val Lys Ile Ser Lys Asn
                    595                 600                 605


        Pro Phe Phe Lys Leu Lys Lys
            610                 615
```

<210> 9
<211> 665
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic consensus sequence

<220>
<221> MOD_RES
<222> (13)..(13)
<223> Phe, Val, Tyr or Ile

<220>
<221> MOD_RES
<222> (15)..(15)
<223> Phe, His, Leu or Ser

<220>
<221> MOD_RES
<222> (17)..(17)
<223> Gly, Gln, Leu, Ala or Lys

<220>

<221> MOD_RES
<222> (21) .. (21)
<223> Ala, Phe or Leu

<220>
<221> MOD_RES
<222> (23) .. (23)
<223> Leu, Gln, Phe, Ser or Ala

<220>
<221> MOD_RES
<222> (25) .. (25)
<223> Gly, Ala, Ser or Leu

<220>
<221> MOD_RES
<222> (27) .. (27)
<223> Thr, Ala, Ser or Cys

<220>
<221> MOD_RES
<222> (28) .. (28)
<223> Ser, His, Asp or Val

<220>
<221> MOD_RES
<222> (29) .. (29)
<223> Pro or Asn

<220>
<221> MOD_RES
<222> (35)..(35)
<223> Arg, Ala, Cys or Ile

<220>
<221> MOD_RES
<222> (39) .. (39)
<223> Val, Asp, Arg or Lys

<220>
<221> MOD_RES
<222> (48)..(48)
<223> Ala or Leu

<220>
<221> MOD_RES
<222> (51)..(51)
<223> Thr, Tyr, Asn or Asp

<220>
<221> MOD_RES
<222> (53)..(53)
<223> Arg, Tyr or Lys

<220>
<221> MOD_RES
<222> (59) .. (59)
<223> Ala, Ile, Gln, Val or Phe

<220>
<221> MOD_RES
<222> (60)..(60)
<223> Val, Ala or Ile

<220>
<221> MOD_RES
<222> (73)..(73)
<223> Val, Lys, Arg, Asp or Gln

<220>
<221> MOD_RES
<222> (75)..(75)
<223> Arg, Gly, Glu or Pro

<220>
<221> MOD_RES
<222> (76)..(76)
<223> Pro, Ala, Lys or Gly

<220>
<221> MOD_RES
<222> (78)..(78)
<223> Arg, Thr, Val or Ile

<220>
<221> MOD_RES
<222> (80)..(80)
<223> Val, Lys, Ser or Arg

<220>
<221> MOD_RES
<222> (83)..(83)
<223> Lys, Glu, Pro or Ala

<220>
<221> MOD_RES
<222> (91)..(91)
<223> Glu, Ala or Gln

<220>
<221> MOD_RES
<222> (95)..(95)
<223> Thr, Gln, Arg, Val or Glu

<220>
<221> MOD_RES
<222> (96)..(96)
<223> Arg, Val or Lys,

<220>
<221> MOD_RES
<222> (104)..(104)
<223> Thr, Ser, Asp or Tyr

<220>
<221> MOD_RES
<222> (108)..(108)

<223> Asp or Glu

<220>
<221> MOD_RES
<222> (119)..(119)
<223> Tyr, Leu, Met or Ala

<220>
<221> MOD_RES
<222> (123)..(123)
<223> Met, Leu or Ile

<220>
<221> MOD_RES
<222> (134)..(134)
<223> Lys, Thr or Glu

<220>
<221> MOD_RES
<222> (137)..(137)
<223> His, Met, Tyr or Phe

<220>
<221> MOD_RES
<222> (147)..(147)
<223> Ile, Asp, Glu or Leu

<220>
<221> MOD_RES
<222> (148)..(148)
<223> Arg, Lys or His

<220>
<221> MOD_RES
<222> (151)..(151)
<223> Asp, Gly or Asn

<220>
<221> MOD_RES
<222> (163)..(163)
<223> Ala, His, Arg, Gln or Ile

<220>
<221> MOD_RES
<222> (165)..(165)
<223> Glu, Thr, Ala, His or Leu

<220>
<221> MOD_RES
<222> (166)..(166)
<223> Val, Gln, Gly, Ile or Thr

<220>
<221> MOD_RES
<222> (168)..(168)
<223> Asp, Glu or Gln

<220>

<221> MOD_RES
<222> (172)..(172)
<223> Ala, Leu, Arg, Val or Thr

<220>
<221> MOD_RES
<222> (174)..(174)
<223> Thr, Glu, Val, Asn or Ser

<220>
<221> MOD_RES
<222> (178)..(178)
<223> Asp or Thr

<220>
<221> MOD_RES
<222> (181)..(181)
<223> Ala, Asp, Glu, Lys or Tyr

<220>
<221> MOD_RES
<222> (182)..(182)
<223> Tyr or Gly

<220>
<221> MOD_RES
<222> (183)..(183)
<223> Arg, Leu, Thr or Ile

<220>
<221> MOD_RES
<222> (187)..(187)
<223> Ile, Val, Leu or Pro

<220>
<221> MOD_RES
<222> (190)..(190)
<223> Gly, Thr, Asp, Trp or His

<220>
<221> MOD_RES
<222> (191)..(191)
<223> Ser, Thr, Val or Gln

<220>
<221> MOD_RES
<222> (192)..(192)
<223> Pro, Gln, Arg, Asp or Tyr

<220>
<221> MOD_RES
<222> (197)..(197)
<223> Gly, Asp, Asn, Lys or Glu

<220>
<221> MOD_RES
<222> (198)..(198)
<223> Thr, Ala, Gly, Asp or Asn

<220>
<221> MOD_RES
<222> (200)..(200)
<223> His, Gln, Lys, Val or Arg

<220>
<221> MOD_RES
<222> (203)..(203)
<223> Trp, Leu, Gly or Phe

<220>
<221> MOD_RES
<222> (204)..(204)
<223> Leu, Tyr or Val

<220>
<221> MOD_RES
<222> (209) .. (209)
<223> Pro, Arg, Val or Lys

<220>
<221> MOD_RES
<222> (211)..(211)
<223> Thr, Asn, Arg or Ser

<220>
<221> MOD_RES
<222> (214)..(214)
<223> Pro, Asn, Ser or Trp

<220>
<221> MOD_RES
<222> (215)..(215)
<223> Tyr, His, Trp or Ala

<220>
<221> MOD_RES
<222> (216)..(216)
<223> Trp, Cys, Gly or Ile

<220>
<221> MOD_RES
<222> (218)..(218)
<223> Gly, Phe, Glu, Ala or Gln

<220>
<221> MOD_RES
<222> (221)..(221)
<223> Gly or Pro

<220>
<221> MOD_RES
<222> (224)..(224)
<223> Tyr, Ile, Glu, Lys or His

<220>
<221> MOD_RES
<222> (225)..(225)

<223> Thr, Ala, Ser, His or Leu

<220>
<221> MOD_RES
<222> (227)..(227)
<223> Ile, Ser, Thr, Val or Leu

<220>
<221> MOD_RES
<222> (233)..(233)
<223> Gln, Glu or Asn

<220>
<221> MOD_RES
<222> (234)..(234)
<223> Arg, Met, Asn, Ile or Leu

<220>
<221> MOD_RES
<222> (238)..(238)
<223> Gly, Ser, Ala or Thr

<220>
<221> MOD_RES
<222> (239) .. (239)
<223> Asp, Trp, Ser, Lys or Tyr

<220>
<221> MOD_RES
<222> (242)..(242)
<223> Leu, Met, Arg, Phe or Thr

<220>
<221> MOD_RES
<222> (251)..(251)
<223> Asp, Glu, Phe, Ile or Leu

<220>
<221> MOD_RES
<222> (252)..(252)
<223> Leu, Asn, Cys or Ser

<220>
<221> MOD_RES
<222> (253)..(253)
<223> Gly, Arg, Thr, Ser or Asp

<220>
<221> MOD_RES
<222> (260)..(260)
<223> Asp, Gln, Glu, Arg or Lys

<220>
<221> MOD_RES
<222> (262)..(262)
<223> Thr, Lys, Met, Val or Phe

<220>

<221> MOD_RES
<222> (268)..(268)
<223> Ala or Val

<220>
<221> MOD_RES
<222> (269) .. (269)
<223> Asp or Gly

<220>
<221> MOD_RES
<222> (270)..(270)
<223> Ala or Leu

<220>
<221> MOD_RES
<222> (271)..(271)
<223> Gly or His

<220>
<221> MOD_RES
<222> (275)..(275)
<223> Gln, Thr, Ala or Val

<220>
<221> MOD_RES
<222> (280)..(280)
<223> Glu, Phe, Ile, Gly or Thr

<220>
<221> MOD_RES
<222> (283)..(283)
<223> Glu, Gln, Thr or His

<220>
<221> MOD_RES
<222> (284)..(284)
<223> Pro, Val or Ala

<220>
<221> MOD_RES
<222> (289) .. (289)
<223> Trp, Asn, Leu, Ser or Tyr

<220>
<221> MOD_RES
<222> (290)..(290)
<223> Glu, Arg or His

<220>
<221> MOD_RES
<222> (294)..(294)
<223> Val, Ile or Thr

<220>
<221> MOD_RES
<222> (297)..(297)
<223> Arg, Glu, Ser or Leu

<220>
<221> MOD_RES
<222> (298)..(298)
<223> Ser, Asn, Arg or Asp

<220>
<221> MOD_RES
<222> (301)..(301)
<223> Ala, Phe, Met, Val or Leu

<220>
<221> MOD_RES
<222> (304)..(304)
<223> Leu, Met, Ala or Thr

<220>
<221> MOD_RES
<222> (305)..(305)
<223> Gln, Gly, His, Glu or Cys

<220>
<221> MOD_RES
<222> (319)..(319)
<223> Ile, Val, Met, Leu or Phe

<220>
<221> MOD_RES
<222> (323)..(323)
<223> Asn, Lys, Gly or His

<220>
<221> MOD_RES
<222> (324)..(324)
<223> Phe, Cys, Val or Ile

<220>
<221> MOD_RES
<222> (330)..(330)
<223> Arg, Gly, Asp, Asn or Ser

<220>
<221> MOD_RES
<222> (334)..(334)
<223> Ser, Thr, Leu, Tyr or Val

<220>
<221> MOD_RES
<222> (337)..(337)
<223> Ser, Gly, Ala or Thr

<220>
<221> MOD_RES
<222> (338)..(338)
<223> Phe, Ser, Gln or His

<220>
<221> MOD_RES
<222> (341)..(341)

<223> Phe, Met, Ala or Gly

<220>
<221> MOD_RES
<222> (342)..(342)
<223> Val, Ile, Met, Thr or Phe

<220>
<221> MOD_RES
<222> (351)..(351)
<223> Val, Ile or Leu

<220>
<221> MOD_RES
<222> (352)..(352)
<223> Ser, Asp, Ile, Val or Lys

<220>
<221> MOD_RES
<222> (379)..(379)
<223> Pro, Leu, Ile or Val

<220>
<221> MOD_RES
<222> (382)..(382)
<223> Ser, Asn, Gln, His or Thr

<220>
<221> MOD_RES
<222> (394)..(394)
<223> Ala, Phe, Tyr, Trp or Glu

<220>
<221> MOD_RES
<222> (398)..(398)
<223> Gln, Ala or Trp

<220>
<221> MOD_RES
<222> (400)..(400)
<223> Ala, Phe or Arg

<220>
<221> MOD_RES
<222> (404)..(404)
<223> Glu, Asp or Thr

<220>
<221> MOD_RES
<222> (406)..(406)
<223> Glu, Ala, Gln or Gly

<220>
<221> MOD_RES
<222> (411)..(411)
<223> Arg, Ala, Glu or Lys

<220>

<221> MOD_RES
<222> (415)..(415)
<223> Pro, Val, Arg, Leu or Thr

5
<220>
<221> MOD_RES
<222> (416)..(416)
<223> Leu, Val, Phe or Ile

10
<220>
<221> MOD_RES
<222> (424)..(424)
<223> Thr, Ala or Lys

15
<220>
<221> MOD_RES
<222> (425)..(425)
<223> Ala, Lys, Val, Ile or Met

20
<220>
<221> MOD_RES
<222> (428)..(428)
<223> Gly or Thr

25
<220>
<221> MOD_RES
<222> (433)..(433)
<223> Asp, Glu, Val, Gly or Phe

30
<220>
<221> MOD_RES
<222> (435)..(435)
<223> Thr, Arg, Ile or Ala

35
<220>
<221> MOD_RES
<222> (436)..(436)
<223> Lys, Leu, Ile, Arg or Gln

40
<220>
<221> MOD_RES
<222> (438)..(438)
<223> Leu, Ser, Asp, Ala or Lys

45
<220>
<221> MOD_RES
<222> (443)..(443)
<223> Val, Glu or Ile

50
<220>
<221> MOD_RES
<222> (448)..(448)
<223> Pro, Asp or Ala

55
<220>
<221> MOD_RES
<222> (453)..(453)
<223> Gly, Ser, Ile or Ala

<220>
<221> MOD_RES
<222> (454)..(454)
<223> Val, Leu, Asn or Gly

<220>
<221> MOD_RES
<222> (456)..(456)
<223> Thr, Leu, Lys or Glu

<220>
<221> MOD_RES
<222> (457)..(457)
<223> Gly, Lys, Asn, Ser or Ala

<220>
<221> MOD_RES
<222> (459)..(459)
<223> Thr, Leu, Asp, Phe or Tyr

<220>
<221> MOD_RES
<222> (466)..(466)
<223> Ala, Trp or Cys

<220>
<221> MOD_RES
<222> (479)..(479)
<223> Asn, Arg or Ser

<220>
<221> MOD_RES
<222> (480)..(480)
<223> Val, Thr, Asn or Cys

<220>
<221> MOD_RES
<222> (491)..(491)
<223> Lys, Arg or Gly

<220>
<221> MOD_RES
<222> (501)..(501)
<223> Asp, Tyr or Glu

<220>
<221> MOD_RES
<222> (502)..(502)
<223> Gly, Lys or His

<220>
<221> MOD_RES
<222> (511)..(511)
<223> Ser, Ala, Glu or Cys

<220>
<221> MOD_RES
<222> (512)..(512)

<223> Ala, Asp or Gly

<220>
<221> MOD_RES
<222> (538)..(538)
<223> Cys, Leu or Asn

<220>
<221> MOD_RES
<222> (539)..(539)
<223> Ala, Thr or Ser

<220>
<221> MOD_RES
<222> (540)..(540)
<223> Tyr, Asn or Ser

<220>
<221> MOD_RES
<222> (541)..(541)
<223> Asn, Met or Ile

<220>
<221> MOD_RES
<222> (542)..(542)
<223> Gly, Phe or Tyr

<220>
<221> MOD_RES
<222> (544)..(544)
<223> Pro, Cys or Phe

<220>
<221> MOD_RES
<222> (546)..(546)
<223> Gly, Glu, His or Asn

<220>
<221> MOD_RES
<222> (552)..(552)
<223> Glu, Asp, His or Tyr

<220>
<221> MOD_RES
<222> (557)..(557)
<223> Val, Glu, Ile, Asn or Thr

<220>
<221> MOD_RES
<222> (559)..(559)
<223> Asp, Lys or Glu

<220>
<221> MOD_RES
<222> (560)..(560)
<223> Pro, Gly, Ala, Asp or Gln

<220>

<221> MOD_RES
<222> (561)..(561)
<223> Ala, Glu, Gln or Lys

<220>
<221> MOD_RES
<222> (562)..(562)
<223> Thr, Val, Arg, Gln or Tyr

<220>
<221> MOD_RES
<222> (564)..(564)
<223> Tyr, Lys or Val

<220>
<221> MOD_RES
<222> (581)..(581)
<223> Asp, Arg or His

<220>
<221> MOD_RES
<222> (587)..(587)
<223> Val, Ala or Ile

<220>
<221> MOD_RES
<222> (597)..(597)
<223> Ala, Met, Leu, Ile or Thr

<220>
<221> MOD_RES
<222> (604)..(604)
<223> Arg, Tyr, Val, Lys or Ile

<220>
<221> MOD_RES
<222> (606)..(606)
<223> Leu, Thr, Asn or Asp

<220>
<221> MOD_RES
<222> (614)..(614)
<223> Tyr, Gly or Trp

<220>
<221> MOD_RES
<222> (618)..(618)
<223> Leu, Phe, Val, Arg or Gly

<220>
<221> MOD_RES
<222> (620)..(620)
<223> Val, Gln, Tyr, Leu or Thr

<220>
<221> MOD_RES
<222> (626)..(626)
<223> Gly, Glu, Lys, Asn or Ser

<220>
<221> MOD_RES
<222> (639)..(639)
<223> Asn, Leu or Pro

<220>
<221> MOD_RES
<222> (643)..(643)
<223> Val or Ile

<220>
<221> MOD_RES
<222> (644)..(644)
<223> Thr or Lys

<400> 9

```
Met Ala His Gly Cys Ser Gly Gly Ala Met Lys Thr Xaa Leu Xaa Ile
1               5                   10              15

Xaa Leu Ala Leu Xaa Leu Xaa Leu Xaa Ala Xaa Xaa Xaa Ala Ala Ala
            20                  25              30
```

```
          Ala Val Xaa Ala Gln Glu Xaa Val Val Asp Val Ser Asp Phe Gly Xaa
                  35              40              45

  5       Lys Pro Xaa Ser Xaa Lys Asn Ala Val Pro Xaa Xaa Gln Ala Ala Ile
                  50              55              60

          Asp Lys Ile Lys Ala Glu Cys Lys Xaa Gly Xaa Xaa Val Xaa Leu Xaa
          65              70              75              80
 10
          Phe Pro Xaa Gly Arg Tyr Asp Phe Trp Pro Xaa Gly Ala Thr Xaa Xaa
                          85              90              95

 15       Glu Tyr Tyr Ile Ser Asn Thr Xaa Thr Glu Gln Xaa Cys Pro Asp Asn
                      100             105             110

          Pro Lys Lys Val Gly Leu Xaa Leu Glu Asp Xaa Lys Asp Leu Thr Ile
                  115             120             125
 20
          Asp Gly Asn Gly Ser Xaa Leu Val Xaa His Gly Arg Met Thr Pro Phe
                  130             135             140

 25       Ala Leu Xaa Xaa Cys Glu Xaa Val Val Leu Lys Asn Phe Ser Ile Asp
          145             150             155             160

          Phe Glu Xaa Pro Xaa Xaa Ala Xaa Val Gln Val Xaa Glu Xaa Gly Val
                          165             170             175
 30
          Thr Xaa Gly Glu Xaa Xaa Xaa Glu Val Glu Xaa His Pro Xaa Xaa Xaa
                  180             185             190

 35       Tyr Arg Ile Val Xaa Xaa Ser Xaa Ile Glu Xaa Xaa Gly Glu Gly Trp
                  195             200             205

          Xaa Ser Xaa Gly Tyr Xaa Xaa Xaa Ile Xaa Phe Asp Xaa Asp Thr Xaa
                  210             215             220
 40
          Xaa Val Xaa Tyr Asn Thr Gly Asp Xaa Xaa Thr Trp Arg Xaa Xaa Asp
          225             230             235             240

 45       Ala Xaa Glu Ile Ala Pro Gly Ile Val Arg Xaa Xaa Xaa Pro Lys Trp
                          245             250             255

          Lys Asp Ala Xaa Phe Xaa Pro Lys Ala Gly Pro Xaa Xaa Xaa Xaa Thr
                          260             265             270
 50
          Val Leu Xaa Met Arg Asp Ile Xaa Arg Asp Xaa Xaa Gly Ile Phe Ile
                  275             280             285

 55       Xaa Xaa Ser Lys Asn Xaa Thr Leu Xaa Xaa Val Lys Xaa His Tyr Xaa
```

66

```
                290                    295                         300


      Xaa Gly Leu Gly Ile Val Ser Gln Tyr Ser Glu Asn Ile Thr Xaa Asp
      305                 310                 315                 320


      Arg Val Xaa Xaa Ala Pro Arg Gly Pro Xaa Ser Gly Arg Xaa Leu Ala
                  325                 330                 335


      Xaa Xaa Ala Asp Xaa Xaa His Phe Ser Gly Cys Lys Gly Lys Xaa Xaa
                  340                 345                 350


      Ile Lys Asn Cys Leu Phe Ala Gly Ala Met Asp Asp Pro Ile Asn Val
                  355                 360                 365


      His Gly Thr Tyr Leu Arg Val Ile Glu Lys Xaa Asp Asp Xaa Thr Leu
                  370                 375                 380


      Lys Leu Arg Phe Met His Asp Gln Ser Xaa Gly Phe Glu Xaa Gly Xaa
      385                 390                 395                 400


      Pro Gly Asp Xaa Val Xaa Phe Val Arg Ser Xaa Thr Met Glu Xaa Xaa
                  405                 410                 415


      Ala Lys Ala Asn Gln Ile Thr Xaa Xaa Arg Pro Xaa Pro Tyr Asp Lys
                  420                 425                 430


      Xaa Glu Xaa Xaa Ser Xaa Arg Glu Phe Ser Xaa Thr Phe Asp Arg Xaa
                  435                 440                 445


      Ile Pro Pro Ala Xaa Xaa Glu Xaa Xaa Gly Xaa Val Ile Glu Asn Leu
                  450                 455                 460


      Thr Xaa Thr Pro Glu Val Glu Ile Arg Asn Asn Tyr Phe Arg Xaa Xaa
      465                 470                 475                 480


      Arg Thr Arg Gly Thr Leu Val Thr Thr Pro Xaa Lys Val Val Ile Glu
                  485                 490                 495


      Asn Asn Thr Phe Xaa Xaa Thr Ser Met Ser Ala Ile Leu Ile Xaa Xaa
                  500                 505                 510


      Asp Ala Asn Gly Trp Tyr Glu Ser Gly Pro Val Lys Asp Val Thr Ile
                  515                 520                 525


      Arg Gly Asn Thr Phe Ile Asn Pro Ala Xaa Xaa Xaa Xaa Xaa Gln Xaa
                  530                 535                 540


      Gly Xaa Ala Val Ile Ser Ile Xaa Pro Glu Asn Pro Xaa Ile Xaa Xaa
      545                 550                 555                 560
```

```
            Xaa Xaa Pro Xaa His His Asn Gly Lys Asp Gly Gly Ile Arg Ile Glu
                        565             570                 575


            Asp Asn Thr Phe Xaa Thr Phe Asp Tyr Pro Xaa Leu Tyr Ala Lys Ser
                        580                 585                 590


            Val Asp Gly Leu Xaa Phe Arg Asn Asn Thr Ile Xaa Arg Xaa Thr Thr
                        595                 600                 605


            Phe Lys Pro Phe His Xaa Asn Lys Asp Xaa Phe Xaa Leu Glu Gly Cys
                    610                 615                 620


            Lys Xaa Val Val Ile Ser Glu Asn Val Phe Glu Gly Glu Thr Xaa Arg
                625                 630                 635                 640


            Gln Ser Xaa Xaa Thr Glu Asn Met Lys Arg Lys Asp Leu Lys Thr Thr
                        645                 650                 655


            Ile Lys Pro Phe Phe Lys Leu Lys Lys
                        660                 665
```

<210> 10
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<220>
<221> MOD_RES
<222> (3)..(3)
<223> Pro or Ala

<220>
<221> MOD_RES
<222> (4)..(4)
<223> Val or Ile

<220>
<221> MOD_RES
<222> (6) .. (6)
<223> Val or Ile

<400> 10

```
                    Asp Asp Xaa Xaa Asn Xaa His Gly Thr
                    1                   5
```

<210> 11
<211> 21
<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<220>

<221> MOD_RES

<222> (2)..(4)

<223> Any amino acid

<220>

<221> MOD_RES

<222> (6) .. (6)

<223> Tyr or Phe

<220>

<221> MOD_RES

<222> (8)..(8)

<223> Ser or Thr

<220>

<221> MOD_RES

<222> (10)..(12)

<223> Any amino acid

<220>

<221> MOD_RES

<222> (14)..(14)

<223> Leu or Val

<220>

<221> MOD_RES

<222> (15)..(15)

<223> Leu or Thr

<220>

<221> MOD_RES

<222> (17)..(17)

<223> Lys or Arg

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Any amino acid

<220>

<221> MOD_RES

<222> (20)..(20)

<223> Any amino acid

<400> 11

```
        Asp Xaa Xaa Xaa Trp Xaa Glu Xaa Gly Xaa Xaa Xaa Asp Xaa Xaa Ile
        1               5               10                  15
```

```
        Xaa Xaa Asn Xaa Phe
                    20
```

<210> 12

<211> 30
<212> PRT
<213> Streptomyces avermitilis

<400> 12

```
        Thr Val Ile Asp Val Thr Asp Phe Gly Ala Asp Pro Ser Gly Lys Ala
        1               5                   10                  15

        Asp Ser Ala Ala Ala Val Ser Ala Ala Met Ala His Ala Lys
                    20                  25                  30
```

<210> 13
<211> 34
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic primer

<400> 13
gcgaattccc atggctcacg gatgctccgg aggg   34

<210> 14
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic primer

<400> 14
gcctcgagaa gcttctagtc cgtgaccacg gaggtgttc   39

<210> 15
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic primer

<220>
<221> MOD_RES
<222> (6) .. (6)
<223> Inosine

<220>
<221> MOD_RES
<222> (9) .. (9)
<223> Inosine

<220>
<221> MOD_RES
<222> (12)..(12)
<223> Inosine

<220>

<221> MOD_RES
<222> (24) .. (24)
<223> Inosine

<400> 15
ttcggngtng tnkgkcagtw cagngagaa   29

<210> 16
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic primer

<220>
<221> MOD_RES
<222> (3)..(3)
<223> Inosine

<220>
<221> MOD_RES
<222> (6) .. (6)
<223> Inosine

<220>
<221> MOD_RES
<222> (9) .. (9)
<223> Inosine

<220>
<221> MOD_RES
<222> (12)..(12)
<223> Inosine

<220>
<221> MOD_RES
<222> (15)..(15)
<223> Inosine

<220>
<221> MOD_RES
<222> (18)..(18)
<223> Inosine

<220>
<221> MOD_RES
<222> (21) .. (21)
<223> Inosine

<220>
<221> MOD_RES
<222> (24) .. (24)
<223> Inosine

<400> 16
gtnccntgna tnttnatngg ntcntcgtg   29

<210> 17
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic primer

<400> 17
atcgactcgg tcaccttcaa ggccgac   27

<210> 18
<211> 28
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic primer

<400> 18
aagacgctgt tggtgatgcg tacggtgc   28

<210> 19
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 19
gcgctcgaaa ttaaccctca ctaaagggga attcggtacc ctcgaggcgc   50

<210> 20
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 20
ctcgagggta ccgaattccg gaa   23

<210> 21
<211> 31
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 21
gatcgcgcct cgagggtacc gaattccgga a   31

<210> 22
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 22
cgcttcggcg tccgttcggg ccag   24

<210> 23
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 23
ccggtgcacc gcaacgtcct catc   24

<210> 24
<211> 46
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic primer

<400> 24
gcgggatccc gggatgggac gtgtttatga catttcccag tttggc   46

<210> 25
<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic primer

<400> 25
gcctcgagaa gctttcactc tgaaatcttc acgtttgtca ctcg   44

<210> 26
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 26
catggatccc aggcctccgg atg   23

<210> 27
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 27
gatccatccg gaggcctggg atc   23

<210> 28
<211> 727
<212> PRT
<213> Streptomyces griseoplanus

<400> 28

```
Met Gly Thr Ala Thr Ala Gln Pro Ala Leu Arg Pro Gln Thr Ser Thr
1               5               10              15

Val Ile Gly Gly Leu His Gly Ala Ala Val Leu Asp Asn Thr Gly Arg
        20              25              30

Thr Val Ile Asp Val Thr Asp Phe Gly Ala Asp Pro Ser Gly Lys Ala
        35              40              45

Asp Ser Ala Ala Ala Val Ser Ala Ala Met Ala His Ala Lys Thr Val
        50              55              60

Gly Gly Pro Thr Thr Leu His Phe Pro Thr Gly Thr Tyr His Ile Trp
65              70              75              80

Pro Glu Arg Thr Pro Lys Arg Glu Leu Tyr Val Ser Asn Thr Val Gly
            85              90              95

Ser Asp Gln Ala Phe Arg Thr Lys Asn Ile Gly Ile Leu Val Glu Asp
        100             105             110

Met Arg Asp Val Val Val Asp Gly Gly Gly Ser Arg Ile Val Asn His
        115             120             125

Gly Phe Gln Thr Val Phe Ala Ala Ile Arg Ser Ser Asp Val Arg Phe
        130             135             140

Thr Asn Phe Ser Gln Thr Trp Val Ala Pro Lys Thr Val Asp Ile Thr
145             150             155             160

Val Ala Asp Ala Gly Val Val Ser Gly Gln Ala Tyr Arg Ile Ile Asp
            165             170             175

Ile Pro Glu Thr Tyr Asp Tyr Ala Val Glu Gly Thr Ser Val Arg Trp
            180             185             190

Asn Gly Glu Arg Gly Pro Ala Thr Gly Gln Pro Tyr Trp Thr Gly Thr
            195             200             205

Asn Ser Phe Asp Tyr Ser Gln Val His Asp Pro Ala Thr Asn Arg Thr
        210             215             220

Trp Arg Thr Ser Asn Pro Val Phe Pro Glu Arg His Glu Asp His Arg
225             230             235             240

Pro Arg Arg Arg Gln Val Arg Ile Thr Tyr Gly Asp Ser Thr Ala Pro
            245             250             255
```

```
Gly Asp Arg Gly Tyr Val Tyr Gln Met Arg Glu Val Thr Arg Asp Thr
        260             265             270

Pro Gly Ala Leu Phe Trp Glu Ser Ser Arg Val Thr Val Asp His Leu
        275             280             285

Arg Leu Gly Tyr Leu His Gly Phe Gly Ile Val Gly Gln Leu Ser Glu
    290             295             300

Asp Ile Gly Ile Asp Ser Val Thr Phe Lys Ala Asp Arg Gly Ser Gly
305             310             315             320

Arg Val Thr Ser Gly Phe Ala Asp His Ile Gln Met Ser Gly Val Lys
            325             330             335

Gly Thr Val Arg Ile Thr Asn Ser Val Phe Asp Asn Pro Gln Asp Asp
        340             345             350

Pro Ile Asn Ile His Gly Thr Tyr Leu Gln Ala Thr Ala Ala Glu Arg
        355             360             365

Glu Thr Leu Gln Leu Arg Tyr Met His Asn Glu Thr Ser Gly Phe Pro
    370             375             380

Gln Phe Tyr Pro Gly Asp Thr Ile Glu Leu Val Asp Lys Arg Thr Met
385             390             395             400

Leu Ala Ala Pro Gly Ala Thr Ala Lys Val Val Ser Val Thr Gly Pro
            405             410             415

Thr Gly Ser Gly Val Pro Ala Gly Thr Asp Pro Asp Thr Tyr Leu Arg
            420             425             430

Thr Met Thr Val Val Leu Asp Arg Thr Leu Pro Ala Ala Val Leu Ala
        435             440             445

Ala Pro Gly Asp Tyr Val Ala Glu Asn Thr Thr Tyr Thr Pro Thr Val
    450             455             460

Glu Ile Thr Gly Asn Thr Phe Gln Ala Val Pro Thr Arg Gly Ile Leu
465             470             475             480

Val Thr Thr Arg Arg Pro Val Arg Ile Glu Asn Asn Arg Phe Asp Gly
            485             490             495

Met Ser Met Ala Ser Ile Tyr Ile Ser Ser Asp Ala Arg Ser Trp Tyr
            500             505             510

Glu Ser Gly Pro Val Arg Asn Val Thr Ile Arg Gly Asn Val Phe Asp
```

```
                  515                      520                      525


          Arg Pro Ala Ser Pro Val Ile Phe Phe Asp Pro Thr Asn Gln Asp Phe
              530                 535                 540


          Val Ala Gly Gln Pro Val His Arg Asn Val Leu Ile Glu Asp Asn Asp
          545                 550                 555                 560


          Phe Asn Leu Thr Gly Gly Thr Ile Leu Ser Gly Arg Gly Val Gly Gly
                          565                 570                 575


          Leu Thr Phe Arg Asp Asn Arg Val Glu Arg Tyr Pro His Leu Arg Leu
                      580                 585                 590


          Thr Gly Pro Ser Arg Ala Leu Arg Val Gly Asp Thr Thr Thr Val Thr
                  595                 600                 605


          Thr Asp Ala Pro Pro Pro Ser His Thr Ser Pro Leu Phe Thr Phe Asp
              610                 615                 620


          Gly Ala Asp Asp Ile Thr Leu Ala Asn Asn Thr Tyr Gly Asn Gly Phe
          625                 630                 635                 640


          Asn Lys Arg Val Asn Thr Ala Asn Met Asp Val Ser Glu Ile Thr Val
                          645                 650                 655


          Thr Ala Asp Gly Leu Ala Leu Asn Ala Asp Ser Ile Ser Ser Ala Pro
                      660                 665                 670


          Val Ala Val Ser Tyr Ser Ser Ser Arg Pro Lys Val Ala Thr Val Asp
                      675                 680                 685


          Ser Glu Gly Val Val Lys Ala Leu Ser Gly Gly Thr Thr Ser Ile Thr
              690                 695                 700


          Ala Arg Ala Thr Ile Gly Gly Val Arg Val Thr Ser Asn Pro Val Lys
          705                 710                 715                 720


          Val Val Val Ala Thr Glu Arg
                          725
```

<210> 29
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

6xHis tag

<400> 29

```
                              His His His His His His
                              1                   5
```

Claims

1. Use of a purified enzyme comprising a polypeptide having a sequence specified by SEQ ID NO: 8 as an α-galactosidase.

2. Use according to claim 1, wherein the enzyme displays a neutral pH optimum and α-galactosidase activity with branched substrate specificity, linear substrate specificity or both.

3. A method of preparing a modified red blood cell, wherein said method comprises;

    (i) suspending group B or group AB erythrocytes in a buffer solution having a neutral pH;
    (ii) incubating the erythrocytes of step i) with the purified enzyme as defined in claim 1;
    (iii) isolating the converted erythrocyte of step ii) from the enzyme and the enzymatically-cleaved immunodominant galactose residue, thereby cleaving the immunodominant B epitopes on the group B or group AB erythrocyte as determined by serological typing or hemagglutination assays.

4. A method according to claim 3, wherein the blood cell lacks immunodominant B epitopes but retains α-1,4-Gal epitopes.

5. A method of producing an α-galactosidase comprising the sequence specified by SEQ ID No. 8, the method comprising;

    a) obtaining a nucleic acid encoding the α-galactosidase of SEQ ID No. 8;
    b) expressing the nucleic acid in a cell transfected therewith to obtain an expressed enzyme; and
    c) purifying the expressed enzyme from the cell.

6. A method for preparing a tissue for xenotransplantation, comprising incubating the tissue to be obtained from a non-human animal source with a polypeptide having the sequence specified by SEQ ID No. 8 thereby removing immunodominant α1,3-linked terminal galactose residues from the tissue, and isolating the tissue from the polypeptide and the enzymatically removed galactose, thereby rendering the tissue suitable for transplantation into humans.

7. The method of claim 6, wherein the tissue is non-immunogenic injectable collagen; bone xenografts; soft tissue and proteoglycan-reduced soft tissue xenografts; xenograft heart valves; meniscal xenografts; and tissue matrices, wherein the tissue is α 1,3-galactose deficient tissue that has been modified using the polypeptide of SEQ ID No. 8.

Patentansprüche

1. Verwendung eines aufgereinigten Enzyms, das ein Polypeptid umfasst, das eine Sequenz aufweist, die durch SEQ ID Nr. 8 spezifiziert ist, als eine α-Galactosidase.

2. Verwendung nach Anspruch 1, wobei das Enzym ein neutrales pH-Optimum und eine α-Galactosidase-Aktivität mit verzweigter Substratspezifität, linearer Substratspezifität oder beiden zeigt.

3. Verfahren zur Herstellung einer modifizierten roten Blutzelle, wobei das Verfahren Folgendes umfasst:

    (i) Suspendieren von Erythrozyten der Gruppe B oder Gruppe AB in einer Pufferlösung mit einem neutralen pH-Wert;
    (ii) Inkubieren der Erythrozyten von Schritt i) mit dem aufgereinigten Enzym, wie in Anspruch 1 definiert;
    (iii) Isolieren des umgewandelten Erythrozyten von Schritt ii) von dem Enzym und dem enzymatisch gespaltenen

immunodominanten Galactoserest, wodurch die immunodominanten B-Epitope an dem Erythrozyten der Gruppe B oder Gruppe AB gespalten werden, wie durch serologische Typisierung oder Hämagglutinationsassays bestimmt.

4. Verfahren nach Anspruch 3, wobei der Blutzelle immunodominante B-Epitope fehlen, sie jedoch α-1,4-Gal-Epitope bewahrt.

5. Verfahren zur Produktion einer α-Galactosidase, die die Sequenz umfasst, die durch SEQ ID Nr. 8 spezifiziert ist, wobei das Verfahren Folgendes umfasst:

a) Erhalten einer Nukleinsäure, die die α-Galactosidase von SEQ ID Nr. 8 kodiert;
b) Exprimieren der Nukleinsäure in einer Zelle, die damit transfiziert ist, um ein exprimiertes Enzym zu erhalten; und
c) Aufreinigen des exprimierten Enzyms aus der Zelle.

6. Verfahren zur Herstellung eines Gewebes zur Xenotransplantation, wobei das Verfahren das Inkubieren des aus einer nichtmenschlichen Tierquelle zu erhaltenden Gewebes mit einem Polypeptid, das die Sequenz aufweist, die durch SEQ ID Nr. 8 spezifiziert ist, wodurch immunodominante α-1,3-verknüpfte terminale Galactosereste aus dem Gewebe entfernt werden, und das Isolieren des Gewebes von dem Polypeptid und der enzymatisch entfernten Galactose umfasst, wodurch das Gewebe für die Transplantation in Menschen geeignet gemacht wird.

7. Verfahren nach Anspruch 6, wobei es sich bei dem Gewebe um nicht-immunogenes injizierbares Kollagen; Knochenxenotransplantate; Weichgewebe- und proteoglykanreduzierte Weichgewebexenotransplantate; Xenotransplantatherzklappen; Meniskusxenotransplantate und Gewebematrizes handelt, wobei das Gewebe α-1,3-Galactose-defizientes Gewebe ist, das unter Verwendung des Polypeptids von SEQ ID Nr. 8 modifiziert wurde.

Revendications

1. Utilisation d'une enzyme purifiée qui comprend un polypeptide ayant une séquence spécifiée par la SEQ ID N° 8 sous la forme d'une α-galactosidase.

2. Utilisation selon la revendication 1, dans laquelle l'enzyme présente un optimum de pH neutre et une activité d'α-galactosidase à spécificité de substrat ramifiée, à spécificité de substrat linéaire, ou les deux.

3. Procédé de préparation d'un globule rouge modifié, ledit procédé comprenant les étapes suivantes :

(i) mise en suspension d'érythrocytes du groupe B ou du groupe AB dans une solution tampon ayant un pH neutre ;
(ii) incubation des érythrocytes de l'étape i) avec l'enzyme purifiée telle que définie dans la revendication 1 ;
(iii) isolation de l'érythrocyte converti de l'étape ii) d'avec l'enzyme et du résidu galactose immunodominant clivé par voie enzymatique afin de cliver ainsi les épitopes B immunodominants sur l'érythrocyte du groupe B ou du groupe AB tels que déterminés par sérotypage ou par des essais d'hémagglutination.

4. Procédé selon la revendication 3, dans lequel la cellule sanguine est dépourvue d'épitopes B immunodominants mais conserve des épitopes α-1,4-Gal.

5. Procédé de production d'une α-galactosidase comprenant la séquence spécifiée par la SEQ ID N° 8, le procédé comprenant :

a) l'obtention d'un acide nucléique codant l'a-galactosidase de SEQ ID N° 8 ;
b) l'expression de l'acide nucléique dans une cellule transfectée avec celui-ci pour obtenir une enzyme exprimée ; et
c) la purification de l'enzyme exprimée à partir de la cellule.

6. Procédé de préparation d'un tissu en vue d'une xénotransplantation, comprenant l'incubation du tissu à obtenir à partir d'une source animale non humaine avec un polypeptide ayant la séquence spécifiée par la SEQ ID N° 8 afin d'éliminer ainsi du tissu les résidus galactose terminaux immunodominants à liaison α-1,3, et l'isolation du tissu

d'avec le polypeptide et du galactose éliminé par voie enzymatique afin de rendre ainsi le tissu apte à être transplanté chez des sujets humains.

7. Procédé selon la revendication 6, dans lequel le tissu est du collagène injectable non immunogène ; des xénogreffes osseuses ; des xénogreffes de tissus mous et de tissus mous à teneur en protéoglycane réduite ; des valves cardiaques de type xénogreffes ; des xénogreffes méniscales ; et des matrices tissulaires, dans lequel le tissu est un tissu déficient en α-1,3-galactose qui a été modifié en utilisant le polypeptide de SEQ ID N° 8.

FIG. 1.

FIG. 2.

FIG. 3.

FIG. 4.

FIG. 5.

FIG. 6.

FIG. 7.

FIG. 8.

FIG. 9.

FIG.10.

```
  1 MAHGCSGGAM SRFVFLGVAL ALLGGATSPA AAAPRVTPvV VDVdDYGADP TGRtDStpAV AAALrHAKSV DRPVRIVFSK
 81 GTYQLYPERA ETRELYMSNT VGADQRYRDK KIGLLVEDMH DVTVDGGGAK LVHHGLQTAF ASIRSTDVTF QNFSFDYAAP
161 EVIDATVATT GVTDGHAYRV LKIPAGSPYR VNGTHITWLG ETSPATGQPY WSGVDGLQYT QIHDPEAQRT WRGDNPLFND
241 VAAVTDLGGR RIRIDYTTAA RPADAGLVYQ MRLIERTEPG AFIWESKNVT MRSMNAYYLQ SFGVVGQFSE NISIDKVNFA
321 PDPRSGRSTA SFADFVQMSG VKGKVSITRS LFDGPHDDPI NIHGTYLEVV GKPGPSTLTL AYKHPQTAGF PQFAPGDEVE
401 FATKRTMTPL ADAHAQVTAV DGPSGMDHTK PLTTMTVTFD RPVPAGVETG GTVVENITAT PSVVISGNVF RNVPTRGLLV
481 TTRKPVLITG NRFDGMSMAS IYVSADAYQW YESGPVADLT IRGNSFTRPS GPVIFVEPTN QVIDPATPVH HNISVEHNSF
561 DIGDVTVVNA KSVGGFAFTG NTVRRLDGAD HPPYTSPLFV FHGSSGIRIA RNHYDKGLNT SVVTD
```

FIG. 11.

pNP (white spot)

α-Gal-pNP (white spot)

H-tri

B-tetra

Origin

NE Ctrl CS PT CS PT

FIG.12.

```
              10        20        30        40        50        60        70        80        90       100       110       120
              |         |         |         |         |         |         |         |         |         |         |         |
SA         MAHGCSGGAMSRFVFLGVALALLGGGATSPAAAAPRVTPVVDVDDYGADPTGRTDSTPAVAAALR---HAKSVDRPVRLVFSKGTYQLYPERAETRELYMSN-TVGADQRYRDKKIGLILV
BTalpha    -------MMSVWFIQLAIFAQS--------RIIEVFPEQ------G-----KDIENIALALKK---AADCKGRPVTVKFSPGIYQLDRAKSSQVLYYISNTTSELDDPDPTKHIGLYL
BFalpha1   -------MKKYIHILPACFLFYAAAH------AQQKDTVYVTDFGAVPYSYENCVTQIQAAID----ECKRTGAKVLSLPEGRYDIWPEGATRKEYYISNTSTEQECPSKVKITVGLML
BFalpha2   -------MKKYIHILPACFLFYAAAH------AQQKDTVYVTDFGAVPYSYENCVTQIQAAID----ECKRTGAKVLSLPEGRYDIWPEGAIRKEYYISNTSTEQECPSKVKITVGLML
BFbeta2    -------MKTILLFALSLLLSLSVSD-----VCAQERVYDISQFGLKANSKKNASPVVRKAIAKIKABCRDGEKVILRFPAGRYNFHEAGSTVREYYISNHD------QDNPKKVGIAL
BFbeta1    -------MKTILLFALSLLLSLSVSD-----VCAQERVYDISQFGLKANSKKNASPVVRKAIAKIKABCRDGEKVILRFPAGRYNFHEAGSTVREYYISNHD------QDNPKKVGIAL
BTbeta     -------MRTFLSLKTCLLSALLLCVN-----SIAASKIISVSDFGLKPDSRINAVPFIQKAID----ACKQHPGSTIVFPKGRYDFWAQHAIEKDYYETNTY-----DVNPKILAVLL
Prim.cons. MAHGCSGGAMKT3L3I2LAL2L2L2A2A222AAAAV3AQE3VVDVSDFG2KP2S3KNAVP22QAAIDKIKAECK2G33V3L3FP3GRXDFWP2GAT22EYYISNT3TEQ2CPDNPKKVGL3L

              130       140       150       160       170       180       190       200       210       220       230       240
              |         |         |         |         |         |         |         |         |         |         |         |
SA         EDMHDVTVDGGGAKIVHHGLQTAFASIRSTDVTFQNFSFDYAAPEVIDATVATTGVTDGHAYRVLKIPAGSPYRVNGT-HITWLGETSPATGQPYWSGVDGLQYTQIHDPEAQRTWRGDN
BTalpha    NTLKNITIDDGCGSTLLMNGEMTISFVLDKCEGIVLKNFNIDYKHPTQTEVEVLEE-----GNDYLIVQVHPTSQYRIVDA-QLEWYGDG------WSFKN--GIAQSYDRISEMTWRSWS
BFalpha1   HEIDDLITEGNGATLMYHGKMTTIALEHCNGVRINNLHIDFERRPAGSEIQYRKV---TGGE-TEVTLHRDTRYEIVNG-KIRLYGEGWRSN-KNHCIEYDPDTESFTYSQGW-NTLSASD
BFalpha2   HEIDDLITEGNGATLMYHGKMTTIALEHCNGVRINNLHIDFERRPAGSEIQYRKV---TGGE-TEVTLHRDTRYEIVNG-KIRLYGEGWRSN-RNHCIEYDPDTESFTYSQGW-NTLSASD
BFbeta2    EDMKNLTIDGQGSEFVFYGRMIPVSLLRSENCVLKNFSIDFEQPHIAQVQVVEN---DPEKGITFEPAPWVDYRISKDSVFEGLGEGWVMR-YSWGIAFDGKTKHVVYNTSD-IGCPTKG
BFbeta1    EDMKNLTIDGQGSEFVFYGRMIPVSLLRSENCVLKNFSIDFEQPHIAQVQVVEN---DPEKGITFEPAPWVDYRISKDSVFEGLGEGWVMR-YSWGIAFDGKTKHVVYNTSD-IGCPTKG
BTbeta     EQINDLTIDGNGSEFIMHGRMQPFTLDHCRNITLKNFSVDWEIPLTAQGIVTQS---TSEY-LEIEIDSHQYPYIIENKRLITFVGEGWKSS-LWAIMQFDPDTHIVLPNTGDNLGWRSYD
Prim.cons. ED2KDLITIDGNGS2LV3HGRMTPFAL32CE2VVLKNFSIDFE2P22A2VQV2E2GVT2GE223EVE3HP232YRIV22S2IE32GEGW2S2GY223I2FD2DT22V2YNTGD32TWR32D

              250       260       270       280       290       300       310       320       330       340       350       360
              |         |         |         |         |         |         |         |         |         |         |         |
SA         PLFNDVAAVTDIGGRRIRIDYTTAARPADAGLVYQMRLIERTEPGAFIWESKNVTMRSMNAYYLQSFGVVGQFSENILSIDKVNFAPD-PRSGRSTASFADFVQMSGVKGKVSITRSLFDG
BTalpha    PMEN-LLRIVELRPNVLYLQYKEKPQ-VGLIHTIFQMRDSFRDEVSGFVNRSKGILLENINFYYLGNFGVVCQYSENITVDRCNFAPR-PGSGRTNAGFADFIQVSGCRGMIDIKNSRFIG
BFalpha1   AREIAPGIVRFNTP-----AEEFMPKAG-----NTLTVRDIIRDQVGFFILESKNITLSRLQMHYMHGLGIVSQYTENITMDRVKCAPR-PDSGRLLAASADMMHFSGCKGKVIIDSCYFAG
BFalpha2   AREIAPGIVRFNTP-----AEEFMPKAG-----NTLTVRDIIRDQVGFFILESKNITLSRLQMHYMHGLGIVSQYTENITMDRVKCAPR-PDSGRLLAASADMMHFSGCKGKVIIDSCYFAG
BFbeta2    AFEVAP--RRICSPKWKDARLVPG-------TVVAMRGWGRPTPGIFMSHDVNTSLLDVKVHYAEGMGLLAQLCEDITILDGFGVCLKGNDPRYFTTQADATHFSGCKGKIVSKNGLYEBG
BFbeta1    AFEVAP--RRICSPKWKDARLVPG-------TVVAMRGWGRPTPGIFMSHDVNTSLLDVKVHYAEGMGLLAQLCEDITILDGFGVCLKGNNDPRYFTTQADATHFSGCKGKIVSKNGLYEG
BTbeta     ATEINPGLLIRLSDPKKEADKFFPAPG-----TVLVLRHSTRDHAGLIFIYHSMDTKLENVKLFHTCGLGILSQYSKNISFNDVHIIPN-TSKKRVLSGHDDGFHFMGCSGLLKENCSWAG
Prim.cons. A2EIAPGIVR232PKWKDA2F2PKAGP2222TVLI3MRDI2RD32GIFI22SKN2TLI33VK2HY32GLGIVSQYSENIT2DRV33APRGP2SGR2LA33AD32HFSGCKGK22IKNCLFAG
```

FIG.12. continued

```
             370       380       390       400       410       420       430       440       450       460       470       480
SA         PHDDPINIHGTYLEVVGKPGPSTLTLAYKHPQTAGFPQFAPGDEVEFATKRTMTPLADAHAQVTAVDGPSGMDHTKPLITMVTFDRPVP-AGVETGGTVVENITATPSVVISGNVFRNV
BTalpha    AHDDPINIHGTHLRVIEFLSDNRLKLRFMHDQTFGFEAFFKGDDIELVDSRSLLVVGKCKVKEAKLVTPREMELTLSSPLSSEVMQQ------KDLVIENVTWTPEVRITNNYFARV
BFalpha1   AQDDDPVNVHGTNLRALEKIDAQTLKLRFMHGQSYGFNAYFKGDTVAFTRAATMERFASA---TVR-----DVRRISDRIVEVRFDRDIP-TSLELNHDCVENMTCTPEVEIRNSYFTRT
BFalpha2   AQDDPVNVHGTNLRALEKIDAQTLKLRFMHGQSYGFNAYFKGDTVAFVRAATMERFASA---TVR-----DVRRISDRIVEVRFDRDIP-TSLELNHDCVENMTCTPEVEIRNCYFTRT
BFbeta2    MMDDAINVHGTYLKVIKRVDDHTLIGRXMHDQSWGFEWGRPGDDVQFVRSETMELIGKQNQITAIRP--YDKGEIRGAREFSITFKEAIDPAINEKSGFGIENLTWTPEVLFAGNTIRNN
BFbeta1    MMDDAINVHGTYLKVIKRVDDHTLIGRYMHDQSWGFEWGRPGDDVQFVRSETMELIGKQNQITAIRP--YDKGEIQGAREFSITFKEAIDPAINEKSGFGIENLTWTPEVLFAGNTIRNN
BTbeta     LMDDPINIHGTCSRIMEVLSPTRIKCKFMQDMSEGMEWGRPDETIGFIEHKTMRTVATG----KMN-----KFEALNKAEFTIELSVPLP-AGVEAGYVIENLTCTPDAEIRNCHFGSC
           **.:.:**:*                 .   :      . *:         .:   :         .                  :          :**:* **.   :
Prim.cons. AMDDPINVHGTYLRVIEK3DD2TLKLRFMHDQS2GFE2G2PGD2V3FVRS3TME23AKANQIT22RP2PYDK2E32S2REFS2TFDR3IPPA22E22G2VIENLT2TPEVEIRNNYFR23

             490       500       510       520       530       540       550       560       570       580       590       600
SA         PTRGLLVTTRKPVLITGNRFDGMSMASLYVSADAYQWYESGPVADLTIRGNSFTR--------PSGPVLFVEPTNQVIDPATPVHHN-----ISVEHNSFDIGDVTVVNAKSVGGFAFTG
BTalpha    PTRGILITTRRKSLIEGNTFYGMQMSGIFVADDGLSWYESGPVHDLTIRQNTFLN-------CGEPIISIDPENREYKGAVHKNIT-----IEENYFYMRKNSSCAIRAKAVDGLMIRH
BFalpha1   STRGTLVTTPRKVVIENNTYYKTGMSAILIEADAEGWYESGPVKDVLIKGNTFID--CAYNGGPGHAVIAIHPSNKIIDAERPVHQN-----IRIEDNTFRTFDYPVLYAKSTAGLLFRN
BFalpha2   STRGTLVTTPRKVVIENNTYYKTGMSAILIEADAEGWYESGPVKDVLIKGNTFID--CAYNGGPGHAVIAIHPSNKIIDAERPVHQN-----IRIEDNTFRTFDYPVLYAKSTAGLLFRN
BFbeta2    RARGTLFSTPKKTVVEDNLFDHTSGTAILLCGDCNGWFETGACRDVTIRRNRFIN-ALTNMFQFTNAVISIYPEIPNLKDQQKYFHGGKDGGIVIEDNEFDTFDAPILYAKSVDGLIFRN
BFbeta1    RARGTLFSTPKKTVVEDNLFDHTSGTAILLCGDCNGWFETGACRDVTIRRNRFIN-ALTNMFQFTNAVISIYPEIPNLKDQQKYFHGGKDGGIVIEDNEFDTFDAPILYAKSVDGLIFRN
BTbeta     RARGLLVSTPGKVIIENNVFE-SSGGSAILIAGDANAWYESGAVKDVLIRNNDFRYPCNSSIYQFCEAVISIDPEIPTPEQKYPYHRN-----IRIMDNTFHLFDYPILFARSVNGLTFSS
           :*** *.:.*   ::   ::  .  .:    *. *   ******.  *: *: * *               . :     .     *         *      .:  :.   *:  .  :
Prim.cons. RTRGTLVTTP2KVVIENNTF23TSMSALLI32DANGWYESGPVKDVTIRGNTFINPA22222Q2G3AVISI3PENP2I2232P2HHNGKDGGIRLIEDNTF2TFDYP2LYAKSVDGL2FRN

             610       620       630       640       650       660
SA         NTVRRLDGADHPPYTSPLFVFHGSSGIRIARNHYDKGLNTSVVTD----------------
BTalpha    NLIYSLDTEKNK--ESDFIQMYNCNEVTIKENRVQLHHLFK-------------
BFalpha1   NTIVRTETFPAASGNPYVFYLNGCKKAVIEGTVFKGETPRQSIKTENMKRKDLKTTIK------
BFalpha2   NTIVRTETFPAVSGNPYVFYLNGCKKAVIEGTVFEGETPRQSIKTENMKRKDLKTTIK------
BFbeta2    NVIKTNTEFKPFHWNKDRFLLERVTNVKISE------------
BFbeta1    NVIKTNTEFKPFHWNKDRFLLERVTNVKISE----------
BTbeta     NTLIRDTTYQPYHYRKEGITLEACKSVVISNNKIEGDVLGRIVTIEKMKPSDVKISKNPFFKLKK
           *  :             .   ::    .  *
Prim.cons. NTI2R3TTFKPFH3NKD2F2LEGCK2VVISENVFEGET2RQS22TENMKRKDLKTTIKPFFKLKK
```

93

FIG. 13

FIG. 14.

FIG. 15.

Fig. 16

```
  1  MGTATAQPAL RPQTSTVIGG LHGAAVLDNT GRTVIDVTDF GADPSGKADS
 51  AAAVSAAMAH AKTVGGPTTL HFPTGTYHIW PERTPKRELY VSNTVGSDQA
101  FRTKNIGILV EDMRDVVVDG GGSRIVNHGF QTVFAAIRSS DVRFTNFSQT
151  WVAPKTVDIT VADAGVVSGQ AYRIIDIPET YDYAVEGTSV RWNGERGPAT
201  GQPYWTGTNS FDYSQVHDPA TNRTWRTSNP VFPERHEDHR PRRRQVRITY
251  GDSTAPGDRG YVYQMREVTR DTPGALFWES SRVTVDHLRL GYLHG
301  DIG            DRGSG RVTSGFADHI QMSGVKGTVR ITNSVEDNPQ
351  DDPINIHGTY LQATAAERET LQLRYMHNET SGFPQFYPGD TIELVDKRTM
401  LAAPGATAKV VSVTGPTGSG VPAGTDPDTY LRTMTVVLDR TLPAAVLAAP
451  GDYVAENTTY TPTVEITGNT FQAVPTRGIL VTTRRPVRIE NNRFDGMSMA
501  SIYISSDARS WYESGPVRNV TIRGNVFDRP ASPVIFFDPT NQDFVAGQ
551            EDND FNLTGGTILS GRGVGGLTFR DNRVERYPHL RLTGPSRALR
601  VGDTTTVTTD APPPSHTSPL FTFDGADDIT LANNTYGNGF NKRVNTANMD
651  VSEITVTADG LALNADSISS APVAVSYSSS RPKVATVDSE GVVKALSGGT
701  TSITARATIG GVRVTSNPVK VVVATER
```

FIG.17

FIG. 18

SPA (U/mg)

FIG. 19

pH Dependence of Galα-pNP Activity of FragB B-zyme

pH

Fig. 20.

A. Substrate specificity of BFα2 (FragA) α-galactosidase.

B. Substrate specificity of BFß1 (FragB) α-galactosidase.

REFERENCES CITED IN THE DESCRIPTION

Patent documents cited in the description

- US 4427777 A **[0011]**
- US 5606042 A **[0012]**
- US 5633130 A **[0012]**
- US 5731426 A **[0012]**
- US 6184017 B **[0012]**
- US 10251271 B **[0014] [0037] [0046] [0049] [0053] [0054] [0059]**
- US 20050208655 A **[0076] [0078]**
- US 6402783 B **[0084]**
- US 7064187 B **[0088]**
- US 6972041 B **[0088]**
- US 6758865 B **[0088]**
- US 6455309 B **[0088]**
- US 6383732 B **[0088]**
- US 6093204 A **[0088]**
- US 5984858 A **[0088]**
- US 6933326 B **[0089]**
- US 20050159822 A **[0089]**
- US 20050028228 A **[0089]**
- US 60836000 B **[0090]**
- US 60731845 B **[0090]**

Non-patent literature cited in the description

- **CLAUSEN ; HAKOMORI.** *Vox Sang,* 1989, vol. 56 (1), 1-20 **[0005]**
- **CLAUSEN et al.** *Proc. Natl. Acad. Sci. USA,* 1985, vol. 82 (4), 1199-203 **[0006] [0036] [0068]**
- **CLAUSEN et al.** *J. Biol. Chem.,* 1986, vol. 261 (3), 1380-7 **[0006]**
- **CLAUSEN et al.** *J. Biol. Chem.,* 1986, vol. 261 (3), 1388-92 **[0006]**
- **ZHU et al.** *Arch Biochem Biophys,* 1996, vol. 327 (2), 324-9 **[0011]**
- **KRUSKALL et al.** *Transfusion,* 2000, vol. 40 (11), 1290-8 **[0011] [0012]**
- **DAVIS et al.** *Biochemistry and Molecular Biology International,* 1996, vol. 39 (3), 471-485 **[0012]**
- **BAKUNINA et al.** *Biochemistry,* 1998, 1420 **[0013]**
- **WANG et al.** *J Biol Chem,* 1990, vol. 265, 21859-66 **[0017]**
- **HENRISSAT.** *Biochem Soc Trans,* 1998, vol. 26 (2), 153-6 **[0017]**
- **RYE ; WITHERS.** *Curr Opin Chem Biol,* 2000, vol. 4 (5), 573-80 **[0017]**
- **CALCUTT et al.** *FEMS Micro Lett,* 2002, vol. 214, 77-80 **[0017]**
- **CLAUSEN et al.** *J Biol Chem.,* 1986, vol. 261 (3), 1380-7 **[0036] [0068]**
- **CLAUSEN et al.** *Biochemistry,* 1986, vol. 25 (22), 7075-85 **[0036] [0068]**
- **CLAUSEN et al.** *J Biol Chem.,* 1987, vol. 262 (29), 14228-34 **[0036] [0068]**
- Method 1.8 in the AABB Technical Manual **[0070]**
- **ZHU, A. ; MONAHAN, C. ; ZHANG, Z. ; HURST, R. ; LENG, L. ; GOLDSTEIN, J.** *Arch Biochem Biophys,* 1995, vol. 324, 65-70 **[0076] [0078]**
- **GALILI U.** *Immunol Cell Biol,* 2005, vol. 83, 674-86 **[0077] [0079] [0082] [0084]**